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ABSTRACT 
Treatment of hormone-dependent breast tumours is typically conducted using hormone-
therapy, with NK cell immunotherapy a novel modality. In this study, the effects of hormone-
therapy and combined hormone-therapy with immunotherapy in MCF-7 breast cancer cells was 
investigated. A hormone pre-treatment of 17β-oestradiol and progesterone was performed to 
simulate the in vivo microenvironment. Subsequently cells were treated with the hormone-
therapy drugs Anastrozole or RU486 alone, or with continued hormone simulation. Combined 
therapy was conducted with in vitro activated NK cells co-cultured with MCF-7 cells 
undergoing hormone-therapy.  
Biomarkers ERα, PR and MUC1 were immunolocalised and expression analysed qualitatively, 
and quantitatively using image analysis software. Hormone pre-treatment reduced biomarker 
expression, stressing the importance of hormone environment simulation for in vitro 
experimentation. Hormone-therapy increased cytoplasmic ERα and decreased PR expression. 
Anastrozole increased MUC1 and RU486 decreased nuclear MUC1. With continued hormone 
simulation, Anastrozole further decreased all biomarkers whereas RU486 decreased ERα, 
increased PR expression with variable effects on MUC1 expression. RU486 induced MUC1/PR 
and MUC1/ERα correlation, which, under continued hormone simulation, was maintained in 
the nucleus only. Anastrozole induced MUC1/PR correlation in the cytoplasm which was 
maintained under continued hormone simulation. Hormone-therapy also induced a decrease in 
apoptosis, with continued hormone simulation abrogating Anastrozole induced apoptosis. 
While hormone-therapy did not increase proliferation, the associated changes observed in 
biomarker expression are linked with tumour progression indicating that short-term treatment 
may be detrimental for overall survival.  
Combined NK cell immunotherapy resulted in decreased PR, while ERα and MUC1 expression 
increased in a hormone-dependent manner. Biomarker correlation was evident, albeit reduced 
with continued hormone simulation. Independently of hormone-therapy and hormone 
stimulation, immunotherapy reduced apoptosis, contrary to expectation. Proliferation was 
marginally reduced by immunotherapy. 
The results indicate that immune cell function is inhibited by interaction with tumour cells, an 
effect that hormone-therapy cannot abrogate. Furthermore, that this study shows treatment 
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alters both nuclear and cytoplasmic expression of biomarkers, indicates that diagnostic 
procedures should consider both cellular compartments in tumour progression. It is further 
shown that qualitative analysis of biomarker expression is not always validated by quantitative 
analysis, with the latter proposed as a more objective and precise method to be used 
diagnostically. 
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INTRODUCTION 
Breast cancer is the leading cancer amongst women worldwide, with the highest mortality rate 
(Jemal et al., 2011; Torre et al., 2015). In developing countries there is a lower incidence 
compared to developed countries (7.1% to 2.4%) but almost half of the diagnosed cases are 
fatal (1.2%). The increased incidence of breast cancer worldwide in the 1980s to 1990s has 
been linked to reproductive factors including oral contraceptive use, hormone replacement 
therapy and obesity (Jemal et al., 2011; Torre et al., 2015). However, in some developed 
countries the incidence rates have decreased in the last 25 years due to early detection and 
treatment (Torre et al., 2015). In contrast, the rates in some developing countries have been 
increasing. While this is partially a factor of increased screening especially with 
mammography, the adoption of a more westernised lifestyle has been implicated in increasing 
breast cancer incidence (Jemal et al., 2011; Youlden et al., 2012).   
Of particular concern in developing countries is access to treatment, with more targeted 
therapies not readily accessible for people of low socioeconomic status. Nevertheless, treatment 
for breast cancer, depending on subtypes, traditionally involves a mixed regimen of surgery, 
chemotherapy and radiation therapy, and hormone-therapy (Nicolini and Carpi, 2009). There 
have been many advances in the aforementioned treatment modalities, yet, even in developed 
countries the vast majority of patients survive only up to 5 years post-diagnosis (Youlden et al., 
2012). The low overall survival rate implicates recurrence and distant metastases (Youlden et 
al., 2012). It is thus of paramount importance that attention is given to understanding alterations 
in breast cancer profiles under treatment. Furthermore, since the immune system has been 
shown to significantly influence tumour progression, more research is required in this regard. 
 
Classification of Breast Tumours 
Breast cancers are classified clinically according to their histopathology of which 
adenocarcinomas are the most prevalent; this is a tumour that originates from the epithelium 
and grows in a glandular pattern (Lester, 2015; Esebua, 2013). Adenocarcinomas are 
categorised by the anatomical location in the gland, whether ductal or lobular. These 
carcinomas are further classified by how far they have spread through the tissue: a carcinoma in 
situ has not spread beyond the basement membrane; however, an invasive/infiltrating 
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carcinoma has (Lester, 2015; Esebua, 2013). The majority of invasive breast tumours present as 
infiltrating ductal carcinoma (Lester, 2015; Esebua, 2013) .  
Breast adenocarcinomas are further characterised by their molecular heterogeneity, which is 
linked with differing biological behaviour (Neve et al., 2006) . Clinical treatment methods thus 
take into consideration a number of subtypes: Luminal, human epidermal growth factor 
receptor 2 (Her2)-enriched, Basal-like, normal breast-like and claudin-low (Eroles et al., 2012; 
Miller, 2004). The Luminal phenotype of breast cancer is commonly referred to as hormone-
dependent breast cancer and is characterised by the presence of the oestrogen receptor (ER) and 
progesterone receptor (PR) (Miller, 2004). The Luminal phenotype can be further subdivided 
into the Luminal A subtype which is ER
+
PR
+
HER2
-
, commonly found in post-menopausal 
patients (Eroles et al., 2012; Miller, 2004); and the Luminal B subtype which is ER
+
PR
+
HER2
-
 
with high Ki67 expression, a marker which indicates a high proliferative rate and associated 
with high metastatic potential (Eroles et al., 2012). The Her2-enriched subtype is ER
-
PR
-
 but 
has an overexpression of HER2. The Basal-like subtype is conversely negative for the 
aforementioned markers (ER
-
PR
-
HER2
-
) and is commonly referred to as the triple negative 
phenotype. The Claudin-low subtype is similar to the Basal-like in that it is triple-negative; 
however, it also presents low expressions of proteins involved in intercellular adhesion (Eroles 
et al., 2012).  
These subtypes have been implicated in the differing of breast cancers in regards to their 
incidence, survival rate and treatment responses (Keller et al., 2010; Prat and Perou, 2011; 
Parise and Caggiano, 2014). ER
-
 subtypes are more aggressive tumours and have been linked to 
increased mortality compared to the ER
+
 subtypes, with the ER
+
PR
+
HER2
- 
subtype (Luminal A 
and B) having the best survival rate (Parise and Caggiano, 2014). Thus, dependent on the 
subtype, treatments can be chosen accordingly (Eroles et al., 2012).  
In order to investigate breast tumour progression in vitro, established cell lines are commonly 
used. The MCF-7 cell line was established from a pleural effusion of a patient presenting breast 
adenocarcinoma (Neve et al., 2006). Molecular studies indicate that MCF-7 cells are of a 
luminal phenotype (ER
+
 PR
+
); however, these cells show variance in the expression of HER2 
(Neve et al., 2006). Morphologically, in monolayer cell cultures, MCF-7 cells present a 
polygonal, ‘cobble-stone’ morphology, with distinct cell boundaries, typical of 
adenocarcinomas (Neve et al., 2006). The MCF-7 cell line was used for this study. 
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Biomarker Expression in Luminal Breast Tumours 
Of particular concern to this study is the luminal phenotype of breast adenocarcinoma, which 
as previously mentioned, is ER
+
PR
+
. Both ER and PR are classified as nuclear hormone 
receptors which mediate the effects of the steroid hormones, oestrogen and progesterone, 
respectively (Faivre et al., 2005; Hill et al., 2012; Renoir et al., 2013). ERα is overexpressed 
in ER
+
 breast tumours and modulates their response to oestradiol (a derivative of oestrogen), 
particularly with regard to cell proliferation and cell survival (Renoir et al., 2013). PR is also 
overexpressed in PR
+
 breast tumours and interacts with progestins (a derivative of 
progesterone) (Faivre et al., 2005). To better understand the role of these steroid hormones in 
tumourigenesis reference can be made to their original role in mammary development. 
Specifically, 17β-oestradiol mediates outgrowth and branching of ducts, whereas 
progesterone mediates branching and the development of the secretory epithelium, for 
subsequent lactation. This action continues through the menstrual cycle (Gellersen et al., 
2009; Knutson and Lange, 2014) . Lifetime exposure and high levels of oestrogen and 
progesterone, are associated with increased risk for breast cancer, particularly the luminal 
phenotype which is well known for its hormone-dependency in tumour progression, 
specifically in initiation, cell proliferation and survival mechanisms (Mendelson and Hardy, 
2006; Knutson and Lange, 2014).  
There are two different isoforms of ER: ERα and ERβ; with three different isoforms of the 
PR noted: PR-A, PR-B and PR-C. The isoforms of both the ER and PR share a similar 
structure with an N-terminal domain (NTD), a DNA binding domain (DBD), a hinge domain 
and a C-terminal domain (CTD) (Acconcia and Kumar, 2006; Lange, 2008; Hill et al., 2012). 
The NTD allows for intermolecular and intramolecular associations as well as gene 
transcription activation (Acconcia and Kumar, 2006; Hill et al., 2012). The DBD binds the 
receptor to hormone response elements (HRE) in the promoter regions of targeted genes (e.g. 
c-myc), i.e. ER binds to oestrogen response elements (EREs) and PR binds to progesterone 
response elements (PREs) (Acconcia and Kumar, 2006; Lange, 2008; Hill et al., 2012). The 
hinge domain is located between the DBD and the CTD and when the receptor is unliganded, 
allows binding to chaperone heat shock proteins (Hsp) to modulate translocation from the 
cytoplasm to the nucleus (Acconcia and Kumar, 2006; Hill et al., 2012). The CTD contains 
the ligand binding domain (LBD) and the F domain. The LBD, as its name suggests, is the 
location at which the hormone is bound; however, it also interacts with the DBD to modulate 
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gene transcription. The F domain also functions to modulate transcriptional activity 
(Acconcia and Kumar, 2006; Hill et al., 2012). In contrast to the classical PR-A and PR-B, 
PR-C has a truncated DBD which doesn’t allow for activation of transcription, however, it 
does increase the transcriptional activity of the classical PRs (Wei et al., 1997).  
The actions of these hormone receptors differ depending on their cellular location, mainly 
cytoplasmic and nuclear location (Acconcia and Kumar, 2006; Lange, 2008; Hill et al., 
2012). Interestingly, it has been discovered that ER and PR can function independently of the 
classical genomic pathway (Acconcia and Kumar, 2006; Gellerson et al., 2009). The genomic 
pathway states that unliganded, the receptors are bound to Hsp and inactive, and when bound 
to a ligand dissociate from Hsp and translocate to the nucleus to bind to HREs. However, 
these receptors also function via a non-genomic pathway, where sequestration in the 
cytoplasm allows these hormones to act without the use of transcription and instead interact 
with other receptors or cytoplasmic kinases (e.g.: Src) (Acconcia and Kumar, 2006; Lange, 
2008; Hill et al., 2012; Welsh et al., 2012).  It is proposed that these two pathways are not 
independent of each other but act in concert to provide a response to the hormones (Acconcia 
and Kumar, 2006; Lange, 2008; Hill et al., 2012), while other studies note that  nuclear and 
cytoplasmic ER may function in direct conflict – promoting or inhibiting tumour progression 
(Björnström and Sjöberg, 2004). 
The localisation of ER and PR in both the nuclear and cytoplasmic compartments are thus of 
paramount concern. Clinically, tumour immunohistochemical assessment of ER is limited to 
the nucleus and cytoplasmic expression is not considered (Welsh et al., 2012). Given that 
biologically, ER and PR function may not be dependent on purely the genomic pathway, 
cytoplasmic assessment of hormone receptors could be of diagnostic and prognostic 
significance, as well as an indication for hormone-therapy types (Welsh et al., 2012).  
A new biomarker that has also been implicated in breast tumour progression is mucin-1 
(MUC1), a large multi-unit transmembrane glycoprotein. This glycoprotein is normally 
expressed on the apical surface of secretory epithelial cells where it plays a protective role as 
part of the glycocalyx (Wei et al., 2006). MUC1 has two subunits, the N-terminal (MUC1-N) 
and C-terminal (MUC1-C) subunit.  The MUC1-N subunit is large, extending beyond the 
glycocalyx, with the MUC1-C subunit tethering the MUC1-N subunit to the cytoskeleton 
(Wei et al., 2006). During tumourigenesis glycosylation patterns change and MUC1 becomes 
homogenously and overexpressed, both in the cell and the tumour as a whole.  This has been 
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specifically noted in breast tumours and thus MUC1 has been established as an oncoprotein 
(Wei et al., 2006; Nath and Mukherjee, 2014). 
In tumour progression MUC1 mediates the secretion of a number of growth factors, inducing 
pro-survival and proliferation mechanisms (Kufe, 2009; Nath and Mukherjee, 2014). 
Moreover, MUC1 is implicated in the induction and maintenance of epithelial-mesenchymal 
transitions, via nuclear translocation of the cytoplasmic domain of MUC1-C where its action 
results in the upregulation of transcription factors Snail, Slug, Vimentin and Twist, known 
inducers of invasive phenotypes (Nath and Mukherjee, 2014). MUC1 functions in the 
inhibition of apoptotic mechanisms via the downregulation of pro-apoptotic and upregulation 
of anti-apoptotic members of the Bcl-2 family (Nath and Mukherjee, 2014). Furthermore, 
MUC1 interacts directly with ER-α stimulating co-activator binding as well as ERα-mediated 
transcription (Wei et al.,, 2006). There are currently no reports of the interaction between PR 
and MUC1 in breast cancer. However, in human uterine cells PR acts differentially, with 
liganded PR-B stimulating and PR-A inhibiting MUC1 expression (Brayman et al., 2006). 
Clinically, breast tumour cytoplasmic MUC1 expression has been shown to be significantly 
associated with PR expression (van der Vegt et al., 2007). 
In metastasis, MUC1 is proposed to prevent cell-cell adhesion due to the large extension and 
aberrant glycosylation of its N-terminal subunit thus promoting cell migration (Gendler, 2001). 
An increase in MUC1 in K562 cells has been shown to inhibit Natural Killer (NK) cell 
mediated lysis in vitro (Zhang et al.,, 1997). Also the secretion of MUC1 is associated with 
immune evasion processes including the inhibition of lymphocyte migration to the tumour site 
and inhibition of NK cell function (Gendler, 2001; Suzuki et al., 2012; Villalba et al., 2013). 
The increased MUC1 expression in many epithelial cancers is introducing a number of MUC1 
targeted therapies which are currently under investigation (Mukhopadhyay et al., 2011; Nath 
and Mukherjee, 2014). MUC1 has been further shown to be expressed in the luminal phenotype 
MCF-7 cell line (Gil et al., 2013), which made this cell line ideal for this study. 
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Analysis of Biomarker Expression in Breast Cancer 
The most cost-effective method to classify breast tumours is visually via 
immunohistochemical assays which can assess receptor expression (e.g. ER, PR, HER2), 
oncogene presentation (e.g. myc) and proliferation markers (e.g. Ki67) (Shyyan et al., 2006). 
However, such assessment requires a qualified, experienced pathologist to interpret the 
results. Lack of experience or capacity as evident in many developing countries, implicates 
subjectivity and possible false negatives or positives in such circumstances (Anderson et al., 
2008).  Furthermore, as previously mentioned, the biomarkers ER, PR and MUC1, which are 
of considerable importance to defining breast cancer subtype, and thus eliciting a treatment 
strategy, are only considered when localised to the nucleus (Welsh et al., 2012). A new 
strategy is required to combine the plethora of data indicating cytoplasmic function in tumour 
progression with new tools for diagnostic analysis.  
A new technique to study these assays would be objective quantification of the images 
produced, which could be performed using image analysis software (Rexhepaj et al., 2008; 
Burguera et al., 2010). We have previously used the online, free image analysis software 
‘CellProfiler’ (Carpenter et al., 2006) to analyse the expression of MUC1 and ERα with 
immunohistochemistry (Gil et al., 2013). For this study, such software allows for 
identification of stained components within cells. This allows for assessment of staining 
intensity and localisation to cellular compartments, amongst numerous other functions 
including determination of cell number, cellular compartment number and size measures 
(Carpenter et al., 2006). Sophisticated algorithms allow for the generation of ‘pipelines’ – 
step-by-step procedures – which allow for high imaging throughput (Carpenter et al., 2006). 
The same parameters would be applied to each image, thus subjectivity, as in qualitative 
assessment, would not be a defining factor of any study. Furthermore, once data is generated, 
sophisticated statistical techniques may be employed to find subtle relationships that would 
otherwise be hidden by qualitative analysis alone (Gil et al., 2013). 
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Hormone-Therapy of Hormone-Dependent Breast Cancer 
Hormone therapy for hormone-dependent tumours has evolved from oophorectomy, where in 
1896, Beatson showed a regression in metastatic breast cancer in two women who had 
undergone this surgery (Beatson, 1896; Dao, 1972; Enmark and Gustafsson, 1999; Speirs et 
al., 2004). The oestrone hormone was later isolated in 1929 and lead to the discovery of a 
relationship between this hormone and breast cancer. The concept of hormone-dependence 
was realised in the 1940s with Huggins’ experiments of orchiectomy with regards to prostatic 
cancer. Jensen discovered the oestrogen receptor in 1958 (Dao, 1972; Enmark and 
Gustafsson, 1999; Speirs et al., 2004) and in 1967 it was proposed that breast cancers may 
also contain hormone receptors like their non-cancerous counterpart and would therefore be 
responsive to hormone manipulation (Edwards et al., 1979). This discovery instigated the use 
of procedures to restrict hormones in both prostate cancers and breast cancers and to discover 
the mechanism by which this worked (Dao, 1972). In 1974, it was determined that 60% of 
breast cancers that contained ER were susceptible to oestrogen manipulation (Edwards et al., 
1979). The fact that not all carcinomas containing ER were susceptible to endocrine therapy 
lead to the theory that progesterone and the progesterone receptor were also involved 
(Edwards et al., 1979). This allowed for novel experimentation in therapeutic intervention 
strategies that were directed at these receptors. 
Chemical oophorectomy, in which luteinizing hormone-releasing hormone (LH-RH) or 
gonadotropin-releasing hormone (GnRH) analogues are used to induce ovarian suppression 
has been indicated for premenopausal women with ER
+
 breast cancer (Ray and Ficek, 2012). 
However, it was found that most ER
+
 breast tumours present in post-menopausal women and 
these patients produce oestrogen extra-gonadally via the aromatase enzyme (Ray and Ficek, 
2012). The local biosynthesis of oestrogen appears associated with developing a more 
aggressive disease, a poorer outcome as well as increased local and distant recurrences 
(Kulendran et al., 2009). Thus in most cases chemical oophorectomy is not commonly used 
as a treatment modality, but rather the current hormone-therapies including selective 
oestrogen receptor modulators (SERM), selective oestrogen receptor downregulators 
(SERD), and aromatase inhibitors (AI) (Howell et al., 2004; Ray and Ficek, 2012). These 
therapies are usually used as an adjuvant (post-surgery) or neo-adjuvant (pre-surgery) 
treatment.  
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SERMs function as receptor antagonists primarily; however, they also function as agonists on 
non-breast tissues (e.g. endometrium and bone) (Jordan, 2001). The first SERM generated 
was Tamoxifen, which was discovered to inhibit induced mammary carcinogenesis in rats in 
1975, followed by widespread clinical use (Jordan, 2001, 2008). Since then, this drug has 
been the standard adjuvant hormone-therapy for both pre-menopausal and postmenopausal 
women (Howell et al., 2004; Ray and Ficek, 2012). SERDs are classified as pure oestrogen 
antagonists; however, the only SERD in use clinically is fulvestrant which is used as a third 
line treatment (Howell et al., 2004; Ray and Ficek, 2012), particularly after patients develop 
resistance to Tamoxifen treatment (Knutson and Radisky, 2013).  
When it was discovered that oestrogen is produced in breast carcinomas themselves, 
independently of the ovaries (Miller and Forrest, 1974) and that the level was significantly 
higher than normal breast tissue (van Landeghem et al., 1985), the use of AIs to inhibit the 
accumulation of oestrogen in breast carcinomas was investigated. AIs bind to the cytochrome 
P450 aromatase enzyme which prevents it from converting androgens to oestrogens (Miller, 
2004).  The first AI to be developed was the non-steroidal aminoglutethimide in 1974 and 
was dubbed a first generation AI; however, this AI was not specific to aromatase but also 
inhibited other cytochrome P450 enzymes (Brueggemeier et al., 2005). The next AI 
developed was formestane, a second generation AI, and although it was more effective and 
more aromatase specific than aminoglutethimide, it still had some non-specific binding 
(Brueggemeier et al., 2005). The last jump in AI development was the third generation AIs 
which did not affect other cytochrome P450 enzymes; these include the non-steroidal 
vorozole, letrozole, anastrozole AIs and the steroidal exemestane AI (Miller, 2004; 
Brueggemeier et al., 2005; Kulendran et al., 2009). Anastrozole, the most widely used of 
these AIs producing the greatest decrease in oestrogen levels (Brueggemeier et al., 2005; 
Kulendran et al., 2009), is of particular interest to this study.  
Research has shown that in postmenopausal women third generation AIs are superior to 
Tamoxifen with regards to inhibition of breast cancer progression and are currently used as a 
first line treatment for this demographic (Kulendran et al., 2009; Ray and Ficek, 2012). In 
patients treated with Anastrozole or Letrozole for 14 days before surgery, ER and PR 
expression, as well as tumour cell proliferation was significantly reduced (Murray et al., 
2009). Anastrozole 15 week treatment also decreased endogenous oestrogen levels in breast 
tumours (Geisler, 2003). The phase III trial ATAC (Anastrozole, Tamoxifen Alone, or in 
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Combination) showed that Anastrozole significantly increased disease-free survival, time-to-
reoccurrence and decreased distant metastases in postmenopausal women with early 
hormone-dependent breast cancer (ATAC Trialists Group, 2005). In the IBIS-II (International 
Breast Cancer Intervention Study II) trial, prophylactic Anastrozole decreased the incidence 
of breast cancer in postmenopausal women who were at an increased risk of breast cancer 
(Cuzick et al., 2014). 
While these results indicate that reduction of hormone receptors may be an ideal expectation, 
clinically downregulation of ERα expression is associated with increased recurrence and 
metastasis (Dhasarathy et al., 2007). Moreover, with prolonged treatment ER
+
 breast tumours 
have been shown to acquire resistance, which is still not fully understood but is known to 
include increased ER co-regulators and receptor cross-talk (Renoir et al., 2013). Furthermore, 
during the metastatic process, circulating tumour cells derived from ER
+
 tumours have been 
shown to downregulate their ER profile (Aktas et al., 2011), thus rendering ER hormone-
therapy inadequate.  
It is now well-known that oestradiol promotes the progression of hormone-dependent tumours. 
However, over the years there have been widely differing opinions on whether progesterone 
has a proliferative and/or metastatic effect on breast cancer. Early studies indicated that 
progesterone treatment inhibited tumourigenicity of pre-cancerous cells but promoted 
tumourigenicity of cancerous cells (Horwitz, 1992). It was further proposed that progesterone 
inhibits breast cancer proliferation (Parazzini et al., 1993). Conversely, more recent studies 
indicate that progesterone alone or in combination with 17β-oestradiol increases the 
proliferative and metastatic potential of breast cancer cells (Faivre et al., 2005; Fu et al., 2008). 
Clinical data shows that high levels of progesterone are associated with increased risk for breast 
cancer, with other studies indicating that progestins are implicated in tumour cell cycle 
progression (Faivre et al., 2005; Knutson and Lange, 2014).  
Despite the contention around progesterone’s effects on cancer, a new type of hormone-therapy 
is being researched, that of anti-progestins, or PR antagonists. The most common anti-progestin 
undergoing study is RU486, also known as mifepristone or the morning-after pill, and of 
particular interest to this study. This drug has a greater affinity for PR compared to 
progesterone (Vegeto et al., 1992), thus it binds to the PR, but at a more N-terminal location 
than that of progesterone (Vegeto et al., 1992). However, it has been identified that RU486 has 
weak oestrogenic activity due to its steroid nature, binding to the hormone-binding domain of 
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the ER (Jeng et al., 1993). RU486 can also act as a PR agonist under certain conditions mainly 
with PR-B undergoing conformations in the NTD (Hill et al., 2012). It has been determined 
that the inhibitory effect of RU486 on cancer cells is not dependent on nuclear PR expression 
(Tieszen et al., 2011; Chen et al., 2014); however, the mechanism of PR-independent RU486 
action remains unknown. 
RU486 has been shown to significantly inhibit tumour growth as well as have various other 
anti-tumour effects in 24 cell lines, including MCF-7 (Chen et al., 2014). With regard to 
induced tumours in rats, RU486 treatment was able to inhibit tumour growth (Bakker et al., 
1987). The first clinical trial was with 200 mg/day RU486 as a treatment for metastatic breast 
cancer in postmenopausal women, this induced partial regression or stabilisation of the tumour 
in over half the patients (12 out of 22) (Romieu et al., 1987). Another trial at 200-400 mg/day 
also showed stabilisation in 6 patients (out of 11) (Klijn et al., 1989). However, in 1996, a trial 
with postmenopausal patients with PR
+
 metastatic breast cancer treated with RU486 showed a 
low overall response rate (Perrault et al., 1996). RU486 has been suggested to have a protective 
effect on normal breast epithelium (Engman et al., 2008). Clinical trials conducted from 2012 - 
2014 tested this theory, by treating healthy patients presenting with the BRCA1/2 mutation and 
thus regarded as a high risk group for breast cancer, with RU486 (Danielsson, 2015). The 
results have yet to be published.  
Interestingly, an association between ER and PR has been discovered and this has implications 
for treatments which target only the one receptor. There has been identified a ligand-
independent direct association of the ER with PR-B, with regard to the c-Src/p21ras/Erk-2 
transducing pathway (Migliaccio et al., 1998). The C-terminal domain of ER binds to the N-
terminal domain of PR-B, which is absent in PR-A. This permits progesterone to stimulate the 
binding of the ligand-free ER to the proto-oncogene c-Src and activate the subsequent cascades 
leading to tumour progression. Conversely, the stimulation of this pathway by oestrogen is 
independent of PR-B (Migliaccio et al., 1998), indicating a role for progesterone in PR
-/low
 
breast tumours .  
Given these findings, a combination of hormone-therapy treatments to target both oestrogen 
and progesterone has been proposed and investigated in vitro. Simultaneous treatment of MCF-
7 cells with RU486 and Tamoxifen induced a synergistic inhibitory effect on the proliferative 
rate for short treatment (< 3 days) (Thomas and Monet, 1992) and significantly increased cell 
growth inhibition, DNA fragmentation, bcl2 downregulation, induction of transforming growth 
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factor β1 (TGFβ1), as well as translocation of protein kinase C activity (El Etreby et al., 1998), 
all of which contribute to tumour progression. In induced mammary tumours in rats, a 
combination of RU486 and Tamoxifen induced a greater tumour regression compared to each 
alone (Bakker et al., 1990). However, the efficacy of this combination therapy has yet to be 
confirmed by additional clinical studies. 
Further interactions have been noted between ER, PR and MUC1. In patients with primary 
ductal carcinoma apical membrane i.e. non-transformed MUC1 expression has been linked to 
smaller tumours, lower tumour grades, PR positivity and increased overall survival (van der 
Vegt et al., 2007). Diffuse cytoplasmic MUC1 expression has been linked to cyclin D1 
positivity and increased relapse-free survival. However, MUC1 has also been determined to be 
an independent risk factor for poor relapse free survival and overall survival (van der Vegt et 
al., 2007). Under oestradiol stimulation, MUC1 has been implicated in interacting directly with 
the ERα and thus stimulating co-activator binding as well as ERα-mediated transcription (Wei, 
et al., 2006), which in breast tumours, is implicated in promoting tumour progression. With 
patients undergoing 3 weeks Tamoxifen treatment before surgery, it was determined that a 
lower percentage of tumour cells expressed MUC1 and that this expression was lower (Hanson 
et al., 2001), corresponding to a possible ER-mediated regulation of MUC1. In our laboratory, 
we have further shown that in the absence of exogenous hormones, short-term treatment (3 
days) with Anastrozole and RU486 increase both ERα and MUC1 in MCF-7 cells (Gil et al., 
2013).   
 
Furthermore, since MUC1 is implicated in facilitating adhesion, many studies have assessed the 
relationship between the PR and MUC1 linked to embryo implantation. Studies conducted on 
endometrial cell lines indicate that PR regulates MUC1 gene expression, with progesterone 
itself capable of upregulating MUC1 expression (Horne et al., 2006; Dharmaraj et al., 2010) 
Since both the endometrium and breast tissue are hormonally regulated, we postulate that in 
luminal phenotype tumours, MUC1 function may be linked with PR or progesterone directly.  
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Immunotherapy of Breast Cancer 
The immune system can recognize and destroy cancerous cells; however, many cancers employ 
immune evasion strategies that circumvent the immune system (Lechner et al., 2011). The 
immune system is made up of the innate immune system and the adaptive immune system. The 
innate immune system comprises of non-specific defence mechanisms using macrophages and 
neutrophils, while the adaptive immune system comprises of antigen-specific defence 
mechanisms mediated by B cells and T cells (Janeway et al., 2001). Lymphocytes originate 
from stem cells in the bone marrow; the B-cells undergoing antigen-independent development 
in the bone marrow and T-cells, in the thymus (Janeway et al., 2001). T cells are divided into 
helper T (TH) cells (CD4
+
) and cytotoxic T lymphocytes/cells (CTLs or TC cells) (CD8
+
). CD4
+
 
TH cells recognise class I histocompatibility molecules (HLA-A, HLA-B, and HLA-C) and 
CD8
+
 CTLs recognise class II histocompatibility molecules (HLA-D) (Roth et al., 2006). 
Another type of lymphocyte involved in cytotoxicity is NK cells, of particular interest to this 
study. NK cells detect cellular surface changes; however, these cells are regarded as part of the 
innate immune system and use a different mechanism to T-cells for antigen recognition (Roth 
et al., 2006). 
NK cells differentiate between cancerous cells and healthy cells by detecting the balance 
between activating and inhibitory signals, although inhibitory signals can overrule activating 
signals as a safeguard mechanism (Yawata et al., 2008; Blattman and Greenberg, 2004). The 
activating receptors on NK cells include NKG2D, NKp30, NKp46, DNAM-1, CD2, NKp80, 
2B4, and NTBA; while the inhibitory receptors include NKG2A, CD85j, and KIR. NK cells 
also express CD16 which is linked to the induction of antibody-dependent cellular cytotoxicity. 
NK cell activation leads to NK-cell induced apoptosis, NK cell proliferation and cytokine 
release (Yawata et al., 2008; Blattman and Greenberg, 2004). NK cells are traditionally 
classified as CD3
-
CD56
+
 lymphocytes forming part of the innate immune response, whereby 
they induce apoptosis in their targeted cells. Two NK cells populations have been ascertained 
depending on CD56
+
 expression, they are known as CD56
dim
 and CD56
bright
 (Farag and 
Caligiuri, 2006). 
Tumours do not exist in isolation with only the neoplastic cells; but in what has been termed the 
tumour microenvironment (TME) containing a wide range of cell types including fibroblasts, 
endothelial cells and cells of the immune system (Leibovici et al., 2011). The TME also 
includes the extracellular matrix as wells as diverse soluble molecules. The immune cells 
13 
 
 
 
contained within the TME are variable and in most cancers the tumours are able to evade the 
immune system and promote tumour progression. The TME contains immune cells of both the 
innate and adaptive immune system including macrophages, dendritic cells, basophils, mast 
cells, eosinophils, NK cells and T cells (Witz, 2009; Leibovici et al., 2011). Regulatory 
immune cells are also found in the TME, including T regulatory (Tregs) cells and myeloid-
derived suppressor cells (MDSCs) (Stewart and Abrams, 2008; Leibovici et al., 2011). 
In breast cancers, it has been found that the macrophages and Tregs found in the TME promote 
tumour progression. Macrophages are implicated in angiogenesis and ECM generation while 
the Tregs suppress T cell, B cell and NK cell function. Macrophage infiltration or increased 
Treg infiltration in breast tumours denotes poor survival (Muranski et al., 2006; Mougiakakos 
et al., 2010). A role for CD8
+
 T cells in breast cancer has not been fully elucidated; the data 
available is conflicting indicating that further research is necessary to understand CD8
+
 T cells 
in breast cancer (Knutson and Radisky, 2013). Interestingly, the breast TME is lacking in NK 
cells (Georgiannos et al., 2003; Macchetti et al., 2006), despite elevated peripheral blood NK 
cell levels (Mozaffari et al., 2007), which may indicate evasion of the immune system 
(Leibovici et al., 2011; Albertsson et al., 2003). However, in cancers in which NK cells have 
invaded the tumour infiltrate there is an association with a better prognosis. These cancers 
include squamous-cell lung carcinoma, gastric carcinoma and colorectal carcinoma (Albertsson 
et al., 2003). This improved infiltration has been linked to NK cell activation and thus NK cell 
function (Albertsson et al., 2003). 
Given the importance of the immune system in tumour progression, a branch of treatment - 
immunotherapy is being investigated (Gattinoni et al., 2006). This treatment manipulates the 
immune system to treat cancers. The various subtypes of immunotherapy to date include non-
specific immunomodulation (NSI), monoclonal antibody (mAB) therapy, cancer vaccines and 
adoptive cell transfer (ACT) (Gattinoni et al., 2006; Rosenberg et al., 2008).  Non-specific 
immunomodulation is the use of immunomodulators to activate endogenous immune cells and 
currently the only modulator in use is interleukin-2 (IL-2), a potent immunostimulatory 
cytokine; however, others are under investigation including IL-15, anti-transforming growth 
factor-β (anti-TGFβ) and anti-programmed death 1 (anti-PD-1) (Rosenberg et al., 2008). mAB 
therapy involves targeting tumour associated antigens and is thus very much dependent on the 
discovery of biomarkers that delineate cancerous tissue from normal tissue. Cancer vaccines 
consist of the immunisation of a patient via whole cells, proteins or other vectors which has had 
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very little success to date (Gattinoni et al., 2006; Rosenberg et al., 2008; Leibovici et al., 2011; 
Dougan and Dranoff, 2012).  
Of particular concern to this study is ACT. ACT is the identification of anti-tumour 
lymphocytes ex vivo, which are then activated and expanded in vitro and then transferred into 
cancer patients (Gattinoni et al., 2006; Rosenberg et al., 2008; Geller et al., 2011). These 
lymphocytes can either be obtained from circulation or from populations known as tumour 
infiltrating lymphocytes (TIL). ACT has been performed with TILs expanded with IL-2 in vitro 
and used to successfully treat lung and liver tumours in mice (Rosenberg et al., 1986, 2008). 
Clinically, successful tumour regression of melanomas was achieved using TILs isolated from 
melanomas and expanded with IL-2 transferred post-lymphodepletion (Rosenberg et al., 1988; 
Rosenberg et al., 2008). ACT has been primarily conducted using T cells due to the fact that 
they are part of the adaptive immune system and can be targeted to tumour-specific antigens 
(June, 2007). However, in cancers in which NK cells have invaded the tumour, there is an 
association with a better prognosis (Albertsson et al., 2003). 
It has been revealed that breast cancer cells modify their MHC receptors to escape from NK 
cell activity, undergo immuno-editing to change their mRNA and protein expression to NK 
cells, produce a suppressive environment and prevent NK cell maturation (Mamessier et al., 
2011). Two immunotherapy strategies involving NK cells have been investigated: NSI with 
regards to endogenous NK cell activation and ACT with activated NK cells. Endogenous NK 
cell activation was executed using IL-2 and a marked increase in NK cells tumour infiltrates 
were noted, however, this increase was still not high enough to induce tumour regression 
(Albertsson et al., 2003). The clinical trials for ACT of in vitro IL-2 activated NK cells into 
tumours produced disappointing results (Arai et al., 2008; Iliopoulou et al., 2010; Cho et al., 
2010; Geller et al., 2011). A study by Re et al. (2006) used interleukin-2 (IL-2) and 
phytohaemogglutinin (PHA) to activate NK cells and increase NK cell induced apoptosis in 
immune-resistant tumours.  This activation has been corroborated independently by Castriconi 
et al. (2004). The use of lymphodepletion and IL-2 therapy followed by NK ACT has proved 
ineffective so far in solid tumours clinically (Geller et al., 2011).  
It has been discovered that NK cells express ERα and ERβ (Curran et al., 2001) and while 
CD56
dim
  NK cells express PR-A and PR-B, CD56
bright
 NK cells lack PR expression (Arruvito 
et al., 2008). This indicates that hormones as well as hormone-therapy drugs would affect NK 
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cell function. However, currently there has been no investigation into the effects of hormone-
therapy on NK cell tumour populations or NK cell cytotoxicity in tumours. 
The low numbers of NK cells in the TME indicates an immune evasion strategy (Georgiannos 
et al., 2003; Macchetti et al., 2006) that needs to be investigated as the presence of NK cells in 
tumours are associated with a better prognosis, which had been linked to NK cell activation 
(Albertsson et al., 2003). 
 
Rationale for the Study 
Tumour cells have a reciprocal interaction with the tumour microenvironment. In hormone-
dependent breast cancer this is particularly of importance with regards to hormone levels. Thus 
an in vitro investigation of the effects of the hormones 17β-oestradiol and progesterone as a 
simulation of an in vivo environment was deemed as necessary with regard to hormone-therapy 
strategies. Additionally, the presence of continuous treatment to mimic circulating hormones 
with regard to hormone-therapy is required. ER and PR expression is important in breast cancer 
prognosis and MUC1, although it is a relatively new biomarker in regards to breast cancer, is 
also implicated in prognostic significance. The quantification of the biomarkers expression is 
particularly useful when determining significant changes in expression levels and localisation. 
Another critical component of the TME is immune cells and a great deal of research has been 
done with regards to tumour immunotherapy, particularly with regards to T-cells. However, 
although NK cells are rarely found in the TME, they are linked to a better prognosis. They are 
also hormone-responsive with ER and PR present. Therefore an investigation into the 
reciprocal interactions between hormone-therapy and NK cell immunotherapy in hormone-
dependent breast tumour cells is required. Moreover, the effects of a hormone-simulated in vivo 
environment to determine if the presence of continuous endogenous hormones affects these 
combined therapeutics is necessary. 
The hypothesis for this study was that hormone-therapy would increase the expression of all 
three biomarkers, and combined hormone-therapy and immunotherapy would reduce the 
expression of these biomarkers. It was further hypothesised that hormone-therapy and 
combined therapy would decrease MCF-7 cell proliferation. Combined therapy was also 
hypothesised to increase MCF-7 cell death, more so than hormone-therapy. 
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Aims and Objectives 
This study thus sought to investigate the effects of hormone-therapy and combined hormone-
therapy with immunotherapy on hormone-dependant breast cancer cells in a hormone simulated 
in vitro environment. 
The objectives were as follows: 
1. To investigate changes in the expression of the biomarkers ERα, PR and MUC1 in the 
MCF7 breast cancer cell line following hormone-therapy and combined hormone-
therapy with immunotherapy.  
2. To determine if hormone-therapy and combined hormone-therapy with immunotherapy 
has an effect on proliferation in the MCF7 breast cancer cell line. 
3. To determine if hormone-therapy and combined hormone-therapy with immunotherapy 
induces apoptosis in the MCF7 breast cancer cell line.  
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MATERIALS AND METHODS 
A stock of MCF-7 cells was first established for subsequent experimentation. Briefly, MCF-7 
cells were plated, followed by the induction of cell cycle synchronisation. In order to simulate a 
hormonal environment, cells were incubated with appropriate concentrations of 17β-oestradiol 
and progesterone. Following this, cells were exposed to either hormone-therapy (Anastrozole 
or RU486) or combined hormone-therapy and hormones. They were then exposed to 
immunotherapy in the form of activated NK cells (Figure 2.1, Table 2.1). The MCF-7 cells 
were then subjected to the appropriate downstream applications: immunocytochemistry to 
examine the expression of PR, ERα, MUC1 and Ki67; or flow cytometry to assess the 
induction of apoptosis. For the immunotherapy, human blood was drawn to isolate the NK 
cells, therefore Human Ethics was obtained (M081036 (TN Augustine)) (Appendix A).  
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Seeding 
1x104 cells  in Media A 
Synchronising 
Media B 
In vitro simulated 
hormone  
environment 
EP 
Controls 
Media B, dDMSO, EP 
Immunotherapy 
1x104 NK cells in 
aforementioned controls 
Hormone-Therapy 
ANAS, RU486, EPA, EPR 
Immunotherapy 
1x104 NK cells in Media B 
Figure 2.1. Flow diagram depicting a summary of the conditions the cells were exposed to for a 
hormone simulated environment and for the hormone-therapy and combined hormone-therapy with 
immunotherapy treatments.  
Following adherence of cells in Media A, cells were synchronised in the cell cycle in Media B. A simulated 
in vivo microenvironment was created using the hormones 17β-oestradiol and progesterone (EP). After the 
EP treatment, cells were either exposed to the hormone-therapy treatments: Anastrozole (ANAS) or RU486; 
or continue hormone stimulation with hormone-therapy: 17β-oestradiol, progesterone and Anastrozole 
(EPA); and 17β-oestradiol, progesterone and RU486 (EPR) (Table 2.1). For combined hormone-therapy and 
immunotherapy, hormone-therapy treated cells (with or without continued hormone stimulation) were 
incubated with NK cells. Appropriate controls for all treatments including Media B alone, dDMSO (diluent 
for all drugs and hormones) were conducted. Following treatment procedures cells were processed for 
immunocytochemistry or flow cytometry. 
 
 
19 
 
 
 
Cell Culture  
MCF-7 cells were cultured in 25cm
2
 Nunc culture flasks containing Media A (Dulbecco’s 
modified Eagle’s medium (DMEM) (Lonza, Bloemfontein, South Africa, BE12-604F) + 10% 
Foetal Calf Serum (FCS) (Biocom Biotech, Clubview, South Africa, A15101) + 0.1% 
Penicillin and Streptomycin (P/S) (Sigma-Aldrich, Aston Manor, South Africa, P3539) 
(Appendix B1) and incubated at 37°C and 5% CO2. When subconfluent, these were 
subcultured using trypsin/ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich, T4049) for 
detachment. Periodically the cells were stored in cryopreservation media DMEM + 60% FCS + 
10% Dimethyl sulfoxide (DMSO) (Saarchem, Johannesburg, South Africa, 186500) (Appendix 
B2) at -80°C to provide a stock of MCF-7 cells for subsequent experimentation (Pawlak and 
Wiebe, 2007).   
 
Cell Seeding  
Each experiment was repeated three (n=3) times and cells were plated in duplicate for each 
assay. Glass coverslips (10mm round) were autoclaved and placed into labelled 24-well plates. 
Cryopreserved MCF-7 cells were thawed and washed twice in 1ml Phosphate Buffered Saline 
(PBS) (Appendix B3) followed by resuspension in 1ml Media A. To determine total cells, live 
cells and the percentage viability, the cell suspension was mixed 1:1 with Trypan Blue, then 
counted using a TC20 Automated Cell Counter (Biorad, Parkwood, South Africa). Each 
coverslip was plated with 1x10
4
 cells followed by 100μl Media A. Cells were incubated at 
37°C and 5% CO2 for 24 hours, for adherence to occur.   
Thereafter, the cells were washed three times with PBS and incubated with 100μl of Media B 
(phenol red-free DMEM (Lonza, 12-917F) + 10% dextran coated charcoal stripped-FCS (DCC-
FCS) + 0.1% P/S) (Appendix B4) at 37°C and 5% CO2 for 48 hours to eliminate the effects of 
oestrogen and progesterone and like substances found in DMEM and FCS (Pawlak and Wiebe, 
2007) and to synchronise the cells in the G1 phase of the cell cycle (Faivre et al., 2005). 
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Hormone-Therapy  
Anastrozole (Sigma-Aldrich, A2736) and RU486 (Sigma-Aldrich, M8046), as well as the 
hormones, progesterone (Sigma-Aldrich, P0130) and 17β-oestradiol (Sigma-Aldrich,  E2758), 
were used at a final concentration of 1μM. This concentration was previously shown to produce 
significant changes (Jeng et al. 1993; Pawlak and Wiebe, 2007). The drugs and the hormones 
were diluted in 0.01% DMSO and Media B (Appendix B7).  
Following cell synchronisation, samples were washed three times with PBS and incubated with 
100μl 1μM 17β-oestradiol and 1μM progesterone (EP) at 37°C in 5% CO2 for 24 hours to 
mimic the hormonal influences of the in vivo environment (Gil et al., 2013). Cells were 
thereafter washed three times with PBS. Since preliminary research showed a significant 
change in ERα and MUC1 expression at 72 hours with Anastrozole or RU486 treatment (Gil et 
al., 2013), cells were therefore incubated with 100μl 1μM of their respective treatments at 37°C 
and 5% CO2 for 72 hours. The hormone-therapy treatments were as follows: Anastrozole 
(ANAS); RU486; 17β-oestradiol, progesterone and Anastrozole (EPA); and 17β-oestradiol, 
progesterone and RU486 (EPR) (Table 2.1).  
Controls for the treatment groups were specifically selected to assess only the effects of the 
hormone-therapy drugs and immunotherapy. The control treatments were as follows: cell 
synchronisation medium (Media B); DMSO diluent (dDMSO); and 17β-oestradiol and 
progesterone (EP) (Table 2.2). The Media B control was selected to provide a baseline without 
any treatment. The dDMSO was selected to assess the effect of the DMSO in which the 
hormones and drugs were dissolved. Lastly the EP control is a hormone control, to determine 
the effects of the hormones by themselves. 
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Table 2.1. Hormone-therapy treatments 
MCF-7 cells were cultured in Media A for 24 hours followed by cell cycle synchronisation with Media B for 48 
hours and the hormone pre-treatment (EP) for 24 hours. Afterwards the hormone-therapy treatments were 
performed for 72 hours. The treatments are Anastrozle (ANAS) and RU486, as well as these drugs with the 
addition of hormones (EPA and EPR). 
Culture Synchronisation Pre-treatment Treatment  
--- hrs --- hrs --- hrs HT hrs 
Media A 24 Media B 48 EP 24 EPA 72 
Media A 24 Media B 48 EP 24 EPR 72 
Media A 24 Media B 48 EP 24 ANAS 72 
Media A 24 Media B 48 EP 24 RU486 72 
 
 
Table 2.2. The control treatments for hormone-therapy  
MCF-7 cells were cultured in Media A for 24 hours followed by synchronisation with Media B for 48 hours and 
the hormone pre-treatment (EP) for 24 hours. Afterwards the control treatments were performed for 72 hours.  The 
control treatments are: cell synchronisation control (Media B); DMSO diluent control (dDMSO); and 17β-
oestradiol and progesterone (EP) hormone control.  
Culture Synchronisation Pre-treatment Treatment  
--- hrs --- hrs --- hrs Control hrs 
Media A 24 Media B 48 EP 24 dDMSO 72 
Media A 24 Media B 48 EP 24 EP 72 
Media A 24 Media B 48 EP 24 Media B 72 
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Immunotherapy 
Magnetic Sorting of NK Cells    
Blood (30ml) was drawn from seemingly healthy volunteers (n=6) by registered nurses into 
EDTA Vacutainers™ (BD Biosciences, Woodmead,  South Africa, 367844). The blood was 
diluted with PBS (1:1), layered onto Ficoll-Paque Premium (GE Life Sciences, South Africa, 
17-5442-03) at a ratio of 3:2 and then centrifuged for 30 min at 400xg. A white leukocyte layer 
was formed between the serum and Ficoll layers and this was transferred to a 10ml tube, 
followed by centrifuging at 400xg and washing with PBS. A sample of the cell suspension was 
diluted 1:1 with Trypan Blue and cell number and viability established using the TC20 
Automated Cell Counter (average viability was 71%). The cell suspension was centrifuged 
again at 400xg for 5 min and the resulting cell pellet resuspended at 1x10
6
 cells/ 80µl 
10%FBS/PBS.  
The cell suspension was thereafter incubated with 20µl APC-conjugated mouse anti-human 
NKp46 antibody (BD Biosciences, 558051), in the dark at room temperature for 15 min. 
Subsequently, cells were washed twice with Miltenyi Buffer (MB) (PBS + 0.5% BSA + 2mM 
EDTA) (Appendix B8) and resuspended at 1x10
7
 cells/ 80µl MB. The cell suspension was 
thereafter incubated with 20µl anti-APC microbeads (Miltenyi Biotec, Cologne, Germany, 130-
090-855) for 15 min in the dark at 4°C. The suspension was then washed twice with MB by 
centrifugation at 400xg for 5 min and resuspended at 1x10
7
 cells/ 500µl MB for subsequent 
magnetic cell sorting. 
For positive selection of NKp46
+
 cells, an MS column (Miltenyi Biotec, 130-042-201) was first 
placed in the magnetic field, primed with 3ml MB and then the cell suspension applied to the 
column followed by 3ml MB. This procedure was repeated three times. The column was then 
removed and 3ml MB added to the column reservoir. Positively selected NKp46
+
 NK cells 
were then flushed out into a collecting tube for subsequent viability assessment and activation. 
The efficacy of this sorting technique for the NK cells was determined using flow cytometry by 
assessing the markers NKp46 and CD56 by TN Augustine in the same laboratory (Augustine et 
al., 2015). 
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Activation of NK Cells   
The magnetically sorted NK cell suspension was centrifuged at 400xg for 5 min. The cells were 
incubated 1:1 with Trypan Blue and viability and cell number assessed with the TC20 
Automated Cell Counter (average viability was 71%). For activation, NK cells were incubated 
at 1x10
6
 cells/100ul Activation Media A (Roswell Park Memorial Institute medium (RPMI)  
1640 (Lonza, BE12-115F) + 0.1% P/S + 1 μg/ml phytohaemagglutinin (PHA) (Sigma-Aldrich, 
L1668) + 0.8 ng/ml Interleukin-2 (IL-2) (Miltenyi Biotec, 130-093-901)) (Appendix B9) at 
37°C and 5% CO2 for 18 hours in a 96-well plate. Cell suspensions were then harvested, 
centrifuged at 400xg for 5 min and then incubated with Activation Media B (RPMI 1640 + 
0.1% P/S + 0.8 ng/ml IL-2) (Appendix B10) for a further 30 hours (Domaica et al., 2009). 
Subsequently NK cells were co-cultured with treated MCF-7 cells. 
 
Co-culture of MCF-7 cells with NK cells   
The activated NK cells were washed in PBS and resuspended in Media B. For determination of 
cell number and viability using the TC20 Automated Cell Counter, the NK cell suspension was 
mixed 1:1 with Trypan Blue (average viability was 61%).  NK cells were added to the treated 
MCF-7 cells at a 1:10 ratio to simulate the low numbers of NK cells found in tumours. This co-
culture was incubated at 37°C and 5% CO2 for 4 hours in the present treatment media (Table 
2.3). Two sets of controls were conducted: 1) hormone-therapy treatments alone (ANAS, 
RU486, EPA, EPR) and controls (Media B, EP, dDMSO), to determine the effect of the NK 
cells themselves; 2) controls as used for the hormone-therapy treatments with the addition of 
NK cells (Media B+NK, EP+NK and dDMSO+NK) (Table 2.4). 
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Table 2.3. Combined hormone-therapy and immunotherapy treatments 
MCF-7 cells were cultured in Media A for 24 hours followed by synchronisation with Media B for 48 hours and 
the hormone pre-treatment (EP) for 24 hours. Afterwards the hormone-therapy treatments were performed for 72 
hours followed by co-culture with activated NK cells (immunotherapy) for 4 hours.  
Culture Synchronisation Pre-treatment Treatment 
--- hrs --- hrs --- Hrs 
Hormone-
Therapy (HT) 
hrs 
Immunotherapy 
(IT) 
hrs 
Media A 24 Media B 48 EP 24 EPA 72 Activated NK cells 4 
Media A 24 Media B 48 EP 24 EPR 72 Activated NK cells 4 
Media A 24 Media B 48 EP 24 ANAS 72 Activated NK cells 4 
Media A 24 Media B 48 EP 24 RU486 72 Activated NK cells 4 
 
Table 2.4. The control treatments for combined hormone-therapy and immunotherapy 
MCF-7 cells were cultured in Media A for 24 hours followed by synchronisation with Media B for 48 hours and 
the hormone pre-treatment (EP) for 24 hours. Afterwards the control treatments were performed. These included 1) 
hormone-therapy treatments alone and appropriate controls; 2) using the controls as determined for the hormone-
therapy treatments with the addition of NK cells. 
Culture Synchronisation Pre-treatment Treatment 
--- hrs --- hrs --- Hrs 
Hormone-
Therapy (HT) 
hrs 
Immunotherapy 
(IT) 
hrs 
Media A 24 Media B 48 EP 24 EPA 72 --- 4 
Media A 24 Media B 48 EP 24 EPR 72 --- 4 
Media A 24 Media B 48 EP 24 ANAS 72 --- 4 
Media A 24 Media B 48 EP 24 RU486 72 --- 4 
Media A 24 Media B 48 EP 24 dDMSO 72 --- 4 
Media A 24 Media B 48 EP 24 EP 72 --- 4 
Media A 24 Media B 48 EP 24 Media B 72 --- 4 
Media A 24 Media B 48 EP 24 dDMSO 72 Activated NK cells 4 
Media A 24 Media B 48 EP 24 EP 72 Activated NK cells 4 
Media A 24 Media B 48 EP 24 Media B 72 Activated NK cells 4 
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Immunolocalisation of ERα, PR, MUC1 and Ki67   
Following hormone-therapy and combined hormone therapy and  immunotherapy treatments, 
immunolocalisation for the hormone receptors, ERα and PR; the glycoprotein MUC1 and the 
proliferation marker, Ki67, was conducted. Cells were washed thrice with PBS, fixed in 4% 
paraformaldehyde (PFA) (Sigma-Aldrich, P6148) for 15 min and washed again. Cells were 
incubated in antigen retrieval buffer (ARB) (Appendix B11) at 95°C for 10 min, permeabilised 
in 0.25% TritonX-100 in PBS for 10 min at room temperature. Non-specific binding sites were 
blocked using 10% normal goat serum in 1% BSA/PBS for 30 min at room temperature. MCF-
7 cells were double-labelled for ERα and MUC1 using 0.5μg/ml mouse anti-human MUC1 
(Abcam, Pretoria, South Africa, ab28081) and 0.5μg/ml rabbit anti-human ERα (Abcam, 
ab31315). Cells were also double-labelled for PR and MUC1 using the aforementioned MUC1 
antibody (0.5μg/ml) and 0.5μg/ml rabbit anti-human PR (Abcam, ab97801). Ki67 was localised 
alone with 1μg/ml rabbit anti-human Ki67 antibody (Abcam, ab15580). Cells were then 
incubated overnight at 4°C. 
Thereafter, the cells were incubated at room temperature in the dark for 2 hours in 1μg/ml of 
each of the secondary antibodies: Alexa Fluor® 488 goat anti-rabbit (Life Technologies, 
Johannesburg, South Africa, A11008) and Alexa Fluor® 594 goat anti-mouse (Life 
Technologies, A11005) where applicable. The cells were incubated at room temperature in the 
dark for 5 min with 1:10000 DAPI (Sigma-Aldrich, 32670) and mounted using Fluoroshield 
(Sigma Aldrich, F6182). The slides were stored at 4°C until viewing.  
 
The controls used were the following: a negative control (all antibodies omitted), primary 
antibody controls for MUC1, ERα, PR (the secondary antibody omitted), secondary antibody 
controls for Alexa Fluor® 488 and Alexa Fluor® 594 (the primary antibody omitted), and 
isotype controls for MUC1, ERα, PR and Ki67 (the primary antibody was incubated with either 
rabbit polyclonal IgG (Abcam, ab27478)(ERα, PR or Ki67) or mouse IgG3 (Abcam, 
ab18392)(MUC1) depending on the primary antibody, then added to the cells). 
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The Effect of Hormone-Therapy and Combined Therapy on Apoptosis  
The flow cytometric Annexin V-FITC apoptosis detection Kit II (BD Biosciences, 556547) was 
used to determine the number of cells undergoing apoptosis. This is done using Annexin V-
FITC to detect the phospholipid phosphatidylserine which translocates to the outer plasma 
membrane when a cell undergoes apoptosis. It also uses propidium iodide (PI) which enters the 
nucleus only when the plasma and nuclear membranes are breached.  
The co-cultures of MCF-7 and NK cells were washed and the cells were detached using 
Accutase (Sigma Aldrich, A6964), a cell detachment solution of proteolytic and collagenolytic 
plant enzymes which ensures high cell viability and maintains cell surface marker expression 
for further analysis (Merten, 2010). The cell suspension was washed by centrifugation at 400xg 
for 5 min. The supernatant was then removed and the pellet resuspended in 1X binding buffer 
(0.01M Hepes (pH 7.4) + 0.14M NaCl + 2.5mM CaCl2) at a concentration of 1x10
6
 cells/ml. 
To the flow cytometric tubes, 100µl of the cell solution was added along with FITC Annexin-V 
and PI. The cell suspension was gently vortexed and incubated for 15 min in the dark at room 
temperature. The samples were analysed using the BD Biosciences LSRFortessa (Department 
of Surgery), and the data acquired using FACSDiva software. The data was subsequently 
analysed using FlowJo X 10.0.7r2. 
The flow cytometer controls (for compensation and quadrant establishment) that were used 
were: MCF-7 cells incubated with 1) only FITC Annexin-V; 2) only PI and 3) with no 
antibodies (See Appendix C). The apoptosis assay controls that were used were: 1) a negative 
control (Media B); 2) an apoptosis positive control (camptothecin (CPT)); and 3) a DMSO 
diluent control (dDMSO control as previously discussed). The CPT control was used as it 
stimulates apoptosis via the mitochondrial pathway, it was used at a concentration of 5µM 
(Hingorani et al., 2011). 
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Acquisition and Analysis of Images  
During the stages of culture and treatment, phase contrast images were taken using an Olympus 
IX51 Inverted Microscope, an Olympus XC10 camera and CellSens software. 
 
Cells were viewed under an Olympus IX51 Inverted Fluorescent Microscope with U-MWIB2 
(green Alexa Fluor 488), U-MIY2 (red Alexa Fluor 594) and U-MNU2 (blue DAPI) filters. 
Images acquired were designated DAPI, MUC1, PR, ER or Ki67. The MUC1, ER and PR 
images were obtained at 20x or 40x magnification, and the Ki67 images were obtained at 10x 
magnification. Fluorescence was captured individually as grayscale images and colour 
representation generated as per fluorescence channels. Images showing Alexa Fluor 488 
(green) or Alexa Fluor 594 (red) were overlaid with DAPI (blue) to illustrate nuclear 
localisation of these markers. Furthermore, where MCF-7 cells were double-labelled i.e. MUC1 
and ER; MUC1 and PR, the colour images were overlaid to identify colocalisation of the 
markers. 
 
To obtain quantitative data, these images were analysed using CellProfiler (Carpenter et al., 
2006). Two pipelines were created in CellProfiler for the analysis of the different types of 
markers. Specifically, Pipeline A was used to analyse the expression of MUC1, ERα and PR 
(Figures 2.2, 2.3), and Pipeline B was used to analyse the expression of Ki67 (Figures 2.4, 2.5). 
Pipeline A thus calculated mean intensity values for ERα, PR and MUC1 expression in the 
nucleus and the cytoplasm for comparison purposes. Pipeline B was designed to calculate the 
percentage of the nuclei that were Ki67 positive (Ki67
+
). 
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Identify Primary 
Objects 
Identify the nuclei from the nuclear stain 
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Measure Object 
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Export to Spreadsheet 
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cell and cytoplasm objects  
Identify Secondary 
Objects 
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image 
Identify Tertiary 
Objects 
Identify the cytoplasm by "subtracting" the 
nuclei objects from the cell objects. 
Figure 2.2. Pipeline A for biomarker analysis using CellProlifer 
The pipeline used to analyse both the MUC1+ERα images as well as the MUC1+PR images producing the values 
mean intensity (the average pixel intensity within the object) for each of the cell, nuclei and cytoplasm objects. 
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E 
Figure 2.3. An illustrative overview of the CellProfiler pipeline created to determine the three objects measured (nucleus, cell and cytoplasm) 
A: Nuclei stained with DAPI (blue). B: Immunolocalisation of MUC1with Alexa Fluor 594 (red cytoplasmic and nuclear staining). C: Area occupied by individual nuclei as 
determined by CellProfiler. D: Area occupied by the entire cell as determine by CellProfiler. E: Area occupied by the cytoplasm of the cell only (C is subtracted from D) 
2
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Figure 2.4. Pipeline B for Ki67 analysis using CellProlifer 
A CellProfiler pipeline used to analyse the Ki67 slides and produce the percentage of nuclei that are Ki67 positive. 
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E 
Figure 2.5. An illustrative overview of the CellProfiler pipeline created to determine the percentage of nuclei positive for Ki67 
A: Nuclei stained with DAPI (blue). B: Immunolocalisation of Ki67 with Alexa Fluor 488 (green). C: Area occupied by individual nuclei as determined by CellProfiler. D: Area 
occupied by Ki67as determine by CellProfiler. E: Composite image showing Ki67
+
 nuclei (red areas, Ki67, associated with blue, nuclei) produced by CellProfiler. 
3
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Statistical Analysis  
Statistical analysis was conducted using the statistics and analytics software package PAST 
(Paleontological Statistics), a free data analysis package which is used for common statistical 
plotting and testing. Normality tests (Shapiro-Wilk, Jarque-Bera, Chi
2
 and Anderson-Darling) 
were conducted to determine normality of the data with significance set at p=0.05. Where 
PAST was unable to perform a normality test on a data set, due to a floating point error, the 
software package Statistical Analysis System (SAS) was used. 
The biomarker data was found to be not normally distributed (p<0.05) (Appendix D, Tables 
D2, D8 and D14) and thus the following tests were employed: non-parametric Kruskal-Wallis 
test and Mann-Whitney test. Significance was set at p=0.001 and for more accurate assessment, 
Bonferroni corrected p-values were used. Spearman’s correlation was also used to determine 
correlation values for the biomarkers, MUC1 and ERα, and MUC1 and PR. 
The Ki67 data was found to be normally distributed (p>0.05) (Appendix D, Table D21) and 
thus the parametric one-way analysis of variance (ANOVA) test was used and pairwise 
comparisons were performed using Tukey’s (default of PAST). Significance was set at p=0.05.  
The flow cytometric data used to analyse the expression of phosphatidylserine and propidium 
iodide staining, was not normally distributed (p<0.05) (Appendix D, Table D24) and thus the 
non-parametric Kruskal-Wallis test was employed. Significance was set at p=0.05. 
The software package Statistica 12.5 was used to produce the bar graphs and correlation 
graphs.  
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RESULTS 
General Morphology of MCF-7 Cells 
The MCF-7 cell line is derived from a pleural effusion of a metastatic mammary carcinoma; it 
is a hormone-dependent cancer (ER and PR positive) and is also positive for MUC1 (Zaretsky 
et al., 2006). These cells, seeded as a single cell suspension, form plaques as they attach to the 
bottom of the culture flask and become a monolayer. The monolayer retains some of the 
characteristics of its epithelial origin. Cells predominantly display a polygonal shape with a 
centrally placed nucleus containing multiple nucleoli (Figure 3.1A). Some cells exhibit a 
mesenchymal morphology (Dhasarathy et al., 2007). These cells are smaller and more 
elongated, with a smaller nucleus and attenuated cytoplasm. The distinction between the two 
cell types is easily seen (Figure 3.1B), with the typical mesenchymal-like morphology 
commonly indicating a less differentiated phenotype.  As the monolayer becomes more 
confluent some of the cells form rosettes (Figure 3.1B). Rosettes are typically associated with 
duct formation (Soule et al., 1973), however no lumen formation was noted (Figure 3.1B). 
 
 
 
 
 
  
A B 
Figure 3.1. Representative photomicrographs showing the morphology of MCF-7 cells under normal 
culture conditions 
A: MCF-7 cells forming plaques illustrating the large polygonal shaped cells with a centrally placed nucleus 
containing multiple nucleoli (black arrow). Phase contrast microscopy, 40x magnification. B: Subconfluent MCF-
7 cells illustrating small elongated cells reminiscent of a mesenchymal morphology (black arrow), large polygonal 
shaped cells (white arrow) and rosette formation (encircled). Phase contrast microscopy, 20x magnification. 
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The Effect of Hormone-Therapy and Combined Therapy on MCF-7 Cell Morphology 
The general morphology of cells in the control treatment groups (Media B, dDMSO and EP) 
did not differ drastically from each other showing large polygonal cells, small elongated cells 
and rosettes (Figure 3.2). The cells in the Media B control treatment group appeared to be more 
densely packed and there also appeared to be more rosettes (Figure 3.2A). However, EP 
treatment appeared to induce an increase in the number of large polygonal cells (Figure 3.2B).  
Hormone-therapy (HT) (Figure 3.3) or combined hormone-therapy and immunotherapy 
treatments (HT+IT) (Figure 3.4) resulted in the majority of cells displaying a large polygonal 
shape, indicative of a more differentiated phenotype, and the presence of  small elongated cells, 
indicative of a more mesenchymal-like phenotype. Specifically under NK cell mediation, 
RU486 induced prominent plaque formation and fewer rosettes as compared to the other 
treatments in both the HT (Figure 3.3) and HT+IT groups (Figure 3.4).  
 
 
 
 
 
 
 
 
 
C 
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Figure 3.2. Representative photomicrographs showing the effects of control treatments on MCF-7 cell morphology 
Control treatment groups: A: Media B. B: EP. C: dDMSO. Phase contrast microscopy, 20x magnification.  
Small, elongated cells with a smaller nucleus and less cytoplasm (black arrow) and larger, polygonal cells (white arrow) are noted. Some cells show rosette formation occurring 
(encircled). The EP treatment appears to have induced more large polygonal cells and the media B treatment appears to have induced more rosette formation. 
3
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Figure 3.3. Representative photomicrographs showing the effects of hormone-therapy on MCF-7 cell 
morphology  
Treatment groups: A: ANAS. B: RU486. C: EPA. D: EPR. Phase contrast microscopy, 20x magnification. 
A heterogeneous population of MCF-7 cells are noted, with some cells displaying a smaller, elongated 
morphology (black arrow) and other cells showing a larger, more polygonal  morphology with indistinct cell 
boundaries (white arrow). Note rosette formation (encircled). 
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Figure 3.4. Representative photomicrographs showing the effects of combined hormone-therapy and 
immunotherapy on MCF-7 morphology  
Treatment groups: A: ANAS+NK. B: RU486+NK. C: EPA+NK. D: EPR+NK. Phase contrast microscopy, 20x 
magnification. In most treatment groups, a mixed morphology is noted, with small elongated cells (black arrow), 
and large polygonal cells (white arrow). Rosette formation was also noted (encircled). Under NK cell mediation, 
Anastrozole appeared to induce more small cells, with a mesenchymal-like morphology (A). The addition of 
hormones resulted in an increase in the number of polygonal cells (C). The RU486+NK treatment group appears 
to have fewer mesenchymal-like cells (B), with cells having formed a plaque with distinct cell boundaries and no 
discernible rosettes. The addition of hormones, appears to have resulted in more cells displaying a mesenchymal-
like morphology. 
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Immunolocalisation of MUC1, ERα and PR 
The ICC technical controls were the following: negative control, primary antibody controls for 
MUC1, ERα and PR, secondary antibody controls for Alexa Fluor® 488 and Alexa Fluor® 
594, and isotype controls for MUC1, ERα and PR. These ICC controls showed no fluorescence 
(see Appendix C, Figure C1) indicating that there was no background fluorescence and no 
autofluorescence. This indicates the specificity of the antibodies and the effectiveness of the 
ICC procedure. 
Following hormone-therapy (HT) and combined hormone-therapy and immunotherapy (HT+ 
IT) of the MCF-7 cells, double-labelling with MUC1 and ERα, or MUC1 and PR was 
conducted. The ERα and PR proteins were visualised with the Alexa Fluor 488 antibody 
producing a green fluorescence. The MUC1 protein was visualised using the Alexa Fluor 594 
antibody, producing a red fluorescence. The nuclei were visualised using DAPI, producing a 
blue fluorescence. Fluorescence was captured individually as grayscale images and colour 
images generated thereafter. For qualitative analysis colour images were overlaid to show 
fluorescence in both the nuclear and cytoplasmic compartments. Where either PR or ERα 
localisation (green) overlapped the DAPI-stained nucleus (blue), a lighter blue-green nucleus 
was noted. For quantitative analysis, images were analysed with CellProfiler using a pipeline 
that determined the mean fluorescence intensity (MFI) of each immunolocalised protein for the 
nucleus and the cytoplasm separately. 
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The Effects of Hormone-Therapy and Combined Therapy on PR Immunolocalisation 
For all controls and treatments performed on the MCF-7 cells, it was observed that there were 
more cells exhibiting a polygonal morphology as opposed to mesenchymal morphology. Cells 
exhibiting the mesenchymal morphology presented a high nuclear and cytoplasmic fluorescent 
intensity (Figure 3.5) while the polygonal-shaped cells vary in PR intensity between the 
nucleus and cytoplasm, depending on control and treatment groups. 
PR is visible in both the cytoplasm and the nucleus of the cells in all control groups and 
treatment groups. The Media B control (cell cycle synchronisation media) induced the highest 
cytoplasmic PR fluorescent intensity (Figure 3.5A) compared to cells in the dDMSO control 
group and EP control group. The latter control groups demonstrated an increase in PR 
fluorescent intensity in the majority of cell nuclei (Figure 3.5B, C). Increased PR nuclear 
expression is noted where overlap between the DAPI (blue fluorescence) and Alexa Fluor 488 
(green fluorescence) results in a lighter blue region (Figure 3.5B). Within these control groups, 
cells treated with Media B exhibited the highest cytoplasmic fluorescent intensity and the cells 
treated with hormones (EP) exhibited notable reduction in cytoplasmic PR expression. In the 
majority of the cells analysed for all the treatments, high nuclear expression was observed in 
the more mesenchymal-like cells and high perinuclear expression in the more polygonal cells; 
however, this may be a function of cell shape and size. 
Cells in the hormone-therapy (HT) groups (ANAS, RU486, EPA and EPR) all exhibited 
differing levels of cellular PR localisation between treatment groups (Figure 3.6).  All HT 
simulations induced a high fluorescent intensity in the nucleus as indicated by the light blue-
green colour (Figure 3.5) due to obscuring of the DAPI stain. Cells treated with Anastrozole 
(ANAS), exhibited low PR cytoplasmic intensity with a higher nuclear presence (Figure 3.6, A) 
compared to the diluent control (Figure 3.5C). With the addition of hormones, no variation in 
cytoplasmic intensity was discernible in EPA treated cells as compared to those treated with 
Anastrozole alone (Figures 3.6A, C). Cells treated with RU486 showed a high fluorescent 
intensity in the perinuclear area as well as the nucleus (Figures 3.6B). However, EPR treatment 
induced a reduction in cytoplasmic fluorescent intensity compared to treatment with RU486 
alone (Figures 3.6D).  Notably, in all treatment groups with the exception of RU486, 
cytoplasmic PR staining appeared reduced compared to the Media B and dDMSO controls 
(Figure 3.5).  
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Cells in the hormone-therapy and immunotherapy (HT+IT) groups (ANAS+NK, RU486+NK, 
EPA+NK and EPR+NK) also exhibited variations in PR fluorescent intensity (Figure 3.7), with 
notable nuclear PR fluorescence. The ANAS+NK treated cells exhibited low cytoplasmic 
fluorescent intensity with variable fluorescent intensity of the nucleus (Figure 3.7A). The 
RU486+NK treatment induced a slight increase in nuclear fluorescent intensity as compared to 
the cytoplasm (Figure 3.7B); however, overall PR fluorescent intensity was remarkably low 
compared to all HT+IT groups. The EPA+NK and EPR+NK treatments induced an 
intermediate to high cytoplasmic PR fluorescent intensity with a high intensity in the nucleus 
(Figure 3.7C, D) compared to both hormone-therapy dugs alone (ANAS+NK; RU486+NK).  
When comparing the HT to the HT+IT treatment groups, Anastrozole alone (ANAS) and with 
hormones (EPA) induced a higher fluorescent intensity in the perinuclear region as opposed to 
the nucleus in cells as in the respective immunotherapy groups (Figures 3.6A, C; Figures 3.7A, 
C). Cells in the EPR and EPR+NK groups responded similarly, with a low cytoplasmic PR 
fluorescent intensity and higher nuclear fluorescent intensity (Figure 3.6D; Figure 3.7D). 
Conversely, there was a higher fluorescent intensity in cells treated with RU486 alone 
compared to RU486-treated cells cultured with NK cells (Figure 3.6B, Figure 3.7B). 
Qualitative assessment thus indicates that PR fluorescent intensity and localisation varies with 
treatment, notably being under considerable influence from RU486. Moreover the definitive 
reduction in cytoplasmic PR fluorescence with the addition of NK cells to RU486-treated cells 
indicates that cells may modulate their PR expression not only to treatment but to immune 
influence as well.  
 
 
 
 
   
 
 
A B C 
Figure 3.5. Representative photomicrographs showing the effects of control treatments on PR expression in MCF-7 cells 
Control treatment groups: A: Media B. B: EP. C: dDMSO. Fluorescent microscopy, 40x magnification. A: Media B treatment results in high cytoplasmic PR intensity 
with a comparative increase in intensity in the perinuclear region (arrow). B: EP treated cells exhibit overall low PR intensity expression with an increased intensity 
(compared to the cytoplasm) in the nucleus (arrowhead) and additionally increased intensity in the perinuclear area in a few cells (arrow). C:  The DMSO diluent control 
induced a high nuclear fluorescent intensity with an intermediate cytoplasmic intensity in the more polygonal cells (white arrow) and a high cytoplasmic intensity in the more 
mesenchymal-like cells (arrowhead), and a few cells demonstrate a higher intensity in the perinuclear area (grey arrow). 
4
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Figure 3.6. Representative photomicrographs showing the effects of hormone-therapy on PR expression in 
MCF-7 cells 
Treatment groups: A: ANAS. B: RU486. C: EPA. D: EPR. Fluorescent microscopy, 40x magnification. A: The 
cells treated with ANAS exhibited a low PR cytoplasmic intensity (arrowhead) and higher nuclear intensity 
(arrow). B: RU486 induced a high nuclear PR fluorescent intensity in most of the cells, with a lower intensity in a 
few cells (arrow) as well as an increased PR concentration in the perinuclear region in some cells (arrowhead). C: 
EPA treated cells show a low cytoplasmic PR fluorescent intensity, with a higher nuclear and perinuclear 
fluorescent intensity (arrow). D: The EPR treatment induced a low cytoplasmic fluorescent intensity and a 
comparatively higher nuclear fluorescent intensity (arrow). 
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Figure 3.7. Representative photomicrographs showing the effects of combined hormone-therapy and 
immunotherapy on PR expression in MCF-7 cells 
Treatment groups: A: ANAS+NK. B: RU486+NK. C: EPA+NK. D: EPR+NK. Fluorescent microscopy, 20x 
magnification (digitally magnified a quarter of the image). A: The majority of cells in the ANAS+NK treatment 
group show a low to intermediate nuclear fluorescent intensity (arrow), with a few cells displaying high nuclear 
fluorescent intensity (arrowhead). There is also a low cytoplasmic PR fluorescent intensity in the cells. B: 
RU486+NK treatment induced a very low fluorescent intensity of PR in both the nucleus and the cytoplasm. C: 
The EPA+NK treatment induced a high PR intensity in the nucleus of some cells (arrowhead), and a low to 
intermediate intensity in the majority of the cells (arrow). There is also a low to intermediate PR fluorescent 
intensity in the cytoplasm of the cells. D: Cells treated with EPR+NK exhibit a low to intermediate nuclear 
fluorescent intensity in the majority of the cells (arrow), and a few cells with a high nuclear fluorescent intensity 
(arrowhead). An intermediate cytoplasmic intensity is also seen with this treatment. 
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Images were then analysed further using CellProfiler. For quantitative analysis of PR 
expression, the normality tests Shapiro-Wilk, Jarque-Bera and Chi
2
 were first performed on the 
data produced by CellProfiler, with significance set at p=0.05. These include total cellular 
expression, nuclear expression and cytoplasmic expression. Most of the data sets were not 
normally distributed (p<0.05) (Appendix D, Table D2) thus the non-parametric Kruskal-Wallis 
one-way analysis of variance was used to compare each data set and pairwise comparisons 
were performed between and within the data sets with the Mann-Whitney test, with 
significance for both set at p<0.001 (Appendix D, Tables D3-D6).  
When assessing PR expression in the control treatment groups, considerable variation was 
noted. The DMSO diluent control (dDMSO) induced a significant increase (p<0.001) in PR 
mean fluorescent intensity (MFI) as compared to the Media B control in both the nucleus and 
cytoplasm (Figure 3.8). This indicates that DMSO, even as a diluent, has an effect on PR 
expression. The EP hormone control induced a nuclear and cytoplasmic PR MFI that was 
significantly decreased (p<0.001) to that of both other controls. Across all the control groups 
(Media B, dDMSO and EP), there was a significant increase (p<0.001) in PR MFI in the 
nucleus compared to the cytoplasm. These results bear out qualitative observations; however, 
quantitative analysis indicates that nuclear expression in the EP group is significantly reduced 
compared to the Media B control group which contradicts qualitative observations (Figure 
3.5A, B).  
Importantly, since hormones and drugs were all dissolved in DMSO, to isolate their effects 
from that of the DMSO diluent, all subsequent data analysis of the effects of hormone-therapy, 
and combined hormone-therapy and immunotherapy on biomarker expression used the 
dDMSO control instead of the Media B control as the comparator group. The EP control group 
remained as an additional hormone control group for combined hormone and drug treatments 
(EPA and EPR). Furthermore, in addition to these controls when comparing the effects of 
hormone therapy alone against hormone-therapy and immunotherapy, the additional control 
comparator groups, dDMSO+NK and EP+NK, were also employed. 
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The Effects of Anastrozole on PR MFI 
Firstly, differences between nuclear and cytoplasmic PR expression was assessed within each 
treatment group. Treatment with Anastrozole (ANAS) showed no significant difference in PR 
MFI between the nuclear and cytoplasmic compartments (Appendix D, Table D3). However, 
with the addition of hormones (EPA) or NK cells with and without hormones (ANAS+NK, 
EPA+NK) there was a distinct reduction in PR cytoplasmic localisation with a corresponding 
increase in nuclear localisation (p<0.001) (Appendix D, Tables D1, D3 and D4). These results 
are borne out by the qualitative observations (Figure 3.5 - Figure 3.7); however, the quantitative 
results highlight shifts in expression more accurately between nuclear and cytoplasmic 
compartments within treatment groups.  
When comparing Anastrozole-induced changes in overall MFI to the dDMSO control, 
Anastrozole alone (ANAS) caused a significant decrease in both nuclear and cytoplasmic PR 
MFI (Figure 3.9). The reduction in cytoplasmic PR staining was easier to visualise compared to 
nuclear alterations (Figure 3.5C, Figure 3.6A). The quantitative reduction in PR cytoplasmic 
MFI was mimicked with the addition of hormones (EPA) (Figure 3.9) with respect to the 
diluent control (dDMSO), the hormone control (EP) and Anastrozole treatment itself (ANAS). 
However, visually this was difficult to interpret with fluorescent images alone (Figure 3.5, 
Figure 3.6). The quantitative results clearly portray that within a hormonal environment 
Anastrozole reduces PR expression, more so that Anastrozole treatment alone.  
With the addition of immunotherapy (combined hormone-therapy and immunotherapy) (Figure 
3.10), Anastrozole (ANAS+NK) remained significantly reduced (p<0.001) compared to the 
diluent control (dDMSO) in both nuclear and cytoplasmic PR expression. These results confirm 
qualitative observations (Figure 3.5C, Figure 3.7A). The addition of hormones (EPA+NK) 
reflected the same trend both quantitatively (Figure 3.10) and qualitatively (Figure 3.5C, Figure 
3.7C). This PR MFI is further significantly reduced compared with the hormone control (EP). 
Compared to Anastrozole itself (ANAS+NK), the PR MFI was significantly increased in the 
nuclear compartment, and decreased in the cytoplasmic compartment in the EPA+NK group 
(Figure 3.10). This suggests that NK mediation of hormone-therapy differentially affects 
cellular compartments. It is only with comparison of hormone-therapy alone and combined 
hormone-therapy and immunotherapy that the full picture emerges. 
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Thus the PR MFI between hormone-therapy and combined hormone-therapy and 
immunotherapy was compared. It was noted that NK cell mediation significantly reduced PR 
expression in both the DMSO (dDMSO vs dDMSO+NK) and EP controls (EP vs EP+NK)  
(Figure 3.11).When Anastrozole, either with hormones (EPA) or without (ANAS), was 
compared to its counterpart with NK cells (EPA+NK, ANAS+NK), it was found that NK cell 
interaction caused a significant decrease (p<0.001) in PR MFI in both the nucleus and the 
cytoplasm (Figure 3.11). This was also noted qualitatively (Figure 3.7). These results highlight 
that combined Anastrozole hormone-therapy with immunotherapy induces decreased PR 
cellular expression, as compared with hormone-therapy alone.  
 
The Effects of RU486 on PR MFI 
We first assessed nuclear and cytoplasmic PR alterations within each treatment group. RU486 
alone showed no variable influence on nuclear compared to cytoplasmic expression of PR 
(p<0.001) (Appendix D, Table D3). With continued hormonal influence (EPR), a comparative 
increase in nuclear PR expression (p<0.001) was induced (Appendix D, Table D3), which was 
also noted visually (Figure 6B, D). With the combination of immunotherapy, a significant 
decrease in nuclear PR MFI (p<0.001) compared to the cytoplasm was noted in the 
RU486+NK group (Appendix D, Table D1, D3), corresponding to qualitative analyses (Figure 
3.7). With hormonal influences, the addition of NK cells to RU486-treated cells (EPR+NK) 
resulted in higher nuclear expression comparatively (p<0.001) (Appendix D, Table D1, D4). 
This indicates that NK cell influence may cause MCF-7 cells to mediate PR translocation 
between cytoplasmic and nuclear compartments.  
When RU486 treatment groups were analysed in relation to the baseline dDMSO control, it 
was found that RU486 alone induced a significant reduction in both nuclear and cytoplasmic 
PR expression (Figure 3.9). Conversely, the addition of a hormonal treatment (EPR) revealed 
increased PR MFI in both cellular compartments (p<0.001) in comparison to both the diluent 
control (dDMSO), the hormone control (EP), and RU486 treatment alone (Figure 3.9).  These 
results were difficult to correlate with qualitative observations (Figure 3.5, Figure 3.6). 
However, the quantitative results indicate that RU486 in a hormonal environment significantly 
increases PR expression, an action in direct opposition to that of Anastrozole treatment.  
Notably, the PR MFI was much higher in the nucleus in the EPR group compared to all other 
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treatment groups (Figure 3.9), which corresponded with visual observations of dense green 
fluorescent staining within the nucleus (Figure 3.6D).  
Within the combined hormone-therapy and immunotherapy treatment, NK cell mediation of 
RU486 function (RU486+NK) was shown to reduce (p<0.001) PR nuclear and cytoplasmic 
expression compared to the diluent control (dDMSO) (Figure 3.10). This reduction was distinct 
and could be assessed visually (Figure 3.5B, Figure 3.7B). With additional hormones 
(EPR+NK), PR MFI showed a significant reduction in both cellular compartments when 
compared with the diluent control and the hormone control (EP) (Figure 3.10). Qualitatively, 
the EPR+NK treatment group had distinct nuclear and cytoplasmic PR localisation (Figure 
3.7D), which appeared greatly reduced compared to the diluent control, and only marginally 
different to the hormone control (EP) (Figure 3.5). Notably, in comparison to RU486 alone, 
EPR+NK induced a significant decrease in cytoplasmic PR MFI, with the converse evident in 
the nucleus. This result echoes that seen in the effects of Anastrozole, with and without 
hormonal stimuli but under NK cell mediation, further indicating that NK cells may mediate 
the action of hormone-therapy drugs on PR expression. 
We thereafter compared the effects of hormone-therapy alone to combined hormone-therapy 
and immunotherapy (Figure 3.11) on PR expression. It was noted that the addition of NK cells 
to the culture system, whether under hormonal influence or not (RU486+NK and EPR +NK) 
induced a significant decrease in PR MFI in both the nucleus and the cytoplasm (Figure 3.11), 
corresponding with visual observations (Figure 3.5 – Figure 3.7). These results reflect that 
while RU486 modulation of PR appears dependent on the hormonal environment, as evidenced 
by the large nuclear and cytoplasmic increase in PR expression in the hormone-therapy group, 
NK cell-mediation of cancer cells may allow RU486 to function independently of hormonal 
influences, as evidenced by the great reduction in PR expression.  
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Figure 3.8. A bar graph showing the nuclear and cytoplasmic PR MFI for the control treatments 
Nuclear expression of PR was consistently higher than cytoplasmic expression in all control treatment groups. 
Cells treated with diluent alone (dDMSO) exhibited a higher PR MFI in both the nucleus and cytoplasm 
(p<0.001) compared to the Media B control. The hormone control (EP) induced a significant reduction in 
nuclear and cytoplasmic PR MFI (p<0.001) compared to the Media B control.  Given that all drugs and 
hormones were reconstituted in DMSO, the dDMSO control group was used as comparator group instead of 
the Media B control for all subsequent analyses. 
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Figure 3.9. A bar graph showing the nuclear and cytoplasmic PR MFI for the control and hormone-therapy 
treatments  
Treatment with EP, ANAS, RU486 and EPA induced a significant decrease (p<0.001) in PR MFI in the nucleus 
and cytoplasm, whereas EPR induced a significant increase (p<0.001) in both compartments as compared to the 
dDMSO control group. When compared to the hormone control (EP), the addition of hormones to Anastrozole-
treated cells (EPA) induced a significant decrease in PR MFI and a conversely large increase in PR MFI in 
RU486-treated cells (EPR) in the nucleus and cytoplasm. The addition of hormones (EPA) resulted in a significant 
decrease in PR MFI compared to Anastrozole alone, and a significant increase in PR MFI compared to RU486 
alone, in both cellular compartments. This indicates that hormones may differentially affect PR expression 
depending on the type of hormone-therapy used. 
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Figure 3.10. A bar graph showing the nuclear and cytoplasmic PR MFI for the control and combined 
hormone-therapy with immunotherapy treatments.  
With combined hormone-therapy and immunotherapy, Anastrozole treatment (ANAS+NK) and RU486 treatment 
(RU486+NK) resulted in a significant decrease (p<0.001) in PR expression in both nuclear and cytoplasmic 
compartments compared to the diluent control (dDMS0). With the addition of hormones to these treatment groups 
(EPA+NK, EPR+NK), PR expression remained significantly reduced (p<0.001) compared to both the diluent 
control and hormone control (EP). However, compared to matched samples without hormonal stimuli 
(ANAS+NK, RU486+NK), the addition of hormones, further increased (p<0.001) nuclear PR MFI and decreased 
cytoplasmic PR MFI (p<0.001). 
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Figure 3.11. Bar graphs showing the cytoplasmic and nuclear PR MFI for the hormone-therapy compared 
to the combined hormone-therapy with immunotherapy treatments 
A: Cytoplasmic PR MFI. B: Nuclear PR MFI. The addition of NK cells (HT+IT, red bars) resulted in a significant 
decrease in overall PR MFI (p<0.001) for controls (dDMSO vs dDMSO+NK, EP vs EP+NK) and treatments, 
compared to hormone-therapy alone (HT, orange bars). The highest MFI occurs in EPR versus EPR+NK 
treatments, indicating that RU486 modulation of PR expression is greatly affected by the hormonal milieu and NK 
cell influence. This trend, albeit with lower MFI in both nuclear and cytoplasmic compartments, was noted for 
Anastrozole treatments as well. 
52 
 
 
 
The Effects of Hormone-Therapy and Combined Therapy on ERα Immunolocalisation 
ERα is visible in both the cytoplasm and the nucleus of the MCF-7 cells in all control groups 
and treatment groups. The Media B control cells exhibited, in the majority of the cells, an 
intermediate ERα cytoplasmic fluorescent intensity with a few cells exhibiting a high 
cytoplasmic fluorescent intensity (Figure 3.12A). The EP control induced a very low 
cytoplasmic fluorescent intensity, almost indistinguishable, with putative nuclear ERα 
localisation as evinced by some light blue staining due to green fluorescence (Alexa Fluor 488) 
overlap with DAPI (Figure 3.12B). Conversely, cells in the DMSO diluent control show an 
intermediate to high cytoplasmic fluorescent intensity, primarily in the perinuclear region, with 
a high nuclear fluorescent intensity (Figure 3.12C).  
ERα expression was noted in the cytoplasm and nucleus of all the hormone-therapy (HT) 
treatment groups (ANAS, RU486, EPA and EPR). Specifically, compared to the Media B and 
dDMSO controls (Figure 3.12A, C) an intermediate level of cytoplasmic fluorescence (green) 
was noted in cells treated with Anastrozole and RU486 (Figure 3.13A, B). It appeared, by the 
light blue nuclear stain, that the RU486-treated cells demonstrated a higher nuclear ERα 
localisation compared to all other HT treatments (Figure 3.13). Cells in this treatment group 
also displayed distinct perinuclear ERα presence. Compared to the hormone control (EP) 
(Figure 3.12B), cells treated with combined hormones and hormone-therapy drugs (EPA, EPR) 
showed marginally higher cytoplasmic fluorescent intensity (Figure 3.13C, D). However, in 
comparison to Anastrozole alone (ANAS), and RU486 alone (RU486) (Figure 13A, B), 
matched samples with hormonal treatment (EPA, EPR) showed lower cytoplasmic 
fluorescence. Nuclear localisation was difficult to determine overall in EPA and EPR treated 
cells, with only a few cells exhibiting a high nuclear fluorescent intensity (Figure 3.13C, D). 
With NK cell co-culture, the combined hormone-therapy and immunotherapy (HT+IT) 
treatments (ANAS+NK, RU486+NK, EPA+NK and EPR+NK) induced an overall intermediate 
cytoplasmic fluorescent intensity. While again difficult to determine, cells in the ANAS+NK 
appeared to exhibit more nuclear ERα localisation (Figure 3.14A) compared to those cells in 
the RU486+NK group, which demonstrated higher cytoplasmic expression (Figure 3.14B).The 
addition of hormones resulted in a noticeable increase in cytoplasmic fluorescence in both the 
EPA+NK and EPR+NK treatment groups (Figure 3.14C, D) when compared to matched 
samples in the HT group alone (EPA and EPR) without NK influence (Figure 3.13C, D)  This 
may indicate that under NK influence MCF-7 cells increase ERα expression.  
 
 
 
 
  
   
 
 
 
 
 
A B C 
Figure 3.12. Representative photomicrographs showing the effects of control treatments on ERα expression in MCF-7 cells 
Control treatment groups: A: Media B. B: EP. C: dDMSO. Fluorescent microscopy, 40x magnification. A: Media B treatment results in an intermediate cytoplasmic 
expression (green) with an increase in intensity in the nucleus (arrow, light blue). B: EP treated cells exhibited an overall very low ERα intensity expression with some cells 
displaying possible nuclear expression (arrow, light blue) C:  The DMSO diluent control induced an intermediate cytoplasmic fluorescent intensity (arrowhead) with a high 
nuclear and perinuclear fluorescent intensity (arrow). 
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A B 
C D 
Figure 3.13. Representative photomicrographs showing the effects of hormone-therapy on ERα expression 
in MCF-7 cells 
Treatment groups: A: ANAS B: RU486. Fluorescent microscopy, 20x magnification C: EPA D: EPR. 
Fluorescent microscopy, 40x magnification. A: The cells treated with Anastrozole showed intermediate levels of 
ERα localisation (green) in the cytoplasm. Some nuclei appear to show higher nuclear fluorescent intensity (arrow, 
light blue)). B: RU486 treatment induced a high fluorescent intensity in the perinuclear region (arrow) and 
cytoplasm.  Light blue nuclei indicated a preponderance of ERα expression. C: Cells in the EPA group show low 
cytoplasmic ERα fluorescent intensity, with few cells demonstrating higher nuclear fluorescent intensity (arrow). 
D: The EPR group exhibited a low cytoplasmic fluorescent intensity with few cells showing a high nuclear 
fluorescent intensity (arrow). 
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Figure 3.14. Representative photomicrographs showing the effects of combined hormone-therapy and 
immunotherapy on ERα expression in MCF-7 cells 
Treatment groups: A: ANAS+NK B: RU486+NK C: EPA+NK D: EPR+NK. Fluorescent microscopy, 20x 
magnification (digitally magnified a quarter of the image). A: The ANAS+NK treated cells shows a majority 
displaying an intermediate ERα cytoplasmic fluorescent intensity (arrow, green). B:  Cells in the RU486+NK 
group exhibited a higher cytoplasmic fluorescent intensity with few cells showing high nuclear ERα expression 
(arrow, light blue). C: Cells in the EPA+NK treatment group showed a higher fluorescent intensity in the 
cytoplasm (arrow). D: Cells in the EPR+NK group showed a high nuclear fluorescent intensity in the majority of 
the cells (arrow, light blue), and a high cytoplasmic fluorescent intensity. 
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Images were thereafter analysed quantitatively using CellProfiler. The normality tests Shapiro-
Wilk, Jarque-Bera and Chi
2
 were performed on the data produced by CellProfiler, with 
significance set at p=0.001. These include total cellular expression, nuclear expression and 
cytoplasmic expression. Most of the data sets were not normally distributed (p<0.001) (see 
Appendix D, Table D8) thus the non-parametric Kruskal-Wallis one-way analysis of variance 
was used to compare each data set and pairwise comparisons were performed between and 
within the data sets with the Mann-Whitney test, with significance for both set at p=0.001 
(Appendix D, Tables D9-D12). 
Control treatments were first assessed to investigate whether ERα expression varied. Compared 
to the Media B control, the DMSO diluent control (dDMSO) and hormone control (EP) 
induced a significant decrease (p<0.001) in ERα mean fluorescent intensity (MFI) in both the 
nucleus and cytoplasm (Figure 3.15). While qualitative analysis confirmed this reduction in the 
EP group, this was not readily discernible in the dDMSO group (Figure 3.12). Importantly, this 
indicates that the diluent DMSO has an effect on ERα expression. As the hormones and drugs 
were all dissolved in DMSO, to isolate their effects from that of the DMSO, treatments 
(including the EP hormone control) were compared to the dDMSO control instead of the Media 
B control. In both areas of the cell the EP hormone control induced a significantly decreased 
(p<0.001) ERα MFI compared to that of the dDMSO control (Appendix D, Tables D7, D9). 
This result was also observed visually (Figure 3.12). The EP control group remained as an 
additional hormone control group for combined hormone and drug treatments (EPA and EPR). 
Furthermore, in addition to these controls when comparing the effects of hormone therapy 
alone against hormone-therapy and immunotherapy, the additional control comparator groups, 
dDMSO+NK and EP+NK, were also employed. 
Across the control groups (Media B, dDMSO and EP) there was a significant increase 
(p<0.001) in ERα mean fluorescent intensity (MFI) in the nucleus as compared to the 
cytoplasm (Appendix D, Tables D7, D9). While a lighter blue nucleus is associated with ERα 
localisation, due to the overlap between the green Alexa Fluor 488 and the blue DAPI stain, 
nuclear localisation was difficult to assess with a degree of accuracy qualitatively (Figure 3.12).   
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The Effects of Anastrozole on ERα MFI 
We firstly determined whether ERα expression varied between nuclear and cytoplasmic 
compartments within treatment groups. It was found that nuclear fluorescent intensity was 
significantly higher (p<0.001) compared to the cytoplasmic compartment whether in all 
hormone-therapy treatment groups whether under immune-mediation or not (Appendix D, 
Tables D7, D9, D10). This was difficult to discern visually (Figure 3.13, Figure 3.14).  
The effects of hormone-therapy treatments on ERα expression were thereafter investigated. 
When compared to the diluent DMSO control, Anastrozole treatment induced a significant 
increase (p<0.001) in cytoplasmic ERα MFI and a conversely significant decrease (p<0.001) in 
nuclear MFI (Figure 3.16). With the addition of hormones (EPA), compared to the hormone 
control (EP) there was a significant increase in ERα MFI (Figure 3.16). However, when this 
group (EPA) was compared to the diluent control, and more importantly to Anastrozole 
treatment alone (ANAS), there was a significant decrease in ERα MFI in both cellular 
compartments (Figure 3.16). Visually, this was discernible particularly with regard to the 
cytoplasm (Figures 3.12, 3.13). The results indicate in a hormonal environment, Anastrozole 
treatment reduces overall ERα expression. 
When NK cells were added (combined hormone-therapy and immunothreapy treatments), 
Anastrozole with hormones (EPA+NK) and without (ANAS+NK) significantly decreased 
(p<0.001) ERα MFI in the nuclear compartment compared to the dDMSO control (Figure 
3.17). However, the aforementioned groups also showed a significant increase (p<0.001) in the 
cytoplasmic compartment compared to the diluent control. When compared to the hormone 
control, the EPA+NK group evidenced a significant increase in both nuclear and cytoplsmic 
ERα MFI (Figure 3.17). This was mimicked in comparison with the effects of Anastrozole 
alone under NK mediation (ANAS+NK). While qualitative analysis bears out these results, it 
remains that nuclear localisation was difficult to assess visually (Figure 3.12, Figure 3.14) with 
more accurate results emanating from the quantitative assessment. Furthermore, quantitative 
asssesment shows that NK cell mediation under hormonal influence, results in Anastrozole 
effectively inducing an increase in ERα expression. 
Comparing the effectiveness of hormone-therapy to combined hormone-therapy and 
immunotherapy (Figure 3.18), it was noted that immune mediation significantly reduced 
(p<0.001) the overall ERα MFI in the dDMSO control (dDMSO vs dDMSO+NK), and 
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Anastrazole group (ANAS vs ANAS+NK). Conversely, NK cell presence resulted in a 
significant increase (p<0.001) in overall ERα MFI in the hormone control group (EP vs 
EP+NK), which was mimicked in the EPA group as well. These results indicate that NK cells 
mediate the expression of  ERα by MCF-7 cells depending on the hormonal environment.  
The Effects of RU486 on ERα MFI 
Assessment of ERα expression in the nuclear and cytoplasmic compartments, within treatment 
groups was first conducted. Within the RU486 alone treatment group (RU486), no significant 
diffference (p>0.001) was found between ERα in the nucleus and cytoplasm (Appendix D, 
Tables D7, D9). However, under continued hormonal influence (EPR) and under NK cell 
mediation (RU486+NK, EPR+NK) ERα expression significantly increased in the nucleus as 
opposed to the cytoplasm (Appendix D, Tables D7, and D10). Qualitatively, the reduction in 
cytoplasmic ERα expression was noted in the EPR group (Figure 3.13D); however, differencs 
between the cytoplasmic and nuclear expression of ERα were more difficult to discern 
accurately in the RU486+NK and EPR+NK groups (Figure 3.14B, D).  
When the eefcts of hormone-therapy treatments were assessed, it was found that compared to 
the dDMSO control, RU486 treatment induced a significant increase (p<0.001) in ERα MFI in 
the cytoplasm; however, there was no significant difference detected in the nucleus (p>0.001) 
(Figure 3.16). With the addition of hormones (EPR) there was a significant decrease in ERα 
MFI when compared to the diluent control, and RU486 treatment alone (Figure 3.16). 
However, when compared to the hormone EP control, the EPR group showed a significant 
increase (p<0.001) in ERα MFI. These results were comparable with qualitative observations 
with marked reduction in both celullar compartments compared to RU486 alone (Figure 3.12C, 
Figure 3.13B, D). This indicates that the addition of hormones affects RU486 modulation of 
ERα expression, specifically effecting a decrease in expression compared to RU486 alone, 
comparable to the results seen with Anastrozole treatment. 
The combination of the RU486 hormone-therapy with NK cell immunotherapy showed a 
significant decrease (p<0.001) in nuclear ERα MFI and significant increase (p<0.001) in 
cytoplasmic MFI when compared to the dDMSO control (Figure 3.17). These results mimicked 
the qualitative observations (Figure 3.12C, Figure 3.14B). With the addition of hormones, 
RU486 action resulted in a significant increase (p<0.001) in MFI compared to both the EP 
hormone control and RU486 alone (RU486+NK), in both the nuclear and cytoplasmic 
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compartments (Figure 3.17). The results indicate that in a hormonal environment under the 
influence of NK cell mediation, RU486 action results in greater expression of ERα.This result 
echoes that of Anastrozole treatment under NK cell and hormonal mediation. 
We further compared the effects of hormone-therapy and combined hormone-therapy and 
immunotherapy on ERα expression. It was noted that NK cell mediation significantly reduced 
ERα MFI in the dDMSO control (dDMSO vs dDMSO+NK) (Figure 3.18). Interestingly the 
reverse was identified in the EP control group with NK cell incubation inducing an increase in 
ERα MFI (Figure 3.18). RU486 alone induced the highest ERα expression in both  nuclear and 
cytoplasmic compartments. However, with the addition of immunotherapy (RU486+NK), 
expression in both compartments was significantly reduced (p<0.001) (Figure3.18). 
Conversely, with the addition of hormones (EPR), immunotherapy (EPR+NK) induced a 
significant increase in ERα MFI. These results indicate that RU486 functions in modulation of 
ERα and that this modulation may be affected by hormonal and immune influences.Specifically 
the addition of NK cells, ameriolates the reduction of ERα expression by the addition of 
hormones to RU486 treatment. 
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Figure 3.15. A bar graph showing the nuclear and cytoplasmic ERα MFI for the control treatments 
In all control groups nuclear ERα expression was higher than that of the cytoplasm. The dDMSO control and EP 
control showed a significantly decreased ERα MFI (p<0.001) compared to the Media B control for both the 
nucleus and the cytoplasm. Since all drugs and hormones were reconstituted in DMSO, the dDMSO control group 
was used as comparator group instead of the Media B control for all subsequent analyses. 
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Figure 3.16. A bar graph showing the nuclear and cytoplasmic ERα MFI for the control and hormone-
therapy treatments  
Anastrozole treatment induced a significant decrease (p<0.0001) in nuclear ERα MFI and a converse significant 
increase in cytoplasmic ERα MFI compared to the diluent control (dDMSO). RU486-treated cells exhibited a 
higher nuclear ERα MFI with only cytoplasmic expression being significantly higher to that of the diluent control. 
Under hormonal stimulation, Anastrozole-induced (EPA) and RU486-induced (EPR) ERα MFI nuclear and 
cytoplasmic intensity was significantly increased compared to the hormone control (EP); however, ER MFI in 
both groups was decreased (p<0.001) compared to the diluent control and each hormone-therapy drug alone 
(ANAS, RU486) in both cellular compartments. This indicates that the presence of hormones modulate the 
function of Anastrozole and RU486 in mediation of ERα expression. 
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Figure 3.17. A bar graph showing the nuclear and cytoplasmic ERα MFI for the control and combined 
hormone-therapy with immunotherapy treatments 
Under immune-mediation, Anastrozole and RU486 induced a significant decrease in nuclear ERα and a significant 
increase in cytoplasmic ERα whether alone (ANAS+NK, RU486+NK) or with hormonal influence (EPA+NK, 
EPR+NK) compared to the diluent control (dDMSO). However, EPA and EPR caused a significant increase in 
MFI in both the cytoplasm and the nucleus when compared to the EP hormone control, and compared to matched 
samples that were not under hormonal influence (ANAS+NK, RU486+NK). This indicates that the action of 
hormone-therapy drugs may be modulated by the presence of hormones. 
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Figure 3.18. Bar graphs showing the cytoplasmic and nuclear ERα MFI for the hormone-therapy compared 
to the combined hormone-therapy with immunotherapy treatments 
A: Cytoplasm. B: Nucleus. In cells treated with the diluent DMSO, the addition of NK cell immunotherapy 
(HT+IT, red bars) induced a significant reduction (p<0.001) in ERα expression in both the nucleus and cytoplasm 
compared to hormone-therapy alone (HT, orange bars). Conversely in the hormone control (EP), NK cell 
mediation resulted in a significantly higher ERα MFI in both cellular compartments. For cells treated with 
Anastrozole and RU486 alone, immunotherapy showed a significant reduction (p<0.001) in fluorescence intensity 
in both the nucleus and the cytoplasm. However with the addition of hormones (EPA, EPR), the effects of the 
drugs was modulated and immunotherapy resulted in a significant increase in nuclear and cytoplasmic ERα MFI 
instead. 
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The Effects of Hormone-Therapy and Combined Therapy on MUC1 Immunolocalisation 
For all controls and treatments performed on the MCF-7 cells, it was observed that there were 
more polygonal cells than mesenchymal cells. Both the mesenchymal cells and the polygonal 
cells vary in MUC1 intensity. MUC1 is visible in both the cytoplasm (red fluorescence) and the 
nucleus of the cells in all control groups and treatment groups (Figure 3.19). MUC1 nuclear 
localisation is described as red/purple staining due to the overlap of Alexa Fluor 594 (red) with 
the blue DAPI nuclear stain. Cells in the Media B control, which was employed for cell cycle 
synchronisation, exhibited intermediate cytoplasmic fluorescent intensity with areas of high 
perinuclear intensity. MUC1 was noticeably localised to the nucleus, as seen by the more 
reddish purple stained nuclei, with areas of red spots (Figure 3.19A). Compared to the Media B 
control, the EP hormone control treatment induced a lower level of MUC1 fluorescence. 
Perinuclear staining was evident, with nuclei demonstrating regions of MUC1 staining 
(red/purple spots within the blue-stained nucleus) (Figure 3.19B). Conversely, the cells in the 
dDMSO control group showed an intermediate cytoplasmic MUC1 fluorescent intensity with 
prominent perinuclear staining. Nuclear MUC1 was also noted (Figure 3.19C). 
In the hormone-therapy (HT) groups (ANAS, RU486, EPA and EPR) MUC1 expression varied 
in intensity and localisation depending on treatment. Anastrozole and RU486 treated cells 
exhibited low to intermediate MUC1 cytoplasmic fluorescent intensity with a higher intensity 
in the perinuclear area and nucleus (Figure 3.20A, B). Cells treated with EPA show high 
cytoplasmic and nuclear fluorescent intensity (Figure 3.20C). EPR treated cells exhibited low 
to intermediate cytoplasmic intensity with an increased intensity in the perinuclear region 
(Figure 3.20D). The addition of hormones appeared to increase the intensity of MUC1 in 
comparison to use of hormone-therapy drugs alone. 
In the hormone-therapy and immunotherapy (HT+IT) groups (ANAS+NK, RU486+NK, 
EPA+NK and EPR+NK) cytoplasmic MUC1 intensity increased (Figure 3.21) compared to 
hormone-therapy alone (Figure 3.20). Cells in the ANAS+NK, RU486+NK and EPR treatment 
groups exhibited intermediate to high MUC1 fluorescence in both the nucleus and cytoplasm 
(Figure 3.21A, B, D). The EPA+NK group induced the highest cytoplasmic fluorescent 
intensity with an increased intensity in the perinuclear and nuclear regions (Figure 3.21C)
 
 
 
 
   
 
 
 
 
 
A B C 
Figure 3.19. Representative photomicrographs showing the effects of control treatments on MUC1 expression in MCF-7 cells 
Control treatment groups: A: Media B. B: EP. C: dDMSO. Fluorescent microscopy, 40x magnification. A: Media B treatment results in intermediate MUC1 cytoplasmic 
fluorescent intensity (red fluorescence) with the majority of cells reddish/purple stained nuclei indicative of MUC1 localisation (arrow, red/purple spots on blue DAPI-stained 
nuclei) and perinuclear fluorescent intensity (bright red fluorescence). B: EP treated cells exhibit overall intermediate MUC1 cytoplasmic fluorescent intensity with an increased 
intensity in the perinuclear region (arrow). C:  The DMSO diluent control induced an intermediate cytoplasmic fluorescent intensity with high intensity MUC1 in the perinuclear 
region (arrow). Nuclear MUC1 is seen as red spots with the blue-stained nuclei. 
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Figure 3.20. Representative photomicrographs showing the effects of hormone-therapy on MUC1 
expression in MCF-7 cells 
Treatment groups: A: ANAS B: RU486 C: EPA D: EPR. Fluorescent microscopy, 20x magnification. A: The 
cells treated with Anastrozole exhibited low to intermediate MUC1 cytoplasmic fluorescent intensity  (red) with 
higher perinuclear intensity (arrow, bright red) and defined nuclear fluorescence (red spots within the purple-
stained nucleus). B: The group treated with RU486 induced a low to intermediate cytoplasmic fluorescent 
intensity with an additionally increased perinuclear (arrow) and nuclear fluorescent intensity. C: EPA treated cells 
show a high cytoplasmic MUC1 fluorescent intensity, with a higher perinuclear fluorescent intensity (arrow). 
MUC1 localisation was high in the nucleus (reddish/purple nuclei). D: The EPR group induced a low to 
intermediate cytoplasmic intensity with an increased perinuclear (arrow) and nuclear intensity. 
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Figure 3.21. Representative photomicrographs showing the effects of combined hormone-therapy and 
immunotherapy on MUC1 expression in MCF-7 cells 
Treatment groups: A: ANAS+NK B: RU486+NK C: EPA+NK D: EPR+NK. Fluorescent microscopy, 20x 
magnification (zoomed in on a quarter of the image). A: The ANAS+NK treated cells showed intermediate to high 
MUC1 cytoplasmic intensity (red) with a comparatively higher nuclear fluorescent intensity (arrow, red spots in 
blue-stained nucleus). B: RU486+NK treatment induced intermediate to high MUC1 cytoplasmic fluorescent 
intensity with notable nuclear localisation. Some cells exhibited distinct perinuclear fluorescent intensity (arrow, 
bright red). C: The EPA+NK group induced the highest level of MUC1 cytoplasmic fluorescence, with MUC1 
evident in the nucleus (red spots) and increased nuclear, and perinuclear intensity (arrow). D: Cells treated with 
EPR+NK exhibit an intermediate to high cytoplasmic fluorescent intensity with a high nuclear fluorescent 
intensity in the majority of the cells (arrow). 
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Quantitative data was acquired from images using CellProfiler. The normality tests Shapiro-
Wilk, Jarque-Bera and Chi
2
 were performed on the data with significance set at p=0.05. These 
include overall, nuclear and cytoplasmic expression (Appendix D, Table D13). Most of the data 
sets were not normally distributed (p<0.05) (Appendix D, Table D14) thus the non-parametric 
Kruskal-Wallis one-way analysis of variance was used to compare each data set and pairwise 
comparisons were performed between and within the data sets with the Mann-Whitney test, 
with significance for both set at p=0.001 (Appendix D, Table D15-18). 
 
We first investigated whether MUC1 expression varied with control treatments. Compared to 
the Media B control, the DMSO diluent control (dDMSO) and the hormone control (EP) 
induced a significant decrease (p<0.001) in MUC1 mean fluorescent intensity (MFI) in the 
nucleus and the cytoplasm (Figure 3.22), which while noted in the qualitative assessment 
(Figure 3.19), was not discernible with a degree of accuracy visually particularly in the nucleus. 
Notably this result indicates that DMSO has an effect on MUC1 expression, as was noted for 
PR and ERα expression. Since the hormones and drugs were all dissolved in DMSO, to isolate 
their effects from that of the DMSO, for all ensuing analyses treatments were compared to the 
dDMSO control instead of the Media B control. The EP control was retained to determine the 
effects of the addition of hormones to the hormone-therapy treatments. Furthermore, where 
hormone-therapy (HT) was compared with combined hormone-therapy and immunotherapy 
(HT+IT), two additional controls were employed, dDMSO+NK and EP+NK.   
The effects of all treatments on the MUC1 nuclear and cytoplasmic expression was first 
assessed. For all controls and treatments, with the exception of RU486 in the hormone-therapy 
group, there was a significant increase (p<0.001) in mean fluorescent intensity (MFI) in the 
nucleus as compared to the cytoplasm (Appendix D, Tables D13, D15, D16). Visually this was 
not readily apparent despite nuclei being consistently reddish-purple, with prominent red spots 
indicating MUC1 localisation (Figure 3.19 - Figure 3.21). Quantitative results have shed more 
light on MUC1 compartmentalisation than was readily visualised. 
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The Effects of Anastrozole on MUC1 MFI 
Within the hormone-therapy treatment groups, Anastrozole treatment induced a significant 
increase (p<0.001) in MUC1 MFI compared to the dDMSO control in both nuclear and 
cytoplasmic compartments (Figure 3.23). However, this was not readily discernible 
qualitatively (Figures 3.19, 3.20).  The addition of hormones (EPA) resulted in a significant 
decrease (p<0.001) in MUC1 expression in both cellular compartments when compared to the 
dDMSO control and Anastrozole treatment only (ANAS). However, compared to the hormone 
control (EP), EPA induced a small, yet significant decrease (p<0.001) in cytoplasmic MUC1 
while marginally increasing (p<0.001) nuclear expression (Figure 3.23). This directly 
contradicts the visual assessment of MUC1 which appeared to exhibit high nuclear and 
cytoplasmic fluorescence, more so than either the diluent or the hormone control (Figure 3.19, 
Figure 3.20). However, given the large data set obtained quantitatively, it is suggested that the 
quantitative assessment is more reliable than subjective visual assessment. Furthermore, it is 
clear that under hormonal stimuli, the action of Anastrozole in increasing MUC1 expression is 
severely inhibited.  
With the addition of NK cells, treatment with Anastrozole (ANAS+NK) or with hormones 
(EPA+NK) induced a significant decrease (p<0.001) in MUC1 cytoplasmic and nuclear MFI 
compared to the dDMSO control (Figure 3.24). The addition of hormones (EPA+NK) resulted 
in significantly higher cytoplasmic and nuclear fluorescence compared to Anastrozole 
(ANAS+NK) and the EP hormone control (Figure 3.24). This was evident in qualitative 
observations (Figures 3.19, 3.21). These results indicate that MUC1 expression may be 
mediated by NK cells as well as the hormonal milieu. 
To further investigate the results, we compared hormone-therapy with combined hormone-
therapy and immunotherapy (Figure 3.25). It was noted that NK cell mediation (HT+IT), 
resulted in a decrease in MUC1 MFI in the diluent control groups (dDMSO vs dDMSO+NK), 
when compared with hormone-therapy alone (HT). This decrease while not significant within 
the cytoplasmic compartment, was significant (p<0.001) when assessing the nuclear 
compartment. Combined hormone-therapy and immunotherapy, conversely, resulted in a 
significant increase in MUC1 expression in the both cellular compartments in the hormone 
control groups (EP vs EP+NK). By far the most drastic decrease (p<0.001) in nuclear and 
cytoplasmic MUC1 MFI observed under NK cell mediation was that in the Anastrozole 
treatment group. As seen previously, the addition of hormones to Anastrozole treatment (EPA) 
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reduced MUC1 MFI. However, compared with hormone-therapy alone (EPA), a significant 
increase in MUC1 expression in both cellular compartments was noted with combined 
immunotherapy (EPA+NK). The results thus indicate that in a hormonal environment, the 
induction effects of Anastrozole on MUC1 are attenuated. Furthermore, NK cell presence may 
cause MCF-7 cells to alter the expression of this biomarker, inducing an increase in MUC1 
expression. 
 
The Effects of RU486 on MUC1 MFI 
Within the hormone-therapy treatment groups, RU486 treatment induced a significant decrease 
(p<0.001) in only nuclear MUC1 MFI as compared to the dDMSO control (Figure 3.23), 
complimenting visual observations (Figure 3.19, 3.20). With the addition of hormones (EPR), a 
significant reduction (p<0.001) in both cytoplasmic and nuclear MUC1 expression was found 
compared to the dDMSO control (Figure 3.23). However, when compared to the hormone 
control (EP) and RU486 treatment alone (RU486), EPR induced a small, yet significant 
(p<0.001) decrease in MUC1 MFI in the cytoplasmic compartment and increase in the nuclear 
compartment (Figure 3.23). Qualitative observations are only tentatively linked to these results, 
and no definitive association can be made with a degree of accuracy (Figures 3.19, 3.20). The 
results indicate that while RU486 function is modulated by the hormonal milieu, it may not be 
to the same extent as that of Anastrozole. Furthermore, the results indicate that the hormonal 
milieu results in differential effects on MUC1 nuclear and cytoplasmic localisation as opposed 
to RU486. 
Investigations of MUC1 expression in the combined hormone-therapy and immunotherapy 
groups revealed that the addition of NK cell immunotherapy to RU486 treatment (RU486+NK) 
caused a significant decrease (p<0.001) in MUC1 MFI in both the nucleus and the cytoplasm 
compared with the diluent control (Figure 3.24). While the addition of hormones (EPR+NK) 
followed this trend, in this group MUC1 was significantly higher than that of the RU486+NK 
treatment group alone and the hormone control (EP) (Figure 3.24). These results contradicted 
visual observations in which all cells within the combined hormone-therapy and 
immunotherapy groups evidenced higher cytoplasmic MUC1 fluorescence (Figure 3.20) and 
distinct nuclear localisation compared to the control groups (Figure 3.19). Again, it is suggested 
that quantitative analysis of large data sets is more ideal for interpretation than qualitative 
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observations. The results furthermore, are reminiscent of the effects of NK cell mediated 
Anastrozole treatment, where the combined influences of NK cells and hormonal stimuli 
increase MUC1 expression. 
We further compared the effects of hormone-therapy alone (HT) with combined hormone-
therapy and immunotherapy (HT+IT) (Figure 3.25). In the RU486 treatment group NK cell 
mediation resulted in a significant decrease (p<0.001) in only cytoplasmic MUC1 MFI. With 
the addition of a hormonal influence (EPR), NK cell mediation resulted in a significant increase 
(p<0.001) in both cytoplasmic and nuclear MUC1 MFI compared to hormone-therapy alone. 
This highlights that with hormone-therapy, under hormonal stimuli, NK cells mediate an 
increase in MUC1 expression in MCF-7 cells.  
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Figure 3.22. A bar graph showing the nuclear and cytoplasmic MUC1 MFI for the control treatments 
Both the diluent and hormone control treatments (dDMSO and EP, respectively) induced a significant decrease 
(p<0.001) in MUC1 MFI in both the nucleus and cytoplasm compared to the Media B control. For subsequent 
analysis since all drugs and hormones were diluted in DMSO, the DMSO control group is used as a baseline 
comparator group instead of the Media B control. 
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Figure 3.23. A bar graph showing nuclear and cytoplasmic MUC1 MFI for the control and hormone-
therapy treatments 
Anastrozole treatment (ANAS) induced the highest MUC1 MFI in both the nucleus and cytoplasm as compared to 
the other HT groups. MUC1 expression was significantly higher (p<0.001) in the ANAS group compared to the 
diluent control (dDMSO). MUC1 expression in RU486-treated cells was comparatively reduced in the nucleus 
only (p<0.001) compared to the diluent control. The addition of hormones (EPA) saw a significant reduction in 
MUC1 MFI compared to the diluent control in both cellular compartments. Compared to the hormone control 
(EP), both EPA and EPR treatments reduced cytoplasmic MUC1, yet increased nuclear MUC1 (p<0.001). Further, 
when EPA and EPR were compare to matched samples without hormone influence (ANAS, RU486), it was found 
that EPA induced a significant reduction in MUC1 cytoplasmic and nuclear expression; while EPR induced a 
reduction in cytoplasmic MUC1 but a concomitant increase in nuclear expression. This indicates that the hormonal 
milieu plays an important role in the regulation of both Anastrozole and RU486 function in relation to MUC1 
expression. 
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Figure 3.24. A bar graph showing the nuclear and cytoplasmic MUC1 MFI for the control and combined 
hormone-therapy with immunotherapy treatments 
NK cell immunotherapy with both RU486 and Anastrozole treatment alone (RU486+NK, ANAS+NK) and 
hormone addition (EPR+NK, EPA+NK) induced a significant decrease (p<0.001) in nuclear and cytoplasmic 
MUC1 MFI compared to the diluent control (dDMSO), and a significant increase (p<0.001) in both cellular 
compartments compared to the hormone control (EP). Compared to cells treated with NK cells and hormone-
therapy alone (ANAS+NK, RU486+NK), the addition of hormones (EPA+NK, EPR +NK)) resulted in 
significantly higher MUC1 MFI in both cellular compartments. This indicates that in the presence of NK cells, 
hormone-therapy is affected by hormonal influences in the mediation of MUC1 expression. 
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Figure 3.25. Bar graphs showing the cytoplasmic and nuclear MUC1 MFI for the hormone-therapy 
compared to combined hormone-therapy with immunotherapy treatments 
A: Cytoplasm. B: Nucleus. Immunotherapy with NK cells (HT+IT, red bars) resulted in a significant (p<0.001) 
decrease only in nuclear MUC1 MFI in the diluent control group (dDMSO) compared with hormone-therapy 
alone (HT). Conversely, HT+IT treatment resulted in a significant increase in nuclear and cytoplasmic MUC1 in 
the hormone control group (EP). In the HT group, Anastrozole induced a notable large increase in MUC1 which 
was significantly attenuated (p<0.001) by the addition of NK cell therapy (HT+IT). This was mimicked under 
RU486 treatment, albeit with a reduced level of MUC1 MFI. With the addition of a hormonal milieu, NK cell 
presence induced an increase (p<0.001) in MUC1 MFI even with Anastrozole treatment (EPA) and RU486 
treatment (EPR). The results indicate that MUC1 expression would be affected not only by hormone-therapy, but 
by the microenvironment (NK cell presence and hormonal stimuli). 
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Summary of Biomarker Analysis – significant results 
The Effects of Control Treatments 
Three separate control treatments were identified for use in this study. The Media B control 
was initially selected as a baseline control for as a cell synchronisation medium. However, it 
was noted that the other two control groups induced biomarker expression significantly 
different to that of the Media B control. Specifically, the diluent control, DMSO, in which all 
hormones and hormone-therapy drugs were diluted, presented significantly higher PR 
expression, and lower ERα and MUC1 expression in both nuclear and cytoplasmic 
compartments compared to the Media B control (Figure 3.26). The expression of all biomarkers 
in EP (hormone control) was significantly lower in both compartments compared to the Media 
B control group (Figure 3.26). Given the importance of the diluent control in assessing effects 
due to the hormones and drugs, this control group was selected as a baseline comparator group.   
Furthermore, when we considered that the EP control (itself diluted in DMSO) simulates an in 
vivo hormonal environment and thus may give additional insight, this control group was 
retained to investigate the effects of additional hormones on hormone-therapy drugs and NK 
cell mediation. 
 
The Effects of Anastrozole 
Anastrozole treatment decreased PR expression, and increased MUC1 expression in both the 
nuclear and cytoplasmic compartments. Variable effects were noted on ERα expression based 
on cellular compartment, being decreased nuclear expression and conversely increased 
cytoplasmic expression (Figure 3.26). Under hormone mediation, expression of all three 
biomarkers decreased compared to matched samples without additional hormonal stimuli 
(Figure 3.26), indicating a particular role for oestrogen and progesterone in ERα, PR and 
MUC1 expression regulation. 
Anastrozole treatment together with NK cell mediation also decreased PR expression and 
MUC1 expression in both cellular compartments. Differential effects were again noted on ERα 
expression where nuclear ERα expression decreased and cytoplasmic expression increased 
(Figure 3.26). The effects seen were similar to that of Anastrozole treatment alone. Additional 
hormone stimulation, combined Anastrozole treatment with NK cell mediation did not 
75 
 
 
 
uniformly affect biomarker expression. Specifically, inducing an increase in nuclear PR and a 
concomitant decrease in cytoplasmic PR expression; whereas ERα was increased and MUC1 
expression conversely decreased in both cytoplasmic compartments (Figure 3.26). This 
indicates that Anastrozole treatment differentially affects biomarker expression in cellular 
compartments under NK cell mediation and hormonal stimuli, which better reflects the in vivo 
microenvironment. 
A comparison of treatment modalities revealed that the combined therapeutic modality 
(hormone-therapy and immunotherapy) induced a significant overall decrease in PR expression 
compared to hormone-therapy alone, regardless of additional hormonal influence (Figure 3.26). 
This differed to ERα and MUC1, whereby expression was reduced with the combined modality 
of Anastrozole and NK cell mediation; however, the addition of hormonal stimuli ameliorated 
the effects of the NK cells, resulting in higher ERα in both cellular compartments (Figure 3.26).  
 
The Effects of RU486 
RU486 treatment induced a decrease in PR expression in both nuclear and cytoplasmic 
compartments. Variable effects were seen on the other biomarkers, with MUC1 nuclear 
expression decreasing and ERα expression increasing in the cytoplasm (Figure 3.26). With the 
addition of hormones differential effects were noted on biomarker expression, and cellular 
localisation. Specifically, there was an increase in PR expression and a converse decrease in 
ERα in both cellular compartments; whereas MUC1 expression decreased in the cytoplasm and 
increased in the nucleus (Figure 3.26).  This indicates that RU486 treatment not only induces 
differential effects on biomarker expression in relation to localisation, but that oestrogen and 
progesterone may indeed alter the effect of this drug.  
The addition of NK cells to RU486 hormone-therapy produced a decreased PR and MUC1 
expression; however, nuclear ERα expression decreased with a contrasting increase in 
cytoplasmic ERα expression (Figure 3.26). Under hormonal mediation, RU486 and NK cell 
mediation resulted in an increase in overall ERα and MUC1 expression, with variable results 
regarding PR expression which increased in the nucleus and decreased in the cytoplasm (Figure 
3.26). This result indicates a definitive role for NK cell mediation of MCF-7 biomarker 
expression during treatment with RU486. 
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When comparing the effects of treatment modalities in altering biomarker expression, it was 
found that the combined therapeutic modality (RU486 hormone-therapy and immunotherapy) 
resulted in a significant decrease in PR and ERα expression in both cellular compartments, with 
MUC1 expression decreasing in the cytoplasm only (Figure 3.26). The addition of hormones, 
together with RU486 and NK cell mediation increased ERα, MUC1 expression in both cellular 
compartments, and conversely decreased overall PR expression (Figure 3.26). These results 
again indicate that the effects of the hormonal milieu in relation to immune cell presence may 
result in variable effects on biomarker expression during RU486 therapy.   
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Figure 3.26. A flow diagram summarising the quantitative results for the expression of the three 
biomarkers 
Green boxes: the effects of the controls. Hormone (EP) and diluent (sDMSO) controls compared to the media B 
control, and hormone (EP) control compared to the diluent (dDMSO) control (*). Blue boxes: the effects of 
hormone-therapy (ANAS and RU486) compared to the dDMSO control. Purple boxes: the effects of combined  
hormone-therapy and immunotherapy (ANAS+NK and RU486+NK) compared to the dDMSO control. Red 
boxes: the effects of hormone therapy and combined therapy, with hormones (EPA, EPA+NK, EPR and 
EPR+NK) compared to matched group without hormone stimulation (ANAS, ANAS+NK, RU486, RU486+NK). 
Orange boxes: the effects of combined hormone-therapy and immunotherapy (ANAS+NK, RU486+NK, 
EPA+NK and EPR+NK) compared to hormone-therapy alone (ANAS, RU486, EPA, EPR) 
The control treatments show a trend of a general decrease in all three biomarkers expression (green boxes). The 
hormone-therapy (HT) and combined therapy (HT+IT) treatments show a general decrease in PR and MUC1 
expression with an increased cytoplasmic ERα and decreased nuclear ERα expression (blue and purple boxes). 
The addition of hormones (+EP) to hormone-therapy decreased ERα and MUC1 with variable effects on PR 
dependent on the hormone-therapy used (red boxes). The addition of hormones (+EP) to the combined therapy 
increased ERα and nuclear PR and decreased cytoplasmic PR, with variable effects on MUC1 dependent on the 
hormone-therapy used (red boxes). The addition of immunotherapy (+NK) decreased PR expression; however, the 
effect on ERα and MUC1 was dependent on the presence of hormones (orange boxes). 
+EP +EP +EP +EP 
+NK cells +NK cells 
+NK cells +NK cells 
* 
KEY 
PR       Progesterone Receptor    
ERα     Oestrogen Receptor α  
n          Nuclear  
c          Cytoplasmic  
EP     Oestrogen + Progesterone  
NK    Natural Killer Cells          
↓        Significantly increased 
↑       Significantly decreased 
Controls 
Effect of HT 
Effect of HT+IT 
Effect of hormones 
Effect of immunotherapy 
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Co-localisation of MUC1 with hormone receptors 
The assessment of co-localisation of the MUC1 and ERα proteins, and the MUC1 and PR 
proteins can only be done described qualitatively from the ICC images, which as previously 
mentioned is a subjective analytical tool. CellProfiler does not lend itself to such image 
analysis, since it requires all fluorescence data to be converted to greyscale. As such, 
attempting to ascertain co-localisation and simultaneously distinguishing between two 
fluorescent markers would not be possible. Thus for qualitative assessment of co-localisation of 
biomarkers, to reiterate, PR and ERα were localised with antibodies conjugated to Alexa Fluor 
488, producing a green fluorescence, while MUC1 was localised with an antibody conjugated 
to Alexa Fluor 594, producing a red fluorescence. These images were also then overlaid with 
DAPI, a nuclear stain, producing a blue fluorescence. As such co-localisation of MUC1 and 
PR, or ERα overlaid with DAPI images produces an interesting array of colours. MUC1 
nuclear dominance is visualised as reddish/purple staining due to overlap of MUC1 (red 
fluorescence) with DAPI (blue fluorescence). ERα or PR nuclear dominance is visualised as a 
pale blueish/green due to overlap of green fluorescence with DAPI. In the cytoplasm, overlap 
of MUC1 (red) and ERα or PR (green) is indicated by variation from red/yellow fluorescence 
(MUC1 dominance) to yellow/green (ERα or PR dominance). 
In order to investigate further whether observed co-localisation is indicative of a relationship 
between the biomarkers, the data obtained was analysed using the Spearman’s rank order 
correlation test. Specifically, this test was conducted to determine if there was a correlation 
between the MUC1 and each hormone receptor that varied with treatment. The correlation 
coefficient, Spearman’s rho (rs), generated would give an indication of how the biomarkers co-
vary. Specifically an rs=1 is indicative of a perfect positive relationship, with biomarkers co-
varying in expression together; an rs=0 indicates no relationship, while an rs= –1 is indicative of 
an inverse relationship. As such, rs scores in between 0 and 1 (or -1 and 0), indicate weak 
correlation (rs <0.5), low correlation (rs <0.6) and strong correlation (rs>0.8) (Adapted from 
Mukaka, 2012).  For the correlation graphs see Appendix C Figures C2-C7, and the table of 
correlation values are in Appendix D Table D19. 
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MUC1 and PR co-localisation 
The cells treated with the controls (media B, DMSO diluent and EP) show a dominant MUC1 
expression in the nucleus (Figure 3.27A), corroborated by individual staining of MUC1 (Figure 
3.19). MUC1 nuclear dominance is visualised by the extensive reddish/purple nuclei which 
stain as such due to the overlap of red fluorescence (MUC1) with DAPI (blue). MUC1 also 
dominated the cytoplasm (red fluorescence), with PR localisation appearing as green spots, or 
lighter yellow/green areas. In the Media B control, in which cells underwent cell cycle 
synchronisation, MUC1 dominated the cytoplasm (red fluorescence), with only some cell 
showing higher PR intensity (green) (Figure 3.27A). Co-localisation of MUC1 and PR in the 
hormone control group (EP) showed low, yet dominant nuclear PR expression evinced by pale 
green/blue nuclei (Figure 3.27B). MUC1 cytoplasmic dominance was more evident in this 
group, with few cells showing yellow/green fluorescence indicating a shift to PR expression 
(Figure 3.27B). Conversely in the diluent control group, the majority of nuclei are MUC1 
positive, with the cytoplasmic compartment showing MUC1 expression primarily in the 
perinuclear region, with PR dominating the cytoplasm as shown by the excess of yellow/green 
staining (Figure 3.27C). Individual images of PR and MUC1 alone, affirm these observations 
(Figure 3.5, Figure 3.19).  
Spearman’s rank order test reveals poor correlations between MUC1 and PR expression in the 
Media B control group in both the nucleus (rs=0.27) and cytoplasm (rs=0.25) (Appendix D, 
Table D19). While the cells in the dDMSO treatment group conversely showed a moderate 
correlation in the nucleus (rs=0.64) and cytoplasm (rs=0.64); only EP treatment produced a 
higher moderate nuclear correlation (rs =0.74) and a moderate cytoplasmic correlation (rs=0.54) 
(Appendix D, Table D19). Overall these results indicate that under the control treatments, no 
definitive correlation between these biomarkers expression exists.  
All of the hormone-therapy treatments show a greater concentration of MUC1 in the nucleus as 
demonstrated by reddish/purple nuclei with distinct red spots indicating MUC1 (red) overlap 
with DAPI (blue) (Figure 3.28). Cells treated with Anastrozole alone, while showing distinct 
red MUC1 cytoplasmic staining, did in fact show high intensity perinuclear PR (Figure 3.28A). 
When compared to the diluent control (Figure 3.27C), cytoplasmic PR expression was greatly 
overwhelmed by MUC1.  RU486 treatment induced a definitive mixed cytoplasmic MUC1/PR 
overlap (red and yellow).  In many cells in which PR expression in the cytoplasm was 
dominant (yellow/green), this was also reflected in the nucleus (pale blue/green) (Figure 
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3.28B). While these results are similar to that of the diluent control, PR cytoplasmic dominance 
is notably increased by RU486 treatment compared to the Media B control (Figure 3.27A).  
With the addition of hormones, cells treated simultaneously with Anastrozole (EPA) showed a 
definitive increase in mixed cytoplasmic MUC1/PR expression (red and yellow) (Figure 
3.28C). Compared to treatment with Anastrozole alone, cell cytoplasm showed greater PR 
expression primarily in the perinuclear region (Figure 3.28A, C). Compared to the hormone 
control (EP) (Figure 3.27B), PR nuclear localisation was distinctly reduced in the EPA group 
(Figure 3.28C). In the EPR group, in which cells were treated with hormones and RU486, 
mixed cytoplasmic MUC1/PR expression (red, yellow) was noted, with no distinct dominance 
of either biomarker (Figure 3.28D). Compared to the hormone control (Figure 3.27B), PR 
expression in the nucleus was greatly reduced by EPR treatment (Figure 3.28D). This may 
indicate that treatment with Anastrozole or RU486 in conjunction with hormonal stimuli or not, 
effectively induces the translocation of PR to the cytoplasm.   
The qualitative observations are better explained by the results of the Spearman’s rank order 
correlation test, which show that Anastrozole and RU486 treatment induces a strong correlation 
(rs=0.84, rs=0.92 respectively) between cytoplasmic MUC1 and PR. While a strong correlation 
between these biomarkers is maintained under RU486 treatment in the nucleus (rs=0.87), under 
Anastrozole treatment this is reduced to only a moderate association (rs=0.69) (Appendix D, 
Table D19). With the addition of hormones, a strong correlation between MUC1 and PR is 
upheld with combined Anastrozole treatment (EPA) in the cytoplasm only (rs=0.795). 
Biomarker correlation in the nucleus of cells in this treatment group becomes much weaker 
(rs=0.56). Interestingly, simultaneous treatment with RU4986 and hormones maintains a strong 
correlation between MUC1 and PR in the nucleus (rs=0.87), with a drastic loss of correlation in 
the cytoplasm (rs=–0.2) (Appendix D, Table D19). These results show firstly, that correlation 
between MUC1 and PR is dependent on cellular compartment; secondly, that hormone-therapy 
can modulate the association between the markers; and lastly, that this modulation is itself 
dependent on the hormonal milieu. 
With the addition of immunotherapy (HT+IT) treated cells all exhibit dominant PR expression 
in the nucleus as shown by the pale blue nuclei (Figure 3.29). This is correlated with the 
individual images of PR, apart from the RU486+NK image (Figure 3.7B) which conversely 
shows very little expression of PR. Overall, the addition of immunotherapy resulted in an 
essentially ‘even’ contribution between MUC1 and PR, although a shift to the red spectrum i.e. 
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MUC1 was noted in those groups under immune mediation with Anastrozole and RU486 
(Figure 3.29A, B). The even spread of mixed MUC/PR is due to the individual intermediate 
cytoplasmic PR expression (Figures 3.7A, 3.7C) and intermediate to high MUC1 expression 
(Figures 3.21A, 3.21C) initially presented. With the continuation of a hormonal milieu, it 
appears that cells under both Anastrozole and RU486 treatment (EPA, EPR) (Figure 3.28C, D), 
expressed a slight dominance of PR as visualised by a more yellow/green fluorescence. These 
alterations indicate more strongly, that a dramatic alteration in PR expression occurs under 
immune mediation compared to matched samples without immune mediation (Figure 3.28). 
Spearman’s correlation produces astonishing results. Under immune-mediation, in the nuclear 
compartment, MUC1 and PR have a strong correlation in all treatment (HT+IT) groups 
(rs>0.8), particularly under RU486 treatment (Appendix D, Table D19). Greater variation is 
seen in the cytoplasmic compartment, where under NK cell influence Anastrozole 
(ANAS+NK) induces only a moderate correlation (rs=0.64) between the two biomarkers, while 
RU486 (RU486+NK) induces a very strong correlation (rs=0.91). With the addition of 
hormonal stimuli, MUC1 and PR show a strong correlation (rs=0.84) under Anastrozole 
treatment (EPA), and conversely, under RU486 treatment become only moderately associated 
(rs=0.77) (Appendix D, Table D19). These results corroborate suppositions implied by 
qualitative observations that MUC1 and PR expression may co-vary and alter not only under 
treatment but with mediation from hormonal stimuli and immune cells.  
 
 
 
 
   
 
  
A B C 
Figure 3.27. Representative photomicrographs showing the effects of control treatments on co-localisation of MUC1 and PR in MCF-7 cells 
Control treatment groups: A: Media B. B: EP. C: dDMSO. Fluorescent microscopy, 40x magnification. MUC1 nuclear dominance is visualised as reddish/purple staining due 
to overlap of MUC1 (red fluorescence) with DAPI (blue fluorescence). PR nuclear dominance is visualised as a pale blueish/green due to overlap of PR (green fluorescence) with 
DAPI. In the cytoplasm, overlap of MUC1 (red) and PR (green) is indicated by variation from red/yellow fluorescence (MUC1 dominance) to yellow/green (PR dominance) A: 
MCF-7 cells treated with Media B show a high intensity of nuclear (white arrow, reddish/purple) as well as cytoplasmic MUC1 (grey arrow, red), with a few cells showing a 
higher cytoplasmic PR expression (arrowhead, yellow/green). B: Cells treated with the hormone control (EP) show pale blue/green nuclei (white arrow), some of which 
demonstrate distinct red spots indicting MUC1 localisation. Overall a dominant cytoplasmic MUC1expression (grey arrow, red) is noted, with few areas showing a yellow/green 
fluorescence indicative of low PR expression (arrowhead). C: The dDMSO treatment induced high nuclear MUC1expression as evidenced by reddish/purple nuclei with red spots 
(white arrow). In the cytoplasm, while many cells showed distinct MUC expression (grey arrow, red), PR expression appeared to dominate this region (arrowhead, yellow/green). 
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C D 
Figure 3.28. Representative photomicrographs showing the effects of hormone-therapy on co-localisation of 
MUC1 and PR in MCF-7 cells 
Treatment groups: A: ANAS. B: RU486. C: EPA. D: EPR. Fluorescent microscopy, 40x magnification. MUC1 
nuclear dominance is a reddish/purple stain due to MUC1 (red fluorescence) overlap with DAPI (blue 
fluorescence). PR nuclear dominance, visualised as a pale blueish/green, is due to PR overlap (green fluorescence) 
with DAPI. In the cytoplasm, overlap of MUC1 (red) and PR (green) is indicated by variation from red/yellow 
fluorescence (MUC1 dominance) to yellow/green (PR dominance) A: Anastrozole treatment induced high nuclear 
MUC1 intensity (white arrow, reddish/purple nuclei with red spots). MUC1 dominated the cytoplasm (grey arrow, 
red), with an increase in perinuclear PR (arrowhead, yellow/green). B: RU486 treatment also induced high nuclear 
MUC1 (white arrow) with mixed cytoplasmic MUC1/PR expression (grey arrow, red and yellow). Many cells 
showed dominant cytoplasmic PR (arrowhead, yellow/green) and simultaneous nuclear PR (pale blueish/green).  
C: In the EPA group, the majority of cells showed high MUC1 nuclear intensity (white arrow, reddish/purple 
nuclei with red spots). Similar to the Anastrozole only treatment, cells showed PR perinuclear dominance, albeit 
more extreme. Overall mixed cytoplasmic PR/MUC1 staining (grey arrow, red and yellow/green) with noted PR 
dominance was seen. D: Cells in the EPR group demonstrated dominant nuclear MUC1 (white arrow, 
reddish/purple nuclei). While cytoplasmic expression showed a mixture of MUC/PR (arrowhead, red and yellow), 
overall MUC1 dominated the cytoplasm. 
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Figure 3.29. Representative photomicrographs showing the effects of combined hormone-therapy and 
immunotherapy on co-localisation of MUC1 and PR in MCF-7 cells 
Treatment groups: A: ANAS+NK. B: RU486+NK. C: EPA+NK. D: EPR+NK. Fluorescent microscopy, 20x 
magnification. PR nuclear dominance is visualised as a pale blueish/green due to overlap of PR (green 
fluorescence) with DAPI (blue fluorescence). In the cytoplasm, overlap of MUC1 (red) and PR (green) is indicated 
by variation from red/yellow fluorescence (MUC1 dominance) to yellow/green (PR dominance). In all treatment 
groups, NK cell mediation resulted in cell nuclei presenting definitive PR dominance (white area, pale blue 
nuclei). A: Cells in the ANAS+NK group show mixed cytoplasmic MUC1/PR (arrowhead, red and yellow) B: In 
the RU486+NK group the majority of cells show mixed MUC1/PR cytoplasmic expression (arrowhead, 
red/yellow), with few cells showing dominant MUC1 (grey arrow, red) few cells exhibit a higher intensity of 
nuclear PR with higher cytoplasmic MUC1. C: The EPA+NK treated cells show a similar mixed MUC1/PR 
cytoplasmic expression (arrowhead) with some cells showing a shit to PR dominance. D: Cells treated with 
EPR+NK also exhibit mixed MUC1/PR expression but a slight dominance in PR expression is suggested by the 
increase in yellow/green fluorescence (arrowhead). 
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MUC1 and ERα Co-localisation 
In the control treatment groups, dominant expression of ERα was noted in the nucleus, 
primarily in the Media B treatment (cell synchronisation media) and EP treatment (hormone 
control) (Figures 3.30A, B). However, a distinct cytoplasmic difference was noted in the Media 
B control, with a higher, more even association of MUC1 and ERα visualised as a red/green 
fluorescence (Figure 3.30A). In the EP control group, the fluorescence was extremely muted, 
with some cells showing a marginally higher level of MUC1 as opposed to ERα, and vice versa 
(Figure 3.30B). The diluent control (dDMSO) showed a dominant MUC1 cytoplasmic 
expression, visualised as red/orange (Figure 3.30C). Notably, enhanced ERα was associated 
with the perinuclear region primarily. In this treatment group, nuclei were predominantly 
MUC1 dominant (reddish blue), with few cells showing the pale blue nuclei associated with 
ERα prominence (Figure 3.30C). Analysis of the correlation between MUC1 and ERα shows 
that Media B treatment induced a strong association between the two biomarkers in the 
cytoplasm (rs=0.82) (Appendix D, Table D19). However, in the same treatment the correlation 
in the nucleus, was moderate (rs=0.75). The EP control induced only moderate correlations in 
both nuclear (rs=0.65) and cytoplasmic (rs=0.72) compartments. Interestingly, cells in the 
diluent control showed weak positive correlation between MUC1 and ERα in the nucleus 
(rs=0.33) and a weak negative correlation in the cytoplasm (rs= –0.32) (Appendix D, Table 
D19). 
In the hormone-therapy groups, cytoplasmic biomarker expression for cells treated with 
Anastrozole alone (ANAS) appear evenly spread (Figure 3.31A). Areas of MUC1 dominance 
(red/green) and ERα dominance (green) were noted (Figure 3.31A); however, staining was 
considerably reduced compared to the diluent control and media B control (Figure 3.30A, C). 
With additional hormonal stimuli (EPA) a distinct shift to the red spectrum is noted, indicative 
of prominent MUC1 cytoplasmic staining (Figures 3.31C). Nuclear expression in both ANAS 
and EPA treatment groups was difficult to assess, with nuclear biomarker expression obscured 
by the DAPI stain (Figures 3.31A, C). While individual staining shows low ERα nuclear 
expression (Figures 3.13A); conversely, the MUC1 single staining image (Figure 3.13C) 
indicates a higher nuclear expression. Furthermore, quantitative assessment of data showed a 
significantly higher nuclear expression compared to cytoplasm expression for both biomarkers 
(Figures 3.16, 3.23). Therefore, we propose that the DAPI stain is obscuring relevant nuclear 
biomarkers expression causing the co-localisation analysis to be ineffective. When assessing 
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whether MUC1 and ERα expression co-varied, it was found that under Anastrozole treatment 
no correlation could be made (nuclear rs= –0.10, cytoplasmic rs=0.09) (Appendix D, Table 
D19). With additional hormonal interaction, Anastrozole treatment (EPA) appeared to induce a 
comparatively increased, yet low correlation in both the nuclear (rs=0.51) and cytoplasmic 
compartments (rs=0.53). 
In the hormone-therapy group, cells treated with RU486 show a dominant ERα expression in 
both the nucleus (pale blue staining) and the cytoplasm (green fluorescence) (Figure 3.31B). 
Individual staining of ERα (Figures 3.13B) and MUC1 (Figure 3.20B) affirms this result, while 
quantitative assessment shows that this treatment induced the highest ERα nuclear and 
cytoplasmic expression (Figure 3.16) and low nuclear and cytoplasmic MUC1 expression 
(Figure 3.23). Interestingly, the addition of simultaneous hormones (EPR) induced a dominant 
MUC1 nuclear (reddish blue nuclei with red spots) and cytoplasmic expression (red 
fluorescence) (Figure 3.30D), as noted in single staining images (Figure 3.13D, Figure 3.20D). 
The quantitative analysis also corroborates the co-localisation result, with the ERα MFI higher 
than the MUC1 MFI (Appendix D, Table D7, and D13) for both the nucleus and the cytoplasm. 
Analysis of the relationship between MUC1 and ERα produced interesting results: RU486 
treatment alone produced a very strong (rs=0.92) and strong (rs=0.79) correlation between the 
biomarkers in the nucleus and cytoplasm respectively (Appendix D, Table D19). However, the 
addition of hormones to treatment (EPR) obliterated this association in both nuclear (rs= –0.24) 
and cytoplasmic compartments (rs= –0.10). These results indicate that Anastrozole and RU486, 
even with hormonal stimuli, induce alterations in the MUC-ERα relationship. 
With the addition of immunotherapy (HT+IT), all treatments induced a dominant expression of 
ERα in the nucleus of the cells (Figure 3.32), corroborated by single staining images and data 
analysis thereof (Figure 3.14, Figure 3.17). Under NK cell mediation, both Anastrozole and 
RU486 treatment induced  dominant MUC1 cytoplasmic expression in the majority of the cells, 
visualised as red/yellow fluorescence, with a few cells expressing dominant ERα expression 
(green fluorescence) (Figures 3.32A, B). In comparison with the diluent (dDMSO) control, 
MUC1 localisation was markedly reduced (Figure 3.30). 
With the addition of hormonal stimuli to combined hormone-therapy and immunotherapy, a 
shift to dominant cytoplasmic ERα expression in the cells treated with Anastrozole (EPA+NK), 
and shift to a dominant MUC1 expression in cells treated with RU486 (EPR+NK) is noted 
(Figure 3.32C, D).  Notably for all treatments in the hormone-therapy and immunotherapy 
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groups, strong correlation (rs>0.8) between MUC1 and ERα was found in both the nucleus and 
cytoplasm (Appendix D, Table D19). Results found in hormone-therapy treatments without NK 
cell influence, indicate that the actions of Anastrozole and RU486 vary with the addition of 
hormonal stimuli; however, that a correlation is maintained between the biomarkers under NK 
cell mediation, indicates that immune cells have a strong influence on the relationship between 
MUC1 and ERα 
  
 
 
 
 
   
   
 
 
A B C 
Figure 3.30. Representative photomicrographs showing the effects of control treatments on co-localisation of MUC1 and ERα in MCF-7 cells 
Control treatment groups: A: Media B. B: EP. C: dDMSO. Fluorescent microscopy, 40x magnification. MUC1 nuclear dominance is visualised as reddish/purple staining due 
to overlap of MUC1 (red fluorescence) with DAPI (blue fluorescence). ERα nuclear dominance is visualised as a pale blueish/green due to overlap of ERα (green fluorescence) 
with DAPI. In the cytoplasm, overlap of MUC1 (red) and ERα (green) is indicated by variation from red/yellow-orange fluorescence (MUC1 dominance) to yellow/green (ERα 
dominance) A: MCF-7 cells treated with Media B showed pronounced nuclear expression of ERα (white arrow, pale blue nuclei).The cytoplasm has an even expression of ERα 
(green) and MUC1 (red); however, a cell undergoing mitosis shows ERα dominance (grey arrow, green) B: MCF-7 cells treated with the hormone control, EP, show ERα nuclear 
dominance (white arrow, pale blue nuclei). Despite very muted fluorescence, some cells show MUC1dominating the cytoplasm (arrowhead, green/red), with yet others showing 
increased ERα (grey arrow, green). C: The diluent control induced pronounced nuclear MUC1 (white arrow, reddish purple) although some cells exhibited  dominant nuclear ERα 
(pale blue nuclei). In the cytoplasm, MUC1 appeared to dominate the cells, seen as orange-red (grey arrow), with ERα more prominent in the perinuclear area (arrowhead, 
yellow/green). 
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Figure 3.31. Representative photomicrographs showing the effects of hormone-therapy on co-localisation of 
MUC1 and ERα in MCF-7 cells 
Treatment groups: A: ANAS. B: RU486. C: EPA. D: EPR. Fluorescent microscopy, 40x magnification. MUC1 
nuclear dominance is visualised as reddish/purple staining due to overlap of MUC1 (red fluorescence) with DAPI 
(blue fluorescence). ERα nuclear dominance is visualised as a pale blueish/green due to overlap of ERα (green 
fluorescence) with DAPI. In the cytoplasm, overlap of MUC1 (red) and ERα (green) is indicated by variation from 
red/yellow-orange fluorescence (MUC1 dominance) to yellow/green (ERα dominance) A: Anastrozole treatment 
induced an even expression of both ERα and MUC1 (arrowhead, red/green) in the cytoplasm. Some cells showed 
a slight dominant ERα fluorescence (grey arrow, green). Nuclear expression was difficult to assess but ERα 
dominant (white arrow, pale blue) with red spots attributable to MUC1B: MCF-7 cells treated with RU486 show 
ERα nuclear (arrow, pale blue) and cytoplasmic (arrowhead, yellow/green) dominance. C: MCF-7 cells treated 
with EPA shows a higher cytoplasmic intensity of MUC1 (arrowhead, red) than Anastrozole treatment alone. 
Nuclear expression is not quite clear but it appears that ERα is dominant. MUC1 localisation is evident as red 
spots within the nucleus within D: EPR treatment induced a very evident MUC1 dominance in both the cytoplasm 
and the nucleus (arrow, reddish blue). ERα is prominent in the perinuclear region (arrowhead, yellow/red). 
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Figure 3.32. Representative photomicrographs showing the effects of combined hormone-therapy and 
immunotherapy on co-localisation of MUC1 and ERα in MCF-7 cells 
Treatment groups: A: ANAS+NK. B: RU486+NK. C: EPA+NK. D: EPR+NK. Fluorescent microscopy, 20x 
magnification. ERα nuclear dominance is visualised as a pale blueish/green due to overlap of ERα (green 
fluorescence) with DAPI (blue fluorescence). Cytoplasmic overlap of MUC1 (red) and ERα (green) is indicated by 
variation from red/yellow-orange fluorescence (MUC1 dominance) to yellow/green (ERα dominance). In all 
treatment groups dominant nuclear ERα (white arrow, pale blue nuclei) was indicated, with some nuclei showing 
red spots indicative of MUC1 localisation.  A: The majority of the cells treated with ANAS+NK show a high 
cytoplasmic MUC1expression (grey arrow, red/yellow). Some cells exhibited a higher ERα expression 
(arrowhead, green). B: Cells treated with RU486+NK showing a similar spread of cytoplasmic MUC1 dominance 
(grey arrow, red/yellow) and cytoplasmic ERα dominance (arrowhead, yellow/green). C: Compared to the 
Anastrozole treatment without hormonal influence (ANAS+NK), EPA+NK induced a shift to ERα cytoplasmic 
dominance was noted (arrowhead, green) with few cells showing higher cytoplasmic MUC1 (grey arrow, 
red/yellow. D: Compared to the RU486 treatment without hormonal influence (RU486+NK), cells treated with 
EPR+NK show a higher intensity of nuclear ERα (white arrow, pale blue) with a few cells showing typical MUC1 
nuclear localisation, evinced by reddish/purple nuclei with red spots.  While the majority of cells have dominant 
MUC1 cytoplasmic expression (grey arrow, red), a few cells have a higher ERα expression (arrowhead, green). 
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The Effects of Hormone-Therapy and Combined Therapy on Proliferation 
Ki67 is a protein found in the nucleus in proliferating cells, it is found during the active phases 
(G1, S, G2, and M) of the cell cycle and is absent in the resting phase (G0) (Scholzen and 
Gerdes, 2000). 
The ICC controls were the following: negative control, primary antibody control for Ki67, 
secondary antibody control for Alexa Fluor® 488, and isotype control for Ki67. All the ICC 
controls showed no fluorescence indicating that there was no background fluorescence, no 
autofluorescence, no non-specific binding of the secondary antibodies, and the specificity of the 
antibodies (see Appendix C, Figure C1). Therefore, the ICC was effective and the results 
accurate. 
To reiterate, following hormone-therapy and immunotherapy of the MCF-7 cells, nuclei were 
visualised using DAPI, producing a blue fluorescence, and Ki67 immunolocalised, producing a 
green fluorescence. Qualitative assessment of the images yielded no meaningful information, 
thus quantitative analysis of the data acquired by CellProfiler was performed to ascertain 
whether hormone-therapy or combined hormone-therapy and immunotherapy induced 
alterations in Ki67 expression. Fluorescence was captured individually as grayscale images. 
The images were analysed with CellProfiler with a pipeline that firstly located the nuclei and 
the Ki67 from their respective images. Where Ki67 intersected with a nucleus, that nucleus was 
labelled Ki67 positive (Ki67
+
) (Figures 3.33, 3.34). These Ki67
+
 nuclei were then represented 
as a percentage of all nuclei to determine the percentage of proliferating cells (Figure 3.23; 
Appendix D, Table D20). 
The normality tests Shapiro-Wilk, Jarque-Bera and Anderson-Darling were performed on the 
data produced by CellProfiler, with significance set at p=0.05. The data was normally 
distributed (p>0.05) (see Appendix D Table D21), therefore, the parametric one-way analysis 
of variance (ANOVA) was used to compare the hormone therapy (HT) and combined 
hormone-therapy with immunotherapy (HT+IT) groups. Pairwise comparisons were performed 
between the groups using Tukey’s (default of PAST). The significance for both was set at 
p=0.05 (see Appendix D, Table D22). 
No significant differences in Ki67 expression were detected between the control groups (Figure 
3.33, Figure 3.35).  Within the hormone-therapy group, treatment with Anastrozole or RU486 
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(ANAS and RU486 groups) (Figure 3.34) induced no significant difference (p>0.05) in 
percentage Ki67
+
 (%Ki67
+
) nuclei compared to the controls (Media B, dDMSO and EP) 
(Figure 3.35).  Furthermore, simultaneous treatment with the hormones, oestrogen and 
progesterone (EPA and EPR groups), had no effect on the anti-proliferative capacity of the 
drugs (Figure 3.34, Figure 3.35). These results were mimicked within the HT+IT group, 
indicating that combined hormone-therapy and immunotherapy had no significant effect on 
proliferation of MCF-7 cells at 72 hours compared to the controls (Figure 3.35). 
We further compared hormone-therapy to combined hormone-therapy and immunotherapy to 
assess whether the addition of NK cells to the respective treatment groups altered the Ki67 
profile. However,  no significant difference (p>0.05) in %Ki67
+
 nuclei in the HT groups as 
compared to the HT+IT groups with their respective treatments was found. Consequently, the 
NK cells had no significant effect when combined with hormone-therapy with regards to 
inhibiting proliferation of the MCF-7 cells (Appendix D, Table D22). However, NK cell 
mediation (HT+IT) treatments consistently produced values lower than in the hormone-therapy 
(HT) treatments indicating a reduced proliferation level. 
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Figure 3.34. Representative CellProfiler composite images showing the effects of hormone-therapy and 
combined hormone with immunotherapy on Ki67 expression 
Treatment groups: A: ANAS. B: RU486. C: EPA. D: EPR. E: ANAS+NK. F: RU486+NK. G: EPA+NK.       
H: EPR+NK. CellProfiler composite image showing nuclei (blue) and Ki67
+
 nuclei (green). 10X magnification.  
While no significant differences in percentage Ki67
+
 nuclei were found (Refer to Figure 3.32), fewer Ki67
+
 nuclei 
were noted in the ANAS+NK and EPR+NK treatment groups. 
Figure 3.33. Representative CellProfiler composite images showing the effects of control treatments on Ki67 
expression 
Control groups: A: Media B. B: dDMSO. C: EP. CellProfiler composite image showing nuclei (blue) and Ki67
+
 
nuclei (green). 10X magnification.  Control treatments showed no differences in Ki67 expression (Refer to Figure 
3.32). 
A B C 
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Figure 3.35. A bar graph showing the mean percentage of Ki67
+
 nuclei  in the controls, hormone-therapy 
and combined hormone-therapy with immunotherapy treatment groups 
There was no significant difference (p>0.05) in % Ki67
+
 nuclei within and between the control, HT and the HT+IT 
groups.  However, the % Ki67
+
 nuclei in the hormone therapy (HT) groups were consistently higher than in the 
combined hormone-therapy and immunotherapy (HT+IT) groups. This indicates that NK cells had a positive effect 
on negating proliferation regardless of treatment. 
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The Effects of Hormone-Therapy and Combined Therapy on Apoptosis 
The flow cytometric Annexin V-FITC apoptosis detection Kit II was used to determine levels 
of induced apoptosis. During the process of cell death, plasma membrane integrity is lost and 
the phospholipid, phosphatidylserine, translocates to the extracellular side of the plasma 
membrane (Cepa et al., 2008). Thus apoptotic events are detected by Annexin V-FITC which 
binds to phosphatidylserine and propidium iodide (PI) enters the nuclei when the plasma 
membrane integrity is completely lost. 
Data was acquired with BD FACSDiva software v6 and analysed using FlowJo (Free Trial). A 
graph with side scatter (SSC) on the y-axis (indicating the granularity of the cells) and forward 
scatter (FSC) on the x axis (indicating the size of the cells), was viewed first (first column of 
Figure 3.36 - Figure 3.38). Dead cell populations and debris (very small cells with little 
granularity) were not gated out, as is the usual procedure with other flow cytometric analyses, 
to determine if there was a difference in the dead cell populations with regards to the different 
treatments. 
Compensation controls were performed to determine and remove any overlap between the 
FITC and PI emission channels (Appendix C, Figure C8).The camptothecin (CPT) control was 
used to establish quadrants as follows: quadrant 1 (Q1) Annexin
+
 PI
-
 determining early 
apoptotic cells, quadrant 2 (Q2) Annexin
+ 
PI
+
 showing late apoptotic cells, quadrant 3 (Q3) 
Annexin
-
 PI
+
 determining necrotic cells, and quadrant 4 (Q4) Annexin
-
PI
-
 showing live cells. 
The data was then viewed graphically with AnnexinV-FITC on the y-axis and PI on the x-axis.  
These quadrants were subsequently applied to all the graphs for the controls (Figure 3.36 
second column), hormone-therapy (HT) groups (Figure 3.37 second column) and the combined 
hormone-therapy with immunotherapy (HT+IT) groups (Figure 3.38 second column).   
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The percentage of cells in each quadrant was calculated (see Figures 3.36 - 3.38 and Appendix 
D, Table D23). The normality tests Shapiro-Wilk, Jarque-Bera and Anderson-Darling were 
performed on the data, with significance set at p<0.05. The majority of the data followed a 
normal distribution (p>0.05), with the exception of the dDMSO treated Q3 (live cells) and EP 
treated Q4 (necrosis) data (Appendix D, Table D24). Therefore the non-parametric Kruskal-
Wallis one-way analysis of variance was used to compare each treatment with significance set 
at p<0.05 (Appendix D, Tables D25-D29). 
Regarding the control treatment groups, the DMSO diluent control (dDMSO) induced a 
significant increase (p<0.05) as compared to the Media B control in early apoptosis (Q1) 
(Figure 3.39) and total apoptosis (Q1+Q2) (Figure 3.43). This indicates that even at low 
concentrations DMSO has a pro-apoptotic effect. Since DMSO was used as a diluent for all the 
hormone-therapy drugs and hormones, the dDMSO control was used as the baseline 
comparator for all further statistical comparisons. The camptothecin (CPT) treatment was used 
as an apoptotic inducer; however, it did not react as required under the conditions in this study, 
and instead it reduced early apoptosis comparatively (Figure 3.39). Furthermore, with the 
hormone control (EP) there was no significant difference in early or late apoptosis as compared 
to the dDMSO control, but there was a significant decrease (p<0.05)  in apoptosis cumulatively 
(Q1+Q2) (Figure 3.43), indicating that the hormones had a protective effect. Therefore, the EP 
hormone control was retained as an additional comparator for the treatment groups with 
continued hormone mediation (EPA, EPR, EPA+NK, EPR+NK). 
Importantly, no treatment significantly increased induced apoptosis as would be expected, but 
rather decreased apoptosis in the vast majority of treatments compared to the diluent control 
and the hormone control. There was also no significant difference with regards to the 
percentage of cells undergoing necrosis (Q4), regardless of treatment (HT or HT+IT) (Figure 
3.41). However, there was a significant difference with regards to the percentage of live cells 
(Figure 3.42) with all treatments (apart from EPA).  
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The Effect of Hormone-Therapy on the Induction of Apoptosis 
Anastrozole treatment induced a significant decrease in early apoptosis (Figure 3.39) and total 
apoptosis (Q1+Q2) compared to the dDMSO control (Figure 3.43). However, under hormone 
mediation there was no significant difference noted in any quadrant as compared to the baseline 
dDMSO control, EP hormone control and Anastrozole alone (Figures 3.39 – Figure 3.43) 
(Appendix D, Table D25, Table D29). 
Mimicking the Anastrozole results, RU486 treatment induced a significant decrease (p<0.05) in 
early apoptosis (Figure 3.39) and total apoptosis (Q1+Q2) (Figure 3.43). This was further 
repeated with the treatments under hormone mediation also inducing a significant decrease 
(p<0.05) in early apoptosis (Figure 3.39) and total apoptosis (Q1+Q2) as compared to the 
dDMSO control (Figure 3.43) (Appendix D, Table D25, Table D29). However, there was a 
significant decrease (p<0.05) with RU486 treatment under hormone mediation in early 
apoptosis as compared to the EP hormone control (Figure 3.39). The hormone mediation 
(EPR), however, had no significant effect (p>0.05) when compared to hormone-therapy alone 
(RU486) (Appendix D, Table D25, Table D29). 
 
The Effect of Combined Hormone-Therapy and Immunotherapy on the Induction of Apoptosis  
With the addition of immunotherapy (NK cells), there is a similar pattern to that of hormone-
therapy alone. Anastrozole and RU486 induced a significant decrease (p<0.05) in early 
apoptosis (Figure 3.39) and total apoptosis (Q1+Q2) as compared to the dDMSO control 
(Figure 3.43) (Appendix D, Table D25, Table D29). With continued hormone mediation, 
RU486 induced a significant decrease in early apoptosis (Figure 3.39) while Anastrozole 
induced a significant decrease in late apoptosis (Figure 3.40) and both significantly decreased 
total apoptosis (Figure 3.43) as compared to the dDMSO control. However, no significant 
difference was noted when compared to the EP hormone control or the drugs (under NK cell 
mediation) regardless of hormone mediation. Interestingly, no significant difference was noted 
with the comparison of the combined therapy to the hormone-therapy alone regardless of 
treatment (Appendix D, Table D25, Table D29). This indicates that the NK cells had no effect 
on the MCF-7 cells regarding apoptosis. 
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Figure 3.36.  Representative scatter graphs showing SCC vs FSC and AnnexinV vs PI of the MCF-7 cells 
treated with the controls 
Control groups: Rows: Media B. dDMSO. EP. Camptothecin (CPT). Columns: SCC vs FSC. AnnexinV vs PI. 
The graphs show two distinct populations, one showing small cells with little granularity (encircled in red) and the 
second showing larger cells with more granularity (encircled in black). The AnnexinV vs PI graphs are divided 
into 4 quadrants showing AnnexinV
+ 
PI
-
 early apoptotic cells (Q1), AnnexinV
+ 
PI
+
 late apoptotic cells (Q2), 
AnnexinV
- 
PI
+
 necrotic cells (Q3) and AnnexinV
-
 PI
-
 live cells (Q4). In all control treatment groups, the majority 
of cells are alive (Q4). The highest levels of induced early apoptosis was noted in the DMSO treatment group 
(dDMSO, Q1) and the highest level of induced late apoptosis was found in the camptothecin treatment group, as 
expected 
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Figure 3.37.  Representative scatter graphs showing SCC vs FSC and AnnexinV vs PI of the MCF-7 cells 
treated with hormone-therapy 
Treatment groups: Rows: ANAS. RU486. EPA. EPR. Columns: SCC vs FSC. AnnexinV vs PI. The SSC vs 
FSC graphs show two distinct populations, one showing small cells with little granularity (encircled in red) and the 
second showing larger cells with more granularity (encircled in black). The AnnexinV vs PI graphs are divided 
into 4 quadrants showing AnnexinV
+ 
PI
-
 early apoptotic cells (Q1), AnnexinV
+ 
PI
+
 late apoptotic cells (Q2), 
AnnexinV
- 
PI
+
 necrotic cells (Q3) and AnnexinV
-
 PI
-
 live cells (Q4). 
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Figure 3.38.  Representative scatter graphs showing SCC vs FSC and AnnexinV vs PI of the MCF-7 cells 
treated with combined hormone-therapy and immunotherapy 
Treatment groups: Rows: ANAS+NK. RU486+NK. EPA+NK. EPR+NK. Columns: SCC vs FSC. AnnexinV 
vs PI. The SSC vs FSC graphs show two distinct populations, one showing small cells with little granularity 
(encircled in red) and the second showing larger cells with more granularity (encircled in black). The AnnexinV vs 
PI graphs are divided into 4 quadrants showing AnnexinV
+ 
PI
-
 early apoptotic cells (Q1), AnnexinV
+ 
PI
+
 late 
apoptotic cells (Q2), AnnexinV
- 
PI
+
 necrotic cells (Q3) and AnnexinV
-
 PI
-
 live cells (Q4). 
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Figure 3.39. A bar graph showing the percentage of cells undergoing early apoptosis (Q1) with the controls 
and treatment groups 
All hormone-therapy treatments, apart from EPA, significantly decreased (p<0.05) the percentage of cells 
undergoing early apoptosis as compared to the dDMSO control. This decrease (p<0.05) was mimicked in the 
combined hormone-therapy with immunotherapy treatments, again with the exception of the EPA+NK treatment. 
When compared to the EP control group, only the EPR treatment caused a significantly decrease (p<0.05) in the 
percentage of cells undergoing early apoptosis. There was also no significant difference detected compared to the 
drugs alone and between the HT and HT+IT groups regardless of treatment. 
Figure 3.40. A bar graph showing the percentage of cells undergoing late apoptosis (Q2) with the controls 
and treatment groups 
The EPA+NK treatment was the only one that induced a significant difference (p<0.05) when compared to the 
dDMSO control with late apoptosis. There were no significant differences detected when compared to the EP 
control, the drugs alone and between the HT and HT+IT groups regardless of treatment 
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Figure 3.42. A bar graph showing the percentage of live cells (Q4) with the controls and treatment groups 
The majority of the treatments (apart from EPA) induced a significantly increased percentage of live cells when 
compared to the dDMSO control treatment. However, there was also no significant difference when compared to 
the EP control, the drugs alone or between the HT and HT+IT groups regardless of treatment. 
Figure 3.41. A bar graph showing the percentage of cells undergoing necrosis (Q3) with the controls and 
treatment groups 
The was no significant differences (p>0.05) noted when compared to the dDMSO control, EP control, drugs alone 
and between the HT and HT+IT groups regardless of treatment. 
103 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
* 
* 
* 
* 
* 
* * 
* 
* 
%
 o
f 
ce
ll
s 
Treatment 
* p<0.05  
   vs dDMSO 
Mean 
Mean±SE 
Control 
HT 
HT+IT 
ANAS 
 
RU486 
 
EPA 
 
EPR 
 
Media B 
 
dDMSO 
 
CPT EP 
Figure 3.43. A bar graph showing the percentage of cells undergoing total apoptosis (Q1+Q2) with the 
controls and treatment groups 
All treatments (apart from EPA) induced a significantly decreased (p<0.05) percentage of cells undergoing 
apoptosis as compared to the dDMSO control.  However, there was also no significant difference noted when 
compared to the EP control, the drugs alone or between the HT and HT+IT groups regardless of treatment. This 
indicates that the addition of NK cell mediation did not induce significant cell death. 
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DISCUSSION 
Biomarker localisation 
Traditionally pathologists diagnose ER
+
 and/or PR
+
 tumours by nuclear immunohistochemistry 
analysis and cytoplasmic staining is disregarded (Welsh et al., 2012). According to the updated 
St Gallen definition of intrinsic subtypes (Goldhirsch et al., 2013) only nuclear expression is 
analysed with regards to ER, PR and Ki-67. With ER and PR ≥20% indicates positivity and 
<20% indicated negativity. With Ki67 positive nuclei the following classifications are used: 
low (<14%), intermediate (14-19%) or high (≥20%). However, with regards to HER2, 
overexpression is regarded as >10% of the cells having intense and complete membrane 
staining (Maisonneuve et al., 2014). However, ERα and PR can exist in the cytoplasm of the 
cells, where it diverges from its traditional nuclear transcriptional functions and instead 
interacts with other receptors and cytoplasmic kinases involved in tumour progression 
(Acconcia and Kumar, 2006; Lange, 2008; Hill et al., 2012; Welsh et al., 2012).  This indicates 
a real need to revise diagnostic definitions to include cytoplasmic localisation of ER and PR 
biomarkers. 
In the present study, quantitative analysis indicated that ERα, PR and MUC1 expression 
essentially varied between nuclear and cytoplasmic compartments with treatment within the 
hormone-therapy and immunotherapy groups. Trends observed did not always correspond to 
the qualitative analysis of the images themselves. This disparity could be due to the subjective 
nature of qualitative analysis. For example, where images show low ERα/PR intensity with 
certain treatments as compared to the normal ERα/PR intensity, if only the nucleus is 
considered, with pure qualitative analysis this could indicate a hormone-negative breast cancer, 
and a false negative diagnosis. Therefore, the impartial analysis of the images is important and 
a quantification program like CellProfiler could be used to standardise tumour diagnosis. This 
program could also allow for additional information about the cells to be analysed, including 
cell numbers, cell size and comparative cellular compartment sizes (Carpenter et al., 2006).  
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The Effects of Hormone-Therapy on MCF-7 Cells 
Hormone therapy employs the use of selective oestrogen receptor modulators (SERM), 
selective oestrogen receptor downregulators (SERD), and aromatase inhibitors (AI). SERMs 
function primarily as ER antagonists, with some agonist properties; SERDs are pure ER 
antagonists and AIs prevent the aromatase enzyme from converting androgens to oestrogens. 
(McDonnell and Goldman, 1994; Miller et al., 2005). The hormones of particular interest in 
hormone-responsive breast cancers are oestrogen and progesterone. In this study, pre-treatment 
with 17β-oestradiol and progesterone were conducted to mimic the tumour microenvironment 
pre-hormone-therapy. Continued treatment with the hormones decreased the expression of all 
three biomarkers used in this study. The comparative reduction of ERα, as noted under 
hormone stimulation in this study affirms findings that agonists, specifically oestradiol, are 
capable of downregulating ERα protein expression indicating transcriptional activity (Pinzone 
et al., 2004). 17β-oestradiol is an active form of oestrogen that activates ER causing an increase 
in DNA synthesis by activating the binding of ER to Src (a tyrosine kinase oncoprotein) which 
also increases cell survival, proliferation and metastasis (Marino and Ascenzi, 2008). In this 
study, cytoplasmic ERα expression was noted, albeit reduced under hormonal stimulation, 
indicating non-genomic functions of this biomarker. Specifically 17β-oestradiol has been 
linked to cell growth, cell survival and metastasis by non-genomic regulation of cellular 
processes by PI3K/Akt activation (PI3K is a lipid kinase that causes the translocation of Akt to 
the plasma membrane where it has functions in cell proliferation, differentiation and survival 
(Acconcia and Kumar, 2006).  
Oestrogen in combination with progesterone as a hormone replacement therapy has a 
significantly higher risk of breast cancer than with oestrogen alone (Fournier et al., 2008), 
indicating a role for progesterone in breast cancer initiation and progression. In this study, cells 
under continued hormone stimulation with 17β-oestradiol and progesterone expressed reduced 
levels of PR. This result equates to ligand-dependent downregulation of PR which has been 
noted in other studies, and is related to hyperactivation of the PR (Shen et al., 2001).  
Progesterone genomic effects include direct binding to progesterone response elements (PREs) 
in genes (which affects c-myc, fatty acid synthetase and MMTV) or via transcription factors 
(affects epidermal growth factor receptor, c-fos, p21, IRS-2 and cyclin D1) (Lange, 2008), 
which increases oncogene expression and thus allows for tumour progression. The intracellular 
cytoplasmic cascades also affected by progesterone and oestradiol include mitogen-activated 
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protein kinase (MAPK), PI3K and c-Src kinase (Itoh et al., 2005; Lange, 2008). These cascades 
cause upregulation of cyclins D1 and E, CDK2 activation, apoptosis mediation as well as an 
accumulation of cells in the in S-phase of the cell cycle (Itoh et al., 2005; Lange, 2008). This 
upregulation of oncogenes and oncoproteins in breast cancer cells therefore encourages tumour 
progression (Leonhardt et al., 2003). The reduction of biomarker expression, particularly ERα 
and PR, in this study is thus more likely to reflect transcriptional activity of these proteins.  
 
The Effects of Anastrozole on MCF-7 Cells 
Anastrozole is an aromatase inhibitor, it binds to the aromatase enzyme and prevents 
conversion of androgens to oestrogens, thus reducing the available pool of oestrogens for 
hormone-dependent cancer progression (Miller et al., 2005). In MCF-7 cells, exogenous 17β-
oestradiol has been shown to upregulate 104 genes including BRCA1, cyclin D1, IGF-binding 
protein4, pS2, BCL2 and down-regulate 109 genes including BAK1, TGFβ, ERBB2, ERBB3 
and Era (Itoh et al., 2005). All these genes are implicated in tumour progression, proliferation, 
immune evasion and anti-apoptosis in cancer cells. Of the genes upregulated and 
downregulated by 17β-oestradiol in the MCF-7 cell line, Anastrozole treatment downregulated 
75% of the upregulated genes, and upregulated 78.9% of the downregulated genes (Itoh et al., 
2005). This shows a reversibility of the oestrogen effects on hormone-dependent breast cancer 
cells.  
Anastrozole treatment (at 1 µmol/L for 1 week) of MCF-7aro cells (cells transfected with the 
aromatase gene) has been shown to downregulate ERα gene expression (Itoh et al., 2005). 
Other studies conversely showed that MCF-7 cells treated with  a combination of 10 nM 17β-
oestradiol and 100 nM Anastrozole for 48 hours marginally increase ERα expression (Smollich 
et al., 2009). In our laboratory, it has previously been found that 72 hour Anastrozole treatment 
caused an increase in nuclear and cytoplasmic ERα expression (Gil et al., 2013). However, in 
the present study, Anastrozole treatment following a hormone pre-treatment (both at 1µM) to 
simulate in vivo conditions induced a decreased ERα nuclear and higher ERα cytoplasmic 
expression, as well as a decreased PR expression. The addition of simultaneous hormone 
treatment further reduced ERα and PR expression.    
The variance in the aforementioned results is perhaps due to the indirect effects of 
progesterone, in the current study, on ERα expression (McDonnell and Goldman, 1994; Lange, 
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2008). In MCF-7 cells, PR-A has been found to regulate ER function (McDonnell and 
Goldman, 1994) indicating that hormone therapies that target only oestrogen and the ER may 
not be as effective as a combination against both oestrogen/ER and progesterone/PR. While 
oestrogen induces proliferation, progesterone seems to be a contrary steroid producing both 
proliferative as well as inhibitory responses in MCF-7 cells as they seem to require the presence 
of other receptors such as ERα and EGFR (Lange, 2008). PRs also associate with co-regulators, 
they can also upregulate genes without PREs through other factors and bind directly to proteins 
in the cytoplasm (Lange, 2008).  
In the current study, Anastrozole treatment induced a reduction in PR expression, more so 
when additional hormonal stimuli were present, indicating a particular role for hormonal 
regulation of the PR. Clinically, patients with ER+/PR+ breast cancers undergoing Anastrozole 
treatment showed that a comparatively higher PR expression, but not ER expression, was 
linked with an increased time to treatment failure and increased overall survival (Anderson et 
al., 2011). Further in vitro studies would need to be performed to determine if long-term 
treatment with Anastrozole following hormone pre-treatment would correspond to clinical 
results.  
Interestingly, Gil et al. (2013) showed that deprivation of hormones from culture media 
resulted in upregulated ERα expression, as a possible compensatory mechanism for low 
hormonal stimuli. Clinically, downregulation of ERα is associated with increased recurrence 
and metastasis (Dhasarathy et al., 2007; Aktas et al., 2011). Thus, in the current study, 
following Anastrozole treatment the reduction in PR and ERα may in fact be indicative of an 
increased invasive profile. Morphologically, cells exhibiting a more mesenchymal phenotype 
(small, elongated cells) are regarded as being more invasive. The MCF-7 cells in this study 
presented a heterogeneous morphology, displaying cells associated with a more mesenchymal 
phenotype, as well as the more typical polygonal cells, indicative of more differentiated 
phenotypes (Dhasarathy et al., 2007).  Invasive phenotypes are characterised as being highly 
proliferative. Ki67 is clinically used as a marker of proliferation (Scholzen and Gerdes, 2000). 
However, the present study showed no significant change in proliferation (Ki67) with any 
hormone-therapy treatment regardless of simultaneous hormone treatment.  
Moreover, while studies implicate progesterone alone or in combination with 17β-oestradiol in 
increasing metastatic potential of breast cancer cells (Faivre et al., 2005; Fu et al., 2008), in the 
current study, treatment with 17β-oestradiol and progesterone alone did not significantly 
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increase the proliferative potential of MCF-7 cells.  These hormones instigate upregulation of 
certain oncogenes which allows for increased proliferation, decreased apoptosis and metastatic 
progression of these cells (Faivre et al. 2005, Fu et al., 2008). However, proliferation is an 
active event and only part of the invasive process. Our results hint at the production of a pre-
metastatic profile which may be mediated by cytoplasmic expression of ERα and PR.  
While clinical assessment of ER/PR expression considers only nuclear presentation, PR and ER 
function in two major ways, genomically causing transcription of target oncogenes and non-
genomically stimulating intracellular signalling cascades (Wen et al., 1994; Zhang and 
Trudeau, 2006). Cytoplasmic staining is associated with non-genomic effects of these 
receptors, and thus may contribute to tumour progression independently of transcriptional 
events. Cytoplasmic ERα, for example, is implicated in the induction of matrix 
metalloproteinase function which promotes tumour invasion (Björnström and Sjöberg, 2004). 
That Anastrozole treatment without additional hormonal influences, increased cytoplasmic ERα 
expression in this study, is thus of concern, considering that such localisation of this marker is 
not considered in clinical diagnosis. 
Additionally, Anastrozole treatment in the present study induced a significant increase in 
MUC1 expression. This corresponds to previous results from our lab performed with no 
hormone pre-treatment (Gil et al., 2013), which indicates that the hormone pre-treatment had 
no definitive effect with regards to MUC1 expression. MUC1 is upregulated in the majority of 
breast cancers and has been implicated in interacting directly with ERα, stimulating co-
activator binding as well as ERα-mediated transcription (Wei et al., 2006). Thus the substantial 
increase in MUC1 intensity, in this study, may be a compensatory mechanism induced by 
MCF-7 cells in response to Anastrozole treatment and the concomitant reduction in ERα 
expression. This increase in MUC1 is postulated to occur as a non-ERα–mediated transcription 
under the influence of other factors. Importantly, the cytoplasmic domain of MUC1 can 
undergo nuclear translocation where it may induce ERα transcription (Wei et al., 2006; 
Khodarev et al., 2009). It is proposed that the increase in MUC1 as noted in this study is thus a 
compensatory mechanism that, given time, would allow for the replenishment of ERα. Long 
term in vitro studies are needed to verify this postulation. Notably, the present study shows that 
simultaneous treatment with hormones and Anastrozole decreased MUC1 expression. This 
contrasted with qualitative analysis which, when co-localised, revealed that MUC1 dominated 
under hormonal stimulation. Correlation analysis of MUC1 and ERα, further showed no 
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definitive association between the biomarkers; however, as seen visually, hormonal stimulation 
resulted in a stronger, yet low correlation being attained.  Interestingly, progesterone binding to 
PR-A inhibits ER transcriptional activity  (Wen et al., 1994) which includes the MUC1 gene 
(Zaretsky et al., 2006) and may thus be responsible for low correlation.  
MUC1 interaction with PR has been indicated in endometrial cell lines, which are also 
hormone-dependent, and ERα in breast cancer cells (Horne et al., 2006; Wei et al., 2006; 
Dharamaraj et al., 2010). In this study, treatment with Anastrozole induced nuclear and 
cytoplasmic MUC1 dominance over PR. It was further determined that under Anastrozole 
treatment MUC1 and PR strongly correlated. However, this correlation was dependent on 
cytoplasmic localisation, again illustrating the importance of considering staining in this 
compartment. Interestingly, MUC1 no longer dominated PR expression with the addition of 
continuous hormone treatment, with the correlation between markers fairly strong in the 
cytoplasm only. This indicates hormonal regulation of MUC1 (Horne et al., 2006; Wei et al., 
2006; Dharamaraj et al., 2010). Our results confirm clinical data that show breast tumour 
cytoplasmic MUC1 expression is significantly associated with PR expression (van der Vegt et 
al., 2007).   
MUC1 can also translocate to the mitochondrial outer membrane, inhibiting the release of 
apoptotic proteins (Kufe, 2009). Previous studies have shown that Anastrozole treatment 
downregulated the anti-apoptotic Bcl-2 gene (Itoh et al., 2005), which would allow for an 
increase in apoptosis. In the present study, we assessed phosphatidylserine expression as an 
early marker of apoptosis, with additional nuclear propidium iodide staining indicating later 
stages of cell death.  Anastrozole induced a significant decrease in cells undergoing apoptosis. 
This divergence with laboratory data (Itoh et al., 2005), conversely supports clinical data which 
shows that Anastrozole treatment is not linked to reduced tumour size (Cuzick et al., 2014).  
While our results could be due to the pre-treatment of the cells with hormones, indicating that 
the hormone environment plays a critical role with regards to protection against apoptosis, with 
concurrent hormone treatment there was no significant difference in apoptotic cell numbers. 
Further studies are necessary to elucidate the role of Anastrozole in apoptosis induction. We 
further propose that since cytoplasmic MUC1 may be involved in limiting apoptosis that the 
effects of Anastrozole may have been impeded by this protein. This postulation requires 
verification. 
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The Effects of RU486 on MCF-7 Cells 
RU486 is a progesterone antagonist usually used as ‘the morning after’ pill to prevent 
pregnancy. It is not commonly used as a cancer hormone-therapy treatment, as progesterone 
effects in hormone-dependent cancer are still not fully understood or agreed upon. However, as 
a progesterone antagonist, it binds to the LBD of the PR inhibiting progesterone-mediated 
activity (Vegeto et al., 1992). Therefore, in the present study, it was interesting to see the 
effects of RU486 on biomarkers in hormone-dependent breast cancer.  
In our lab, it has been previously found that 72 hour RU486 treatment caused a significant 
increase in ERα and MUC1 expression in the nucleus and cytoplasm (Gil et al., 2013). The 
present study confirms the increased ERα expression, particularly in the cytoplasm. However, 
the hormone pre-treatment conversely affected MUC1 expression, causing a significant 
decrease compared to results found by Gil et al. (2013). In this study RU486 treatment induced 
a significant decrease in PR expression as well. This correlates to the clinical study conducted 
by Horwitz (1992) whereby 3 week RU486 treatment decreased tumour PR expression. 
However, in the present study, the simultaneous treatment with RU486 and hormones caused 
an increase in PR expression while concomitantly reducing MUC1 and ERα expression. The 
results of this study indicate that PR expression was affected by hormonal stimuli; however, PR 
mediated transcriptional activity is not fully dependent on progesterone alone (Lange, 2008).  
As previously discussed, a higher PR expression correlates to an increase in the time to 
treatment failure and thus overall survival (Anderson et al., 2011). Therefore, the short-term 
treatment in this study with simultaneous RU486 and hormones (indicative of an in vivo 
environment) would indicate a potential positive impact on patient survival. However, 
cognisance must be given that cytoplasmic PR as noted in this study, may mediate signal 
transduction pathways independently of transcriptional events, which include promoting cells 
through the cell cycle and thus promoting tumour progression (Leonhardt et al., 2003).  
However, it must be noted that RU486 treatment in this study had no significant effect on 
expression of the proliferative marker Ki67, regardless of additional hormonal stimulation. 
These results contradict reports of RU486 inhibition of hormone-dependent breast cancer cell 
proliferation (Horwitz et al. 1992). This inhibition was shown to be mediated by PR 
expression, and in our study, PR expression in RU486 treated cells alone, was decreased. With 
the addition of hormones and despite the increase in PR expression, RU486 was still unable to 
inhibit proliferation. Progestins have been shown to stimulate proliferation, therefore the 
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combination of hormones with RU486, may have abrogated the inhibitory effect of the drug 
(Moore et al., 2006).  Further analysis must be undertaken to identify the mechanism 
responsible for the stasis seen in the current study.  
As previously mentioned, MUC1 gene expression has been linked to progesterone-PR 
mediated transcription in endometrial cell lines (Horne et al., 2006; Dharmaraj et al., 2010). 
The results obtained in the current study indicate that MCF-7 cells are also influenced by 
progesterone and the PR. RU486 treatment induced a strong correlation between PR and 
MUC1, and ERα and MUC1, regardless of cellular localisation. With simultaneous treatment 
with hormones, the strong correlation between PR and MUC1 expression was maintained in the 
nucleus only. Importantly, RU486 has PR agonist effects acting specifically on the PR-B 
isoform (Hill et al., 2012). The PR antibody used in this study did not differentiate between 
isoforms therefore any agonist effects could not be isolated. That RU486 has PR-independent 
actions that have yet to be fully understood (Tieszen et al., 2011, Chen et al., 2014), and may 
explain the effects seen on ERα expression and MUC1 expression.  
RU486 has been shown in short-term clinical studies to inhibit mammary tumour growth 
without inducing a reduction in tumour size (Horwitz, 1992). In the present study, RU486 with 
or without simultaneous hormone treatment induced a significant decrease in the number of 
apoptotic cells. However, the additional hormone stimulation did result in a lower number of 
cells undergoing apoptosis, reflecting observations that progesterone and oestrogens inhibit 
apoptosis in breast cancer cells (Moore et al., 2006). Furthermore, RU486 has weak 
oestrogenic activity (Jeng et al., 1993), the effects of which may abrogate the antagonistic 
function of the hormone-therapy drug. Further experimentation is required to fully map the 
effects of RU486 on cell death. 
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The Effect of Immunotherapy on MCF-7 Cells 
Cancer immunotherapy is the manipulation of the immune system for the treatment of cancers. 
These include monoclonal antibody therapy, non-specific immunomodulation, vaccines and 
adoptive cell transfer (Rosenberg et al., 2008). Adoptive cell transfer (ACT) is the 
identification of anti-tumour lymphocytes ex vivo which are then cultured and expanded and 
used to treat patients (Rosenberg et al., 2008). Considerable research has been performed with 
T-cells and fewer with NK cells. NK cells are not typically found in breast tumours; however, it 
has been established that patients infused with NK cells can undergo remission (Fujisaki et al., 
2010).  
NK cells are part of the innate immune system and they differentiate between cancerous cells 
and healthy cells by detecting the balance between the activating and inhibitory signals they 
receive (Sutlu and Alici, 2009). The activating receptors on NK cells include NKp46 (Sutlu and 
Alici, 2009) which in the current study was used to positively select the NK cells employing a 
magnetic cell sorting technique. This marker is found on the majority of NK cells and a high 
concentration is associated with a high cytotoxic capacity (Miller, 2001). The magnetically 
sorted NK cells were activated with IL-2, which induces proliferation and differentiation, and 
PHA, a mitogen (Domaica et al., 2009). Flow cytometric analysis of NK cell phenotype was 
conducted in our laboratory after magnetic sorting was performed (Augustine et al., 2015). This 
indicated 4 populations based on the CD56 and NKp46 markers. However, after activation with 
IL-2 and PHA only 2 populations were observed and both were CD56
dim
 NKp46
bright
, 
CD56
dim
NKp46
dim
 (Augustine et al., 2015). It has been shown that CD56
dim
 NK cells express 
the oestrogen receptor isoforms, ERα and ERβ (Curran et al., 2001); and the progesterone 
receptor isoforms PR-A and PR-B (Arruvito et al., 2008). These cells may thus be susceptible 
to hormones and hormone-therapy. This indicates that hormones as well as hormone-therapy 
drugs would affect NK cell function.  
In the present study, NK cells were co-cultured with MCF-7 cells during hormone and 
hormone-therapy treatments to simulate ACT. All the treatments induced a significant decrease 
in PR expression. However under NK cell mediation, the addition of hormones to both RU486 
and Anastrozole treatment induced a further reduction in cytoplasmic PR expression while 
concomitantly increasing nuclear PR expression. These results correlate with observations that 
cytoplasmic PR isoforms decrease in response to 24hr RU486 treatment, with nuclear PR 
expression remaining elevated for a longer duration (Wei et al., 1997). Moreover, while the 
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present study did not distinguish between the PR isoforms, high levels of PR-A are implicated 
in more aggressive tumour behaviour compared to high expression of PR-B (Jacobsen et al., 
2005). It is thus necessary to conduct further experiments using the different isoforms to more 
accurately assess implications of alterations in PR expression. However, the data suggests that 
NK mediation together with hormone-therapy, under hormone stimulation, differentially affects 
cellular compartments, which is important when considering the genomic and non-genomic 
effects of PR.  
Under immune mediation MUC1 and PR showed a strong nuclear correlation, with both 
Anastrozole and RU486 treatment, with PR dominating the nucleus. With the addition of 
hormones, correlation between the biomarkers reduced, with slight dominance of PR in the 
cytoplasm. These results again implicate PR genomic transcription of factors involved in 
tumour progression (Wen et al., 1994; Zhang and Trudeau, 2006). While tumour progression 
also takes into account cellular proliferation, in the current study, immunotherapy decreased the 
presentation of the Ki67 proliferative marker in all hormone-therapy treatment groups; however 
this result was not significant and thus impedance of proliferation cannot be affirmed.  
NK cell mediation also had a strong influence on the relationship between MUC1 and ERα, 
affirming the association between these two markers as previously mentioned (Wei et al., 
2006). MCF-7 cells treated with combined immunotherapy and Anastrozole or RU486 
hormone-therapy induced a significant increase in cytoplasmic ERα expression and decrease in 
nuclear ERα expression. With additional simultaneous hormone treatment, there was a 
comparative increase in expression in both compartments. As previously mentioned, 
downregulation of ERα is associated with increased recurrence and metastasis in a clinical 
setting (Dhasarathy et al., 2007; Aktas et al., 2011); thus this result may indicate that this three-
pronged approach shows the efficacy of  NK  cell mediated ACT. However, we must consider 
that ERα can in turn mediate transcription of MUC1 (Wei et al., 2006). The results may thus 
conversely indicate a shift to MCF-7 cell defence against NK cell cytotoxic capacity, since 
MUC1 facilitates evasion of the immune response (Yawata et al., 2008). 
MUC1 expression in combined hormone-therapy and immunotherapy mimic the PR results, 
with a decrease in expression noted with both Anastrozole and RU486 treatment. However, the 
addition of simultaneous hormone treatment, increased MUC1 expression, indicating that the 
hormones partially abrogated the effects of the combined hormone-therapy and 
immunotherapy. 17β-oestradiol  has been shown to significantly decrease NK cell activity in 
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NK cells isolated from mice (Curran et al., 2001). Added to which is that MUC1 has a large 
impact on protein-protein interaction in cancer cells and can influence cancer progression. 
These results bear out observations that MUC1 expression may be induced in MCF-7 cells to 
limit NK cell function.  
NK cells function primarily in cytotoxicity, and it was thus expected that activated NK cells 
would induce apoptosis in MCF-7 cells. However, in this study, using Anastrozole or RU486 
significantly decreased the induction of apoptosis even under hormone mediation. Clinical 
studies have shown that Anastrozole treatment of postmenopausal ER
+
 breast cancer patients 
causes an increase in total white blood cell count but no change in lymphocyte count 
specifically (Ray and Ficek, 2012). The treatment also caused increased cytokines, IFNγ and 
IL-12, and decreased IL-4 and IL-10 levels (Ray and Ficek, 2012). This indicates that NK cell 
numbers may not be as important as the functionality of NK cells. In the present study, a low 
NK cell concentration was used to treat the MCF-7 to mimic the tumour environment more 
closely; however, the concentration used was still higher than found naturally in tumours. There 
is no information about the effect of NK cells on PR expression in breast cancer. However, as 
previously mentioned, CD56
dim
 NK cells express the oestrogen receptor isoforms, ERα and 
ERβ (Curran et al., 2001); and the progesterone receptor isoforms PR-A and PR-B (Arruvito et 
al., 2008), and it is thus possible that the hormone therapies may have indeed directly affected 
NK cell function.  
 
The Difference between Hormone-Therapy and Combined Therapy  
In the current study, NK cell presence induced a decrease in MUC1 expression with 
Anastrozole and RU486 treatment, compared to the hormone-therapy alone. This decrease in 
MUC1 could potentially make the MCF-7 cells more susceptible to NK cell-mediated cytotoxic 
action; however, this was not evident as no increase in apoptotic cells was noted. However, it 
must be noted that MUC1 can be secreted – this form of MUC1 would have been undetectable 
in this study – and has been shown to inhibit cytotoxic lymphocyte function (Zhang et al., 
1997). With the addition of hormonal stimuli to the immunotherapy procedure, MUC1 
effectively increased under both Anastrozole and RU486 treatment. This indicates a mechanism 
of hormonal regulation of MUC1. It has been documented that increased MUC1 inhibits NK 
cell mediated lysis in NK-sensitive K562 cells with a radiolabelling lysis assay at 4 hours  
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(Zhang et al., 1997). However, when K562 cells were co-incubated with MUC1, MUC1 bound 
to NK cells effectively inhibiting NK cell-mediated apoptosis (Zhang et al., 1997). Although 
Cooley et al. (1999) found that MCF-7 cells are not inherently resistant to NK cells, other 
studies have reported otherwise (Burns et al., 2003). Furthermore, IL-2 activation of NK cells 
has been seen to reduce the effect of this resistance (Burns et al., 2003; Sutlu and Alici, 2009). 
Therefore, MUC1 mediated inhibition of NK cell function could be an explanation for the 
decreased apoptotic activity seen in the current study, notwithstanding that MUC1 as 
previously mentioned can inhibit the release of apoptotic proteins from the mitochondria (Kufe, 
2009). 
Oestrogen also has a function in inhibiting apoptosis in the MCF-7 cell line by increasing anti-
apoptotic Bcl-2 protein expression and decreasing pro-apoptotic caspase-3 activation (Kandouz 
et al., 1996). In breast cancer, progesterone increases anti-apoptotic bcl-xL expression and 
decreases apoptotic bcl-2 expression, promoting cell survival by decreasing apoptosis (Moore 
et al., 2000), and thereby promoting tumour progression. Further evidence for the amelioration 
of apoptosis induction by hormonal intervention is indicated by 1µM oestrogen treatment 
reducing NK cell cytotoxic activity in mice, thereby increasing spontaneous tumour generation 
(Ferguson and McDonald, 1985). In the current study, the combined therapeutic modality, 
whether using RU486 or Anastrozole treatment, in a hormone environment increased ERα 
expression compared to hormone-therapy alone. Conversely, without the hormones, ERα 
expression was decreased. This highlights that NK cell function is somehow impeded in our 
culture system.  
NK cells have been found, both in in vitro and mouse in vivo studies to be able to target tumour 
cells (Levy et al., 2011). Despite an increase in NK stimulatory molecules found in tumour 
cells, NK cells are rarely found in the tumour (Levy et al., 2011; Leibovici et al., 2011). 
However, tumour infiltrating NK cells have abnormal receptor expressions indicating the 
interaction between tumour cells and NK cells may result in loss of receptor expression for 
immune evasion (Levy et al., 2011). In breast cancer, the NK cell activating receptors shown to 
be decreased are NKp30, NKG2D, DNAM-1 and CD-16, while the inhibitory receptors shown 
to be increased are NKG2A and CD-27 (Mamessier et al., 2011). These alterations decreased 
the cytotoxic capacity of NK cells via degranulation (CD107). However, it did not affect their 
cytokine production of IFN-γ and TNF-α. Thus, it has been suggested that cytokine-mediated 
activation of NK cells may overcome this barrier either in vivo or ex vivo (Levy et al., 2011). A 
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clinical trial administrating IL-2 activated NK cells and IL-2 to patients with tumours showed 
an increase in NK cell mediated cytotoxicity in lymphoma, melanoma and renal cancers (Geller 
et al., 2011). The cytokine IL-2 has been implicated in tumour shrinkage, increased NK cell 
cytokine production as well as increased NK cell proliferation  (Lechner et al., 2011). Other 
cytokines that have also been found to have various anti-cancer effects include TNF-α, IFNs 
and IL-12 (Leibovici et al., 2011). However, these cytokines can also induce tumour 
progression. In the present study, no significant effect was found with regards to NK cell 
cytotoxic activity on the MCF-7 cells although IL-2 stimulation was used. A further study 
would be to assess cytokine production by NK cells when used as a treatment in conjunction 
with hormone-therapy, as well as assess their cytotoxic capacity and effects on receptor 
expression in breast cancer cells.  
In the current study, combined therapy induced a significant decrease in PR expression as 
compared to hormone-therapy alone, regardless of hormone mediation. The PR has been linked 
to mature peripheral NK cells (CD56
dim
CD16
+
KIR
+
) only and when activated by progesterone 
causes caspase-dependent cell death and suppresses cytokine secretion (particularly IL-12-
induced IFN-y secretion) (Arruvito et al., 2008). These effects are inhibited by RU486. 
However, the CD56
bright
 NK cells are not affected in this way (Arruvito et al., 2008). In the 
present study, there was a significant decrease in the number of cells undergoing apoptosis 
when treated with the NK cells regardless of the hormone-therapy treatment. This could be 
explained by the low ratio of NK cells to MCF-7 cells used in this study, although this was 
done to mimic the low numbers of NK cells within a tumour (Mamessier et al., 2011). A future 
study would be to determine if the NK cells have a change in their receptor status and/or if 
there is hormone induced apoptosis of the NK cells themselves.  
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Further Studies and Limitations 
There have been many advances in breast cancer treatments, yet despite this, the majority of 
patients rarely survive longer than 5 years (Youlden et al., 2012). Breast cancer 
immunotherapy, including NK cell ACT, has also proved ineffective so far (Rosenberg et al., 
2008; Geller et al., 2011). These ineffective treatment modalities suggest a more complex 
tumour interaction with the tumour microenvironment. Therefore, a more complex strategy is 
needed to combat the tumour evasiveness of the current treatments. In the current study, the 
impact of a combination hormone-therapy and NK cell immunotherapy was investigated in 
MCF-7 cells. The results indicate that the combined treatment modality reduced biomarker 
expression of the MCF-7 cells when compared to hormone-therapy alone. 
A restriction of this study was the yield of NK cells by the volume of blood permitted per 
volunteer (Human Ethics Clearance M081036). It would be advisable to increase the volume of 
blood obtained for isolation of lymphocytes, ethical issues permitting, to allow for the 
establishment of increased MCF-7:NK cell ratios. NK cells also express ERα and ERβ (Curran 
et al., 2001) and PR-A and PR-B (Arruvito et al., 2008) implicating hormones in immune 
control. Further studies would involve assessing ER and PR expressions in NK cell populations 
after hormone-therapy.  In the current study we looked at apoptosis in the MCF-7 cells after 
hormone-therapy and NK cell immunotherapy. A limitation noted was that camptothecin 
treatment did not induce a significant increase in apoptosis to act as a definitive positive 
apoptosis control; therefore, another apoptotic inducer for MCF-7 cells would have to be found. 
Staurosporine (1 µM) has been found to significantly increase phosphatidylserine translocation 
in MCF-7 cells at 4 hours (Mooney et al., 2002) and its use is thus proposed for the induction 
of early apoptosis. A further study would be to assess cytokine production by NK cells, as well 
as assess their cytotoxic ability and effects on receptor expression in breast cancer cells.  
The current study investigated short-term treatment of MCF-7 cells with hormone-therapy 
(72 hours) and immunotherapy (4 hours). A further study is needed to determine if long-term 
treatment with hormone-therapy and immunotherapy would affect the results. This long-term 
treatment would correspond to clinical treatment of breast cancer with hormone-therapy. 
Adding onto this, an investigation regarding these therapies in a 3D culture system would 
mimic tumour morphology more closely than in a 2D culture system (Kim, 2005; Augustine et 
al., 2015). This would produce more clinically relevant and accurate results. 
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Importantly, we have shown that the selection of appropriate controls is essential to the 
development of experimental protocols and the interpretation of results. In this study, it was 
determined that the three levels of control treatments used showed considerable variation in 
relation to the expression of PR, ERα and MUC1. Media B was the cell culture medium used to 
induce cell cycle synchronisation. The dDMSO was viewed as a more meaningful control, 
given that it served as the diluent control for all hormone-therapy drugs and the hormones 
themselves, while the EP control served as a hormone control for 17β-oestradiol and 
progesterone action alone. In an animal model in vivo the hormones and drugs can be dissolved 
in peanut oil (Watts et al., 1994; Asselin-Labat et al., 2010); which in itself remains an 
additional variable. While the use of DMSO as a diluent for the hormone-therapy drugs and the 
hormones may be regarded as a limitation of this study, we have identified that this diluent 
affected biomarker expression as well as the number of apoptotic cells. Comparisons were thus 
performed with regards to DMSO and not the Media B control to account for this limitation. It 
must be noted that hormones, as steroids, would not be dissolvable in PBS. Ethanol could be 
employed as a diluent; however it too would have most likely has its own effects on MCF-7 
cells. With regards to in vitro treatment of cells, some studies used DMSO as a vehicle control 
with regards to 17β-oestradiol (Bursch et al., 1996; Itoh et al., 2005; Wessler et al., 2006; 
Sukocheva et al., 2009), progesterone (Sukocheva et al., 2009), anastrozole (Itoh et al., 2005; 
Gil et al., 2013) and RU486 (Sukocheva et al., 2009; Gil et al., 2013). Ethanol is also used as a 
vehicle control with 17β-oestradiol (Métivier et al., 2003; Wu et al., 2004; Sonne-Hansen and 
Lykkesfeldt, 2005; Brayman et al., 2006; Moore et al., 2006; Maia et al., 2008), progesterone 
(Ahola et al., 2002; Richer et al., 2002; Brayman et al., 2006; Moore et al., 2006; Dharmaraj et 
al., 2010), anastrozole (Smollich et al., 2009) and RU486 (Ahola et al., 2002; Wu et al., 2004; 
Brayman et al., 2006; Moore et al., 2006). Although these studies compare their treatments to 
the vehicle control they do not indicate whether the vehicle they used actually had an effect on 
the cells. Other studies using 17β-oestradiol, progesterone, anastrozole or RU486 do not 
indicate a vehicle control and compare their results to untreated cells (Cho et al., 2004; Wei et 
al., 2006). This study highlights the necessity of examining expression patterns induced by 
diluents alone. 
Another limitation is the PR antibody utilized in this study, rabbit anti-human PR (Abcam 
ab97801). It is a general PR antibody, binding to PR regardless of isoform. The different PR 
isoforms have been implicated in differing responses in breast cancer and a high ratio of PR-
A/PR-B has been associated with a poorer outcome in patients undergoing hormone-therapy 
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(Hopp et al., 2004). Therefore, another study would be to assess these isoforms with regards to 
the treatment modalities in this study. This would provide additional information regarding 
these treatment mechanisms in breast cancer. It has been noted that oestrogen alters breast 
cancer gene profiles, with Anastrozole partially abrogating these alterations (Itoh et al., 2005). 
Progesterone also alters breast cancer gene expression, mainly via PR-B (Richer et al., 2002). 
Therefore, a comprehensive gene expression analysis with the treatment modalities outlined in 
this study would be valuable.  
Lastly, it is proposed that Anastrozole and RU486 treatment, together targeting both hormones 
and hormone receptors would produce a unique response. This dual hormone-therapy approach 
may reduce the ability of breast cancer cells to minimise the effects of one drug by the cross-
talk of the other hormone and hormone receptor.  
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CONCLUSION 
The quantification of biomarker expressions to classify breast cancers is a useful tool, and with 
this quantification a standardisation for diagnosis is beneficial. The results of this study indicate 
that consideration of both cytoplasmic and nuclear staining is important to understanding 
tumour progression and treatment, where much remains unknown. Increased nuclear 
expression would indicate increased genomic effects while increased cytoplasmic expression 
would indicate increased activation of signalling pathways important in tumour progression. 
The use of a hormone pre-treatment to simulate the in vivo hormone environment is also an 
important step for hormone-dependent breast cancer research in vitro. This step alters the MCF-
7 cells biomarker expression and thus subsequent treatments performed on these cells can have 
effects contrasting to those in which this step was overlooked.  
Hormone-therapy treatments produced an increased cytoplasmic ERα expression, which is 
associated with hormone-therapy resistance. However, this was partially ameliorated with the 
addition of the simultaneous hormone treatment, indicating an oestrogen and progesterone 
hormonal influence in ERα expression. Hormone-therapy produces variable effects on MUC1 
expression, with Anastrozole increasing and RU486 decreasing MUC1 expression. This, again, 
was partially ameliorated under hormonal mediation, indicating that MUC1 expression also is 
influenced with oestrogen and progesterone. Hormone therapy treatments caused a decrease in 
PR expression, which was further reduced with the Anastrozole treatment under hormone 
mediation. Interestingly, under hormone mediation, RU486 induces an increase in PR 
expression, indicating an interaction between these three compounds. Notably, the combination 
of Anastrozole hormone-therapy in a continued simulated hormone environment results in a 
decrease in all three biomarkers, this is a phenotypic change associated with metastatic 
processes, which is contra-indicated with regards to breast cancer treatment.  
The addition of immunotherapy to the hormone-therapy treatment produced a decrease of all 
three biomarkers. Conversely, NK cell mediation under hormonal influence, results in an 
increase in ERα, MUC1 and nuclear PR expression with a decrease in cytoplasmic PR 
expression. These results indicate that NK cells mediate the expression of  these biomarkers 
depending on the hormonal milieu. This also indicates that NK cell influence may cause MCF-
7 cells to mediate PR expression between cytoplasmic and nuclear compartments. 
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Increased PR expression or MUC1 homogenous expression is associated with genomic effects 
including oncogene transcription as well as inhibition of apoptosis. Furthermore these 
biomarkers also interact with ERα and are thus also implicated in ERα mediated tumour 
progression. MUC1 has also been associated with immune evasion which is essential for 
metastasis. Therefore, not only is the level of biomarker expression important, but so is the 
cellular location in breast cancer diagnosis and treatment. There also seems to be a more 
definite role for progesterone in hormone-therapy as well as NK cell immunotherapy than 
currently apparent. The effect of hormones and hormone-therapy on NK cells and other cells of 
the immune system should also be taken into account when treating hormone-dependent breast 
cancer. These results may explain why despite advances in treatment strategies, overall survival 
remains poor with recurrence common. An expanded study is needed looking at longer 
hormone-therapy treatment times to mimic the clinical conditions in which these drugs are 
used, and to validate the postulations of this study.  
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APPENDIX B: RECIPES 
B1. Media A  
- 45ml DMEM (Lonza 12-604) 
- 5ml FBS 
- 50µl P/S 
All were added together in 50 ml tubes under sterile conditions and stored at 4°C. 
 
B2. Cryopreservation media  
- 10% DMSO 
- 60% FBS 
- 30% DMEM (Lonza 12-604) 
Mixed all together in a 10 ml centrifuge tube and stored at -20°C. 
 
B3. Phosphate Buffered Solution (PBS) 
- 8g sodium chloride (NaCl) 
- 0.2g potassium chloride (KCl) 
- 1.44g di-sodium hydrogen orthophosphate (Na2HPO4) 
- 0.24g potassium di-hydrogen orthophosphate (KH2PO4) 
- 1l dH2O 
All the solids were dissolved in 800 ml dH2O and the pH adjusted to 7.4.  
This was then adjusted to 1l with additional dH2O and autoclaved. Stored at 4°C.  
 
B4. Media B  
- 45ml Phenol red free DMEM (Lonza 12-917)  
- 5ml DCC-stripped FBS 
- 50µl P/S 
All were added together in 50 ml tubes under sterile conditions and stored at 4°C. 
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B5. DCC-stripped FBS 
- 20ml Tris-HCl (0.1 M, pH 8.0) 
- 180ml dH20 
- 0.05g dextran T500 
- 0.5g activated charcoal powder 
- 80ml Heat inactivated FBS 
Added all together except FBS and mixed overnight at 4°C in an airtight container. 
Filled 8 10ml tubes with suspension and centrifuged at 1000x g for 20 min. 
Discarded supernatant, refilled tubes with DCC suspension and repeated centrifugation. 
Discarded supernatant and added 10 ml FBS to each tube. 
Repeated centrifugation, sterile filtered supernatant with 0.2 μm filter and discarded pellet. 
Stored at -20°C. 
 
B6. 0.1 M Tris-HCl  
- 1.22g Tris 
- 100ml dH2O 
- 2M HCl 
Dissolved Tris in 80 ml dH2O and adjusted the pH to 8.0 with the HCl.  
Adjusted this to 100 ml with additional dH2O. 
 
B7. 1000x treatment stock solutions (1mM) 
- 0.0029g Anastrozole powder 
- 0.0043g RU486 powder 
- 0.0027g 17β-oestradiol powder 
- 0.0031g progesterone powder 
- 1ml DMSO (x4) 
- 9ml Media B (x4) 
To each labelled 10 ml centrifuge tubes (see below), 1 ml DMSO was added.  
To each tube, the appropriate powders (hormone/drugs/none) were added and dissolved (see below). 
To each tube 9 ml Media B was added.  
Each solution was sterilised with a 0.2 μm filter and stored at -20°C. 
 
ANAS = 1 ml DMSO + 9 ml Media B + anastrozole powder 
RU486 = 1 ml DMSO + 9 ml Media B + RU486 powder 
EP = 1 ml DMSO + 9 ml Media B + 17β-oestradiol powder + progesterone powder 
dDMSO = 1 ml DMSO + 9 ml Media B 
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B8. Miltenyi buffer 
- 100ml PBS  
- 0.5g BSA  
- 2mM EDTA 
The BSA and EDTA were dissolved in the PBS.  
Stored at 4°C. 
B9. Activation Media A 
- RPMI 1640  
- 10% FBS 
- 0.1% P/S  
- 1 μg/ml phytohaemagglutinin (PHA)  
- 0.8 ng/ml Interleukin-2 (IL-2) 
All were added together and used immediately. 
 
B10. Activation Media B 
- RPMI 1640 
- 10% FBS 
- 0.1% P/S  
- 0.8 ng/ml IL-2 
 
B11. Antigen Retrieval Buffer (ARB)  
- 100ml dH2O  
- 1.22g Tris(hydroxymethyl)aminomethane 
- 5g urea 
The Tris and urea were dissolved in 80 ml dH2O.  
The pH was adjusted to 9.5. 
This was adjusted to 100 ml and stored at 4°C. 
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APPENDIX C: SUPPLEMENTARY IMAGES 
   
   
  
 
 
Figure C1. Representative photomicrographs showing the ICC controls 
Treatment groups: A: negative control B: MUC1 primary antibody control C: ERα primary antibody control D: 
PR primary antibody control E: Alexa Fluor® 488 secondary antibody control F: Alexa Fluor® 594 secondary 
antibody control G: IgG isotype control H: IgG3 isotype control. That no fluorescence is noted bar the DAPI stain 
confirms the efficacy of the technique. Fluorescent microscopy, 40x magnification. 
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Figure C2.  The graphs for MUC1 and ERα correlation in the nucleus (N) and cytoplasm (C) under 
treatment with the controls  
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Figure C3.  The graphs for MUC1 and ERα correlation in the nucleus (N) and cytoplasm (C) under 
treatment with hormone-therapy  
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Figure C4.  The graphs for MUC1 and ERα correlation in the nucleus (N) and cytoplasm (C) under 
treatment with combined hormone-therapy and immunotherapy  
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Figure C5.  The graphs for MUC1 and PR correlation in the nucleus (N) and cytoplasm (C) under treatment 
with controls 
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Figure C6.  The graphs for MUC1 and PR correlation in the nucleus (N) and cytoplasm (C) under hormone-
therapy treatment 
  
Correlations (muc1 er corr.sta 81v*1948c)
ANAS_Nuc lM I
ANAS_Cy toM I
RU486_Nuc l_M I
RU486_Cy to_M I
EPA_Nuc l_M I
EPA_Cy to_M I
EPA_Nuc l_M I
EPA_Cy to_M I
ANAS_Nuc l_M I
ANAS_Cy to_M I
RU486_Nuc l_M I
RU486_Cy to_M I
EPA_Nuc l_M I
EPA_Cy to_M I
EPA_Nuc l_M I
EPA_Cy to_M I
146 
 
 
 
   MUC1 
   ANAS+NK RU486+NK EPA+NK EPR+NK 
   N C N C N C N C 
P
R
 
A
N
A
S
+
N
K
 
N
 
 
C
 
R
U
48
6+
N
K
 
N
 
C
 
E
P
A
+
N
K
 N
 
C
 
E
P
R
+
N
K
 
N
 
C
 
 
Figure C7.  The graphs for MUC1 and PR correlation in the nucleus (N) and cytoplasm (C) under combined 
hormone-therapy and immunotherapy treatments 
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Figure C8. Compensation controls for the Annexin V-PI flow cytometric analysis 
A: Annexin V-FITC stained cells B: PI stained cells 1: Scatterplots of SSC versus FSC 2: Histograms with single 
stained samples (green) unstained samples (blue). 
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B1 
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APPENDIX D: DATA TABLES 
Table D1. The PR expression MFI values  
Treatment Overall (Cell) Cytoplasm Nucleus 
dDMSO 0.066359081 0.063169406 0.087405914 
EP 0.015219127 0.014652951 0.01941196 
ANAS 0.013463791 0.013228454 0.014575683 
RU486 0.016541366 0.016043812 0.019008076 
EPA 0.010852946 0.010710104 0.011970915 
EPR 0.099298576 0.081116268 0.252515427 
dDMSO+NK 0.009459212 0.009426827 0.009787098 
EP+NK 0.009307124 0.009224041 0.009583287 
ANAS+NK 0.009133525 0.009427954 0.009426509 
RU486+NK 0.008764956 0.009184811 0.009093418 
EPA+NK 0.009525461 0.009066107 0.009733158 
EPR+NK 0.009243808 0.008731791 0.009467947 
 
Table D2. The p-values for the normality tests performed on the PR data (p<0.05) 
Treatment Category Shapiro-Wilk Jaque-Bera Chi
2
 
Anderson-
Darling 
dDMSO Overall 0.26 0.3841 0.43858 0.3568 
 Cytoplasm 0.2364 0.3499 0.62101 0.2592 
 Nucleus 0.04134 0.05167 0.22239 0.2459 
EP Overall 0.96 0.9093 0.69489 0.9293 
 Cytoplasm 0.9314 0.9188 0.38046 0.8723 
 Nucleus 0.07439 0.02842 0.087321 0.1143 
ANAS Overall 0.801 0.341 0.273 0.1611 
 Cytoplasm 0.08768 0.2541 0.41422 0.147 
 Nucleus 0.2506 0.4619 0.52709 0.2938 
RU486 Overall 0.0605 0.2886 0.37978 0.0991 
 Cytoplasm 0.03949 0.2453 0.22739 0.0552 
 Nucleus 0.5307 0.6582 0.7697 0.6098 
EPA Overall 0.2867 0.457 0.33075 0.5454 
 Cytoplasm 0.3654 0.4752 0.17841 0.6509 
 Nucleus 0.2546 0.2695 0.58558 0.2714 
EPR Overall 0.01249 0.03536 0.002326 0.01467 
 Cytoplasm 0.454 0.5447 0.46018 0.5934 
 Nucleus 0.000677 0.1056 0.078731 0.000312 
dDMSO+NK Overall <0.0001 <0.001 <0.001 <0.005 
 Cytoplasm <0.0001 <0.001 <0.001 <0.005 
 Nucleus <0.0001 <0.001 <0.001 <0.005 
EP+NK Overall <0.0001 <0.001 <0.001 <0.005 
 Cytoplasm <0.0001 <0.001 <0.001 <0.005 
 Nucleus <0.0001 <0.001 <0.001 <0.005 
ANAS+NK Overall 1.17E-21 0 3.41E-09 2.81E-24 
 Cytoplasm <0.0001 <0.001 <0.001 <0.005 
 Nucleus 1.26E-17 0 2.50E-05 3.06E-22 
RU486+NK Overall <0.0001 <0.001 <0.001 <0.005 
 Cytoplasm <0.0001 <0.001 <0.001 <0.005 
 Nucleus 6.42E-25 0 4.29E-12 1.49E-59 
EPA+NK Overall 2.23E-27 0 1.05E-11 2.27E-48 
 Cytoplasm 1.70E-27 0 5.74E-13 3.70E-54 
 Nucleus 1.23E-25 0 1.46E-08 3.70E-39 
EPR+NK Overall <0.0001 <0.001 <0.001 <0.005 
 Cytoplasm 3.28E-11 0 8.10E-06 0.003255 
 Nucleus 1.22E-08 0 4.66E-05 0.000607 
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Table D3. The p-values for the Mann Whitney pairwise tests performed on the hormone-therapy PR data (p<0.001) (Bonferroni corrected \ uncorrected; Bonferroni 
corrected values used) 
 
 
ANAS DMSO EP EPA EPR RU486 
 
 
O N C O N C O N C O N C O N C O N C 
A
N
A
S
 O  
0.0009521 0.3042 3.00E-13 3.00E-13 3.00E-13 2.84E-07 1.56E-10 0.0002568 4.85E-11 5.39E-07 4.09E-11 1.04E-09 1.04E-09 1.04E-09 2.05E-09 3.78E-11 2.91E-08 
N 0.4142 
 
8.66E-05 3.00E-13 3.00E-13 3.00E-13 0.06223 1.74E-10 0.9672 9.42E-12 4.89E-10 7.24E-12 1.04E-09 1.04E-09 1.04E-09 7.68E-05 1.00E-08 0.002122 
C 1 0.03769 
 
3.00E-13 3.00E-13 3.00E-13 4.28E-08 1.56E-10 6.49E-06 1.84E-10 3.38E-06 1.03E-10 1.04E-09 1.04E-09 1.04E-09 1.54E-10 1.85E-11 1.89E-09 
D
M
S
O
 O 1.30E-10 1.30E-10 1.30E-10  1.58E-06 0.2518 3.03E-12 3.03E-12 3.03E-12 8.98E-15 8.98E-15 8.98E-15 5.13E-10 4.05E-11 7.97E-06 2.30E-14 2.30E-14 2.30E-14 
N 1.30E-10 1.30E-10 1.30E-10 0.0006851  3.24E-08 3.03E-12 3.03E-12 3.03E-12 8.98E-15 8.98E-15 8.98E-15 0.0007856 4.05E-11 0.2168 2.30E-14 2.30E-14 2.30E-14 
C 1.30E-10 1.30E-10 1.30E-10 1 1.41E-05  3.03E-12 3.03E-12 3.03E-12 8.98E-15 8.98E-15 8.98E-15 7.58E-11 4.05E-11 4.34E-07 2.30E-14 2.30E-14 2.30E-14 
E
P
 
O 0.0001234 1 1.86E-05 1.32E-09 1.32E-09 1.32E-09  1.16E-09 0.04507 1.97E-11 2.88E-11 1.97E-11 3.47E-09 3.47E-09 3.47E-09 0.0114 6.35E-07 0.1427 
N 6.80E-08 7.57E-08 6.80E-08 1.32E-09 1.32E-09 1.32E-09 5.06E-07  7.35E-10 1.97E-11 1.97E-11 1.97E-11 3.47E-09 3.47E-09 3.47E-09 3.17E-06 0.5354 1.58E-07 
C 0.1117 1 0.002824 1.32E-09 1.32E-09 1.32E-09 1 3.20E-07  1.97E-11 9.74E-11 1.97E-11 3.47E-09 3.47E-09 3.47E-09 0.0001079 1.73E-08 0.003145 
E
P
A
 
O 2.11E-08 4.10E-09 8.02E-08 3.91E-12 3.91E-12 3.91E-12 8.57E-09 8.57E-09 8.57E-09  5.90E-07 0.43 1.87E-10 1.87E-10 1.87E-10 3.11E-13 3.11E-13 3.11E-13 
N 0.0002343 2.13E-07 0.00147 3.91E-12 3.91E-12 3.91E-12 1.26E-08 8.57E-09 4.24E-08 0.0002565  4.23E-08 1.87E-10 1.87E-10 1.87E-10 3.68E-13 3.38E-13 4.72E-13 
C 1.78E-08 3.15E-09 
4.49E-08 
 
3.91E-12 3.91E-12 3.91E-12 8.57E-09 8.57E-09 8.57E-09 1 1.84E-05  1.87E-10 1.87E-10 1.87E-10 3.11E-13 3.11E-13 3.11E-13 
E
P
R
 
O 4.53E-07 4.53E-07 4.53E-07 2.23E-07 0.3417 3.30E-08 1.51E-06 1.51E-06 1.51E-06 8.13E-08 8.13E-08 8.13E-08  1.44E-08 1.44E-08 2.93E-10 2.93E-10 2.93E-10 
N 4.53E-07 4.53E-07 4.53E-07 1.76E-08 1.76E-08 1.76E-08 1.51E-06 1.51E-06 1.51E-06 8.13E-08 8.13E-08 8.13E-08 6.26E-06  1.44E-08 2.93E-10 2.93E-10 2.93E-10 
C 4.53E-07 4.53E-07 4.53E-07 0.003467 1 0.0001888 1.51E-06 1.51E-06 1.51E-06 8.13E-08 8.13E-08 8.13E-08 6.26E-06 6.26E-06  2.93E-10 2.93E-10 2.93E-10 
R
U
4
8
6
 O 8.91E-07 0.03339 6.68E-08 9.99E-12 9.99E-12 9.99E-12 1 0.001378 0.04695 1.35E-10 1.60E-10 1.35E-10 1.27E-07 1.27E-07 1.27E-07  0.0003402 0.2645 
N 1.65E-08 4.35E-06 8.03E-09 9.99E-12 9.99E-12 9.99E-12 0.000276 1 7.54E-06 1.35E-10 1.47E-10 1.35E-10 1.27E-07 1.27E-07 1.27E-07 0.148  2.48E-05 
C 1.27E-05 0.923 8.22E-07 9.99E-12 9.99E-12 9.99E-12 1 6.88E-05 1 1.35E-10 2.05E-10 1.35E-10 1.27E-07 1.27E-07 1.27E-07 1 0.01078  
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Table D4. The p-values for the Mann Whitney pairwise tests performed on the hormone-therapy and immunotherapy PR data (p<0.001) (Bonferroni corrected \ 
uncorrected; Bonferroni corrected values used) 
 
 
ANAS+NK DMSO+NK EP+NK EPA+NK EPR+NK RU486+NK 
 
 
O N C O N C O N C O N C O N C O N C 
A
N
A
S
+
N
K
 O 
 
9.16E-127 1.30E-21 4.94E-70 2.27E-206 2.82E-55 3.06E-94 1.99E-224 1.45E-41 3.68E-185 1.734E-310 6.65E-132 7.00E-32 2.11E-146 3.84E-11 1.07E-221 8.47E-16 2.15E-246 
N 3.99E-124 
 
3.83E-182 0.08086 4.27E-56 0.0002801 1.28E-25 4.33E-23 2.33E-76 5.84E-09 1.22E-104 0.369 1.38E-47 0.02882 1.74E-84 1.13E-277 1.34E-82 7.86E-285 
C 5.67E-19 1.67E-179 
 
2.33E-115 3.13E-233 1.28E-98 8.46E-172 5.40E-275 9.11E-117 3.61E-246 0 1.30E-198 4.82E-78 5.37E-207 1.02E-44 7.54E-188 1.02E-06 4.28E-221 
D
M
S
O
+
N
K
 
O 2.15E-67 1 1.01E-112  7.60E-43 0.09662 1.74E-07 3.46E-20 6.19E-30 2.03E-09 4.74E-71 0.3128 2.48E-23 0.003287 5.99E-44 3.98E-230 1.69E-65 3.08E-240 
N 9.86E-204 1.86E-53 1.36E-230 3.31E-40  1.13E-50 3.73E-138 2.12E-18 4.17E-194 1.47E-32 0.01497 1.63E-65 1.10E-159 3.36E-49 5.56E-197 3.47E-257 3.33E-139 8.17E-259 
C 1.23E-52 0.1218 5.58E-96 1 4.90E-48  0.004125 8.69E-28 6.24E-19 5.19E-15 9.54E-82 0.00277 3.22E-15 1.71E-06 2.37E-32 3.08E-224 1.46E-58 5.59E-236 
E
P
+
N
K
 O 1.33E-91 5.58E-23 3.68E-169 7.55E-05 1.62E-135 1  1.40E-109 2.49E-28 9.53E-69 9.36E-248 5.38E-23 8.50E-10 2.79E-40 2.28E-36 4.724E-317 1.64E-60 0 
N 8.66E-222 1.89E-20 2.35E-272 1.51E-17 9.23E-16 3.78E-25 6.08E-107  4.64E-194 2.10E-05 8.35E-46 1.16E-30 3.89E-144 2.66E-16 1.71E-201 0 3.23E-140 0 
C 6.31E-39 1.02E-73 3.97E-114 2.69E-27 1.82E-191 2.71E-16 1.08E-25 2.02E-191  1.47E-140 0 8.76E-76 0.008753 7.50E-99 0.0001791 6.52E-305 7.76E-39 1.419E-319 
E
P
A
+
N
K
 O 1.60E-182 2.54E-06 1.57E-243 8.83E-07 6.38E-30 2.26E-12 4.15E-66 0.009138 6.40E-138  5.74E-74 3.31E-13 2.54E-107 5.20E-05 1.87E-161 0 8.21E-129 0 
N 7.54E-308 5.31E-102 0 2.06E-68 1 4.15E-79 4.07E-245 3.63E-43 0 2.50E-71  2.17E-132 1.36E-295 1.56E-106 0 0 1.69E-215 0 
C 2.89E-129 1 5.67E-196 1 7.08E-63 1 2.34E-20 5.05E-28 3.81E-73 1.44E-10 9.44E-130  2.71E-52 0.001595 1.53E-95 0 6.48E-99 0 
E
P
R
+
N
K
 O 3.05E-29 6.00E-45 2.10E-75 1.08E-20 4.77E-157 1.40E-12 3.70E-07 1.69E-141 1 1.11E-104 5.90E-293 1.18E-49  5.38E-74 1.14E-09 2.19E-288 5.23E-43 1.909E-312 
N 9.17E-144 1 2.34E-204 1 1.46E-46 0.0007435 1.21E-37 1.16E-13 3.26E-96 0.02262 6.76E-104 0.6937 2.34E-71  4.22E-121 0 7.24E-111 0 
C 1.67E-08 7.58E-82 4.44E-42 2.60E-41 2.42E-194 1.03E-29 9.92E-34 7.46E-199 0.07789 8.14E-159 0 6.64E-93 4.94E-07 1.84E-118  3.09E-264 1.30E-27 2.16E-292 
R
U
4
8
6
+
N
K
 
O 4.66E-219 4.89E-275 3.28E-185 1.73E-227 1.51E-254 1.34E-221 2.055E-314 0 2.84E-302 0 0 0 9.54E-286 0 1.34E-261  6.75E-77 0.0001995 
N 3.68E-13 5.82E-80 0.0004417 7.37E-63 1.45E-136 6.33E-56 7.11E-58 1.41E-137 3.38E-36 3.57E-126 7.34E-213 2.82E-96 2.28E-40 3.15E-108 5.64E-25 2.94E-74  7.33E-98 
C 9.35E-244 3.42E-282 1.86E-218 1.34E-237 3.55E-256 2.43E-233 0 0 6.172E-317 0 0 0 8.303E-310 0 9.38E-290 0.08676 3.19E-95  
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Table D5. The p-values for the Mann Whitney pairwise tests performed on the hormone-therapy compared to the hormone-therapy and immunotherapy PR 
expression nucleus data (p<0.001) (Bonferroni corrected \ uncorrected; Bonferroni corrected values used) 
 
ANAS+NK DMSO+NK EP+NK EPA+NK EPR+NK RU486+NK ANAS DMSO EP EPA EPR RU486 
ANAS+NK 
 
4.27E-56 4.33E-23 1.22E-104 0.02882 1.34E-82 1.02E-20 7.88E-30 3.11E-18 5.52E-25 1.01E-15 8.64E-24 
DMSO+NK 2.82E-54 
 
2.12E-18 0.01497 3.36E-49 3.33E-139 2.13E-20 1.92E-29 5.27E-18 4.49E-24 1.27E-15 1.99E-23 
EP+NK 2.86E-21 1.40E-16 
 
8.35E-46 2.66E-16 3.23E-140 8.85E-21 3.18E-30 2.27E-18 6.29E-25 7.97E-16 5.30E-24 
EPA+NK 8.06E-103 0.9879 5.51E-44 
 
1.56E-106 1.69E-215 5.91E-21 2.18E-30 1.98E-18 6.34E-25 7.24E-16 3.89E-24 
EPR+NK 1 2.22E-47 1.75E-14 1.03E-104 
 
7.24E-111 5.91E-21 1.89E-30 1.89E-18 3.09E-25 6.98E-16 3.67E-24 
RU486+NK 8.83E-81 2.20E-137 2.13E-138 1.11E-213 4.78E-109 
 
1.09E-20 9.01E-30 3.26E-18 6.73E-25 1.04E-15 9.39E-24 
ANAS 6.73E-19 1.41E-18 5.84E-19 3.90E-19 3.90E-19 7.16E-19 
 
3.00E-13 1.74E-10 4.89E-10 1.04E-09 1.00E-08 
DMSO 5.20E-28 1.27E-27 2.10E-28 1.44E-28 1.25E-28 5.95E-28 1.98E-11 
 
3.03E-12 8.98E-15 4.05E-11 2.30E-14 
EP 2.05E-16 3.48E-16 1.50E-16 1.31E-16 1.25E-16 2.15E-16 1.15E-08 2.00E-10 
 
1.97E-11 3.47E-09 0.5354 
EPA 3.64E-23 2.97E-22 4.15E-23 4.19E-23 2.04E-23 4.44E-23 3.23E-08 5.93E-13 1.30E-09 
 
1.87E-10 3.38E-13 
EPR 6.64E-14 8.37E-14 5.26E-14 4.78E-14 4.60E-14 6.87E-14 6.88E-08 2.68E-09 2.29E-07 1.23E-08 
 
2.93E-10 
RU486 5.70E-22 1.31E-21 3.50E-22 2.57E-22 2.42E-22 6.20E-22 6.60E-07 1.52E-12 1 2.23E-11 1.93E-08 
  
Table D6. The p-values for the Mann Whitney pairwise tests performed on the hormone-therapy compared to the combined hormone-therapy and immunotherapy PR 
expression cytoplasm data (p<0.001) (Bonferroni corrected \ uncorrected; Bonferroni corrected values used) 
 
ANAS+NK DMSO+NK EP+NK EPA+NK EPR+NK RU486+NK ANAS DMSO EP EPA EPR RU486 
ANAS+NK 
 
1.28E-98 9.11E-117 1.30E-198 1.02E-44 4.28E-221 1.02E-20 7.88E-30 3.11E-18 1.07E-24 1.01E-15 8.64E-24 
DMSO+NK 8.46E-97 
 
6.24E-19 0.00277 2.37E-32 5.59E-236 1.90E-20 1.92E-29 4.34E-18 1.58E-18 1.27E-15 1.52E-23 
EP+NK 6.02E-115 4.12E-17 
 
8.76E-76 0.0001791 1.419E-319 7.06E-21 3.18E-30 2.26E-18 5.03E-24 7.97E-16 4.92E-24 
EPA+NK 8.60E-197 0.1828 5.78E-74 
 
1.53E-95 0 5.95E-21 2.18E-30 1.98E-18 1.32E-19 7.24E-16 3.89E-24 
EPR+NK 6.74E-43 1.57E-30 0.01182 1.01E-93 
 
2.16E-292 5.27E-21 1.89E-30 1.88E-18 1.05E-23 6.98E-16 3.56E-24 
RU486+NK 2.82E-219 3.69E-234 9.364E-318 0 1.42E-290 
 
1.09E-20 9.01E-30 3.26E-18 7.04E-25 1.04E-15 9.39E-24 
ANAS 6.73E-19 1.26E-18 4.66E-19 3.93E-19 3.48E-19 7.16E-19 
 
3.00E-13 6.49E-06 1.03E-10 1.04E-09 1.89E-09 
DMSO 5.20E-28 1.27E-27 2.10E-28 1.44E-28 1.25E-28 5.95E-28 1.98E-11 
 
3.03E-12 8.98E-15 4.34E-07 2.30E-14 
EP 2.05E-16 2.87E-16 1.49E-16 1.31E-16 1.24E-16 2.15E-16 0.0004285 2.00E-10 
 
1.97E-11 3.47E-09 0.003145 
EPA 7.08E-23 1.04E-16 3.32E-22 8.72E-18 6.92E-22 4.64E-23 6.82E-09 5.93E-13 1.30E-09 
 
1.87E-10 3.11E-13 
EPR 6.64E-14 8.37E-14 5.26E-14 4.78E-14 4.60E-14 6.87E-14 6.88E-08 2.86E-05 2.29E-07 1.23E-08 
 
2.93E-10 
RU486 5.70E-22 1.00E-21 3.25E-22 2.57E-22 2.35E-22 6.20E-22 1.25E-07 1.52E-12 0.2075 2.05E-11 1.93E-08 
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Table D7. The MFI values for the ERα expression 
Treatment 
Overall 
(Cell) 
Cytoplasm Nucleus 
Media B 0.05485177 0.05016156 0.07280618 
dDMSO 0.009204749 0.009096929 0.009720602 
EP 0.008494155 0.008478679 0.008594465 
ANAS 0.054962757 0.0512726 0.07391729 
RU486 0.009998437 0.010004132 0.010010256 
EPA 0.008764179 0.008721687 0.009100168 
EPR 0.008891058 0.008843711 0.009193471 
dDMSO+NK 0.008408984 0.008327775 0.008717904 
EP+NK 0.009195583 0.009118333 0.009411306 
ANAS+NK 0.009053005 0.008991113 0.009225404 
RU486+NK 0.008992182 0.008917346 0.009236711 
EPA+NK 0.009152391 0.009103248 0.009317897 
EPR+NK 0.009275839 0.009203269 0.0094431 
 
Table D8. The p-values for the normality tests performed on the ERα data 
Treatment Category Shapiro-Wilk Jaque-Bera Chi
2
 
Anderson-
Darling 
dDMSO Overall 1.62E-09 7.53E-69 4.78E-07 5.75E-11 
 Cytoplasm 4.72E-08 4.12E-28 0.00016559 1.03E-09 
 Nucleus 7.24E-06 1.45E-16 3.37E-02 8.04E-05 
EP Overall <0.0001 <0.001 <0.001 <0.005 
 Cytoplasm <0.0001 <0.001 <0.001 <0.005 
 Nucleus <0.0001 <0.001 <0.001 <0.005 
ANAS Overall <0.0001 <0.001 <0.001 <0.005 
 Cytoplasm <0.0001 <0.001 <0.001 <0.005 
 Nucleus <0.0001 <0.001 <0.001 <0.005 
RU486 Overall 1.41E-02 1.20E-01 0.2673 1.09E-02 
 Cytoplasm 0.001892 0.0169 0.11195 0.001038 
 Nucleus 0.009197 0.0148 0.10188 0.02716 
EPA Overall 1.58E-13 4.35E-58 6.06E-07 5.72E-16 
 Cytoplasm 1.42E-12 5.64E-56 0.00018435 1.60E-11 
 Nucleus 2.79E-16 4.12E-126 5.68E-12 2.50E-24 
EPR Overall <0.0001 <0.001 <0.001 <0.005 
 Cytoplasm <0.0001 <0.001 <0.001 <0.005 
 Nucleus <0.0001 <0.001 <0.001 <0.005 
dDMSO+NK Overall 7.10E-47 0 0 2.19E-135 
 Cytoplasm 3.28E-47 0 0 2.72E-125 
 Nucleus 3.14E-45 0 0 4.45E-170 
EP+NK Overall 5.50E-23 8.97E-224 5.32E-06 1.32E-27 
 Cytoplasm 5.97E-25 0 1.75E-05 1.13E-31 
 Nucleus <0.0001 <0.001 <0.001 <0.005 
ANAS+NK Overall 6.36E-15 5.98E-30 0.00053098 2.15E-18 
 Cytoplasm 1.27E-12 2.80E-19 6.20E-06 1.52E-14 
 Nucleus 8.41E-28 1.49E-296 1.97E-10 4.22E-50 
RU486+NK Overall 1.20E-10 7.03E-12 0.0032746 7.63E-12 
 Cytoplasm 1.53E-12 1.07E-16 0.0016766 1.24E-15 
 Nucleus 3.49E-26 0 3.63E-07 2.08E-39 
EPA+NK Overall 6.43E-13 1.19E-09 8.74E-10 8.31E-21 
 Cytoplasm 1.48E-13 1.97E-09 1.67E-12 1.63E-23 
 Nucleus 1.09E-12 8.74E-25 0.019309 1.18E-09 
EPR+NK Overall 8.28E-13 5.52E-18 0.001705 3.12E-10 
 Cytoplasm 2.82E-13 1.33E-18 0.00025994 1.08E-10 
 Nucleus 5.63E-18 2.30E-42 0.0014969 1.91E-22 
153 
 
 
 
Table D9. The p-values for the Mann Whitney pairwise tests performed on the hormone-therapy ERα data (p<0.001) (Bonferroni corrected \ uncorrected; Bonferroni 
corrected values used) 
 
 
ANAS DMSO EP EPA EPR RU486 
 
 
O N C O N C O N C O N C O N C O N C 
A
N
A
S
 
O 
 
7.53E-06 0.1211 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 
N 0.003277 
 
3.39E-08 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 
C 1 1.48E-05 
 
1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 
D
M
S
O
 O 7.91E-22 7.91E-22 7.91E-22  4.77E-15 
0.000895
2 
2.56E-24 3.93E-24 2.07E-24 2.55E-11 0.8989 1.25E-15 6.27E-22 6.27E-22 6.27E-22 6.85E-23 2.46E-22 2.32E-23 
N 7.91E-22 7.91E-22 7.91E-22 2.07E-12  2.77E-18 2.56E-24 3.76E-24 2.07E-24 7.67E-22 1.16E-07 1.50E-22 6.27E-22 6.27E-22 6.27E-22 1.40E-07 1.85E-05 1.12E-08 
C 7.91E-22 7.91E-22 7.91E-22 0.3894 1.20E-15  1.66E-23 1.77E-22 1.29E-23 5.95E-06 0.1789 3.24E-10 6.27E-22 6.27E-22 6.27E-22 8.43E-24 2.52E-23 4.86E-24 
E
P
 
O 7.91E-22 7.91E-22 7.91E-22 1.11E-21 1.11E-21 7.21E-21  1.24E-05 0.2104 1.15E-21 1.46E-23 5.67E-21 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 
N 7.91E-22 7.91E-22 7.91E-22 1.71E-21 1.64E-21 7.70E-20 0.005412  2.14E-07 1.78E-18 1.10E-21 7.60E-17 1.53E-17 2.30E-18 3.25E-17 1.82E-24 1.82E-24 1.82E-24 
C 7.91E-22 7.91E-22 7.91E-22 8.99E-22 8.99E-22 5.60E-21 1 9.32E-05  1.92E-22 4.09E-24 1.24E-21 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 1.82E-24 
E
P
A
 
O 7.89E-22 7.89E-22 7.89E-22 1.11E-08 3.34E-19 0.002589 4.99E-19 7.72E-16 8.35E-20  3.69E-06 0.1684 0.004112 0.01418 0.003554 2.15E-24 2.25E-24 1.98E-24 
N 7.89E-22 7.89E-22 7.89E-22 1 5.06E-05 1 6.34E-21 4.80E-19 1.78E-21 0.001604  7.01E-08 1.42E-09 9.19E-09 8.42E-10 4.18E-20 1.48E-17 5.67E-21 
C 7.89E-22 7.89E-22 7.89E-22 5.42E-13 6.52E-20 1.41E-07 2.47E-18 3.31E-14 5.41E-19 1 3.05E-05  0.04093 0.09183 0.03587 1.89E-24 1.89E-24 1.82E-24 
E
P
R
 
O 7.91E-22 7.91E-22 7.91E-22 2.73E-19 2.73E-19 2.73E-19 7.91E-22 6.66E-15 7.91E-22 1 6.17E-07 1  0.000719 0.2441 1.82E-24 1.82E-24 1.82E-24 
N 7.91E-22 7.91E-22 7.91E-22 2.73E-19 2.73E-19 2.73E-19 7.91E-22 1.00E-15 7.91E-22 1 4.00E-06 1 0.313  4.71E-05 1.82E-24 1.82E-24 1.82E-24 
C 7.91E-22 7.91E-22 7.91E-22 2.73E-19 2.73E-19 2.73E-19 7.91E-22 1.41E-14 7.91E-22 1 3.66E-07 1 1 0.02048  1.82E-24 1.82E-24 1.82E-24 
R
U
4
8
6
 O 7.91E-22 7.91E-22 7.91E-22 2.98E-20 6.07E-05 3.67E-21 7.91E-22 7.91E-22 7.91E-22 9.37E-22 1.82E-17 8.24E-22 7.91E-22 7.91E-22 7.91E-22  0.1357 0.2561 
N 7.91E-22 7.91E-22 7.91E-22 1.07E-19 0.008051 1.10E-20 7.91E-22 7.91E-22 7.91E-22 9.78E-22 6.42E-15 8.24E-22 7.91E-22 7.91E-22 7.91E-22 1  0.01537 
C 7.91E-22 7.91E-22 7.91E-22 1.01E-20 4.87E-06 2.11E-21 7.91E-22 7.91E-22 7.91E-22 8.60E-22 2.47E-18 7.89E-22 7.91E-22 7.91E-22 7.91E-22 1 1  
 
 
 
   1
5
2
 
   1
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Table D10. The p-values for the Mann Whitney pairwise tests performed on the combined hormone-therapy and immunotherapy ERα data (p<0.001) (Bonferroni 
corrected \ uncorrected; Bonferroni corrected values used) 
 
 
ANAS+NK DMSO+NK EP+NK EPA+NK EPR+NK RU486+NK 
 
 
O N C O N C O N C O N C O N C O N C 
A
N
A
S
+
N
K
 O 
 
1.14E-96 8.62E-19 0.001295 1.88E-101 0.000416 8.40E-68 7.07E-243 1.15E-17 8.75E-22 1.11E-135 9.58E-06 1.68E-109 2.82E-242 2.85E-56 9.09E-14 3.01E-66 2.23E-59 
N 4.96E-94 
 
2.81E-171 1.95E-31 6.42E-24 3.44E-74 0.007294 2.89E-73 1.53E-34 2.74E-12 2.11E-20 1.05E-31 2.71E-08 3.35E-81 0.09152 7.98E-119 0.7262 1.23E-191 
C 3.75E-16 1.22E-168 
 
2.79E-19 5.97E-134 0.006508 2.21E-130 2.96E-305 1.34E-61 5.63E-57 2.75E-191 8.38E-28 7.59E-168 5.76E-302 3.65E-106 0.917 2.10E-115 1.43E-20 
D
M
S
O
+
N
K
 
O 0.5633 8.50E-29 1.21E-16  4.32E-53 1.82E-07 5.42E-21 2.35E-114 0.006032 3.21E-06 3.54E-61 0.4063 8.70E-45 1.20E-118 2.93E-19 1.13E-15 5.60E-25 4.65E-44 
N 8.17E-99 2.79E-21 2.60E-131 1.88E-50  3.70E-82 6.77E-31 0.008691 5.17E-64 1.96E-37 0.005604 3.68E-54 3.24E-08 2.51E-05 3.69E-24 2.70E-104 4.08E-17 1.19E-133 
C 0.181 1.49E-71 1 7.93E-05 1.61E-79  7.59E-57 1.90E-167 1.27E-21 6.04E-25 4.20E-104 1.45E-10 1.14E-84 1.26E-168 3.71E-49 0.01179 2.93E-57 3.06E-20 
E
P
+
N
K
 O 3.65E-65 1 9.60E-128 2.36E-18 2.94E-28 3.30E-54  1.75E-86 1.06E-20 5.59E-06 1.75E-29 3.04E-20 9.26E-15 2.98E-93 0.4243 5.25E-95 0.009095 4.57E-161 
N 3.08E-240 1.26E-70 1.29E-302 1.02E-111 1 8.25E-165 7.62E-84  4.31E-159 2.13E-91 1.85E-12 3.39E-125 2.83E-28 0.02549 3.07E-67 1.52E-219 5.33E-49 9.23E-270 
C 5.02E-15 6.67E-32 5.84E-59 1 2.25E-61 5.52E-19 4.62E-18 1.87E-156  0.005647 8.18E-77 0.02944 1.39E-53 1.16E-160 2.21E-18 1.05E-45 1.19E-25 8.12E-107 
E
P
A
+
N
K
 O 3.80E-19 1.19E-09 2.45E-54 0.001395 8.52E-35 2.63E-22 0.00243 9.26E-89 1  1.06E-40 9.10E-06 1.56E-24 4.41E-99 2.16E-05 4.52E-44 8.37E-10 1.01E-92 
N 4.81E-133 9.18E-18 1.19E-188 1.54E-58 1 1.83E-101 7.61E-27 8.06E-10 3.56E-74 4.62E-38  7.05E-66 0.0002927 3.42E-18 1.66E-22 2.03E-144 3.02E-14 1.10E-196 
C 0.004168 4.59E-29 3.65E-25 1 1.60E-51 6.32E-08 1.32E-17 1.48E-122 1 0.003959 3.07E-63  7.89E-47 4.23E-132 6.43E-18 6.74E-22 2.55E-24 1.08E-61 
E
P
R
+
N
K
 O 7.33E-107 1.18E-05 3.30E-165 3.79E-42 1.41E-05 4.96E-82 4.03E-12 1.23E-25 6.03E-51 6.76E-22 0.1273 3.43E-44  9.42E-37 7.15E-11 8.78E-122 1.60E-05 3.08E-179 
N 1.23E-239 1.46E-78 2.50E-299 5.23E-116 0.01093 5.50E-166 1.30E-90 1 5.05E-158 1.92E-96 1.49E-15 1.84E-129 4.10E-34  1.13E-76 4.10E-217 7.26E-55 2.32E-266 
C 1.24E-53 1 1.59E-103 1.28E-16 1.60E-21 1.61E-46 1 1.34E-64 9.60E-16 0.009385 7.22E-20 2.80E-15 3.11E-08 4.90E-74  1.19E-77 0.08186 2.15E-133 
R
U
4
8
6
+
N
K
 
O 3.95E-11 3.47E-116 1 4.91E-13 1.18E-101 1 2.29E-92 6.61E-217 4.55E-43 1.97E-41 8.85E-142 2.93E-19 3.82E-119 1.78E-214 5.19E-75  3.43E-89 2.99E-16 
N 1.31E-63 1 9.15E-113 2.44E-22 1.77E-14 1.27E-54 1 2.32E-46 5.18E-23 3.64E-07 1.31E-11 1.11E-21 0.006954 3.16E-52 1 1.49E-86  3.88E-143 
C 9.71E-57 5.36E-189 6.23E-18 2.02E-41 5.19E-131 1.33E-17 1.99E-158 4.01E-267 3.53E-104 4.39E-90 4.78E-194 4.68E-59 1.34E-176 1.01E-263 9.35E-131 1.30E-13 1.69E-140  
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Table D11. The p-values for the Mann Whitney pairwise tests performed on the hormone-therapy compared to the combined hormone-therapy and immunotherapy 
ERα expression nucleus data (p<0.001) (Bonferroni corrected \ uncorrected; Bonferroni corrected values used) 
 
ANAS+NK DMSO+NK EP+NK EPA+NK EPR+NK RU486+NK ANAS DMSO EP EPA EPR RU486 
ANAS+NK 
 
6.42E-24 2.89E-73 2.11E-20 3.35E-81 0.7262 6.56E-26 0 3.14E-25 0.000145 5.42E-157 0 
DMSO+NK 4.24E-22 
 
0.008691 0.005604 2.51E-05 4.08E-17 5.35E-10 1.10E-201 1.96E-40 1.23E-19 8.68E-88 4.24E-22 
EP+NK 1.91E-71 0.5736 
 
1.85E-12 0.02549 5.33E-49 4.99E-10 0 6.18E-86 5.14E-48 1.15E-112 1.91E-71 
EPA+NK 1.39E-18 0.3699 1.22E-10 
 
3.42E-18 3.02E-14 6.51E-16 0 5.77E-48 1.69E-20 4.39E-127 1.39E-18 
EPR+NK 2.21E-79 0.001658 1 2.25E-16 
 
7.26E-55 1.02E-07 0 2.07E-86 1.74E-52 1.05E-97 2.21E-79 
RU486+NK 1 2.69E-15 3.52E-47 1.99E-12 4.79E-53 
 
7.82E-24 1.703E-310 4.13E-21 0.000224 9.24E-134 1 
ANAS 4.33E-24 3.53E-08 3.29E-08 4.30E-14 6.73E-06 5.16E-22 
 
8.75E-50 7.48E-32 4.52E-23 2.26E-09 4.33E-24 
DMSO 0 7.23E-200 0 0 0 0 5.78E-48 
 
1.51E-190 5.06E-213 1.13E-160 0 
EP 2.07E-23 1.30E-38 4.08E-84 3.81E-46 1.37E-84 2.73E-19 4.93E-30 9.99E-189 
 
1.31E-05 4.72E-119 2.07E-23 
EPA 0.009574 8.09E-18 3.39E-46 1.12E-18 1.15E-50 0.01481 2.98E-21 3.34E-211 0.000866 
 
1.79E-112 0.009574 
EPR 3.58E-155 5.73E-86 7.61E-111 2.90E-125 6.93E-96 6.10E-132 1.49E-07 7.48E-159 3.11E-117 1.18E-110 
 
3.58E-155 
RU486 0 6.42E-24 2.89E-73 2.11E-20 3.35E-81 0.7262 6.56E-26 0 3.14E-25 0.000145 5.42E-157 
  
 
Table D12. The p-values for the Mann Whitney pairwise tests performed on the hormone-therapy compared to combined hormone-therapy and immunotherapy ERα 
expression cytoplasm data (p<0.001) (Bonferroni corrected \ uncorrected; Bonferroni corrected values used) 
 
ANAS+NK DMSO+NK EP+NK EPA+NK EPR+NK RU486+NK ANAS DMSO EP EPA EPR RU486 
ANAS+NK 
 
0.006508 1.34E-61 8.38E-28 3.65E-106 1.43E-20 1.34E-06 0 6.66E-124 6.42E-59 4.10E-178 0 
DMSO+NK 0.4295 
 
1.27E-21 1.45E-10 3.71E-49 3.06E-20 0.00182 1.44E-205 1.41E-83 1.37E-45 1.48E-151 0.4295 
EP+NK 8.85E-60 8.37E-20 
 
0.02944 2.21E-18 8.12E-107 0.4168 0 5.48E-186 1.22E-144 1.41E-164 8.85E-60 
EPA+NK 5.53E-26 9.59E-09 1 
 
6.43E-18 1.08E-61 0.8051 0 4.71E-146 5.99E-96 4.00E-156 5.53E-26 
EPR+NK 2.41E-104 2.45E-47 1.46E-16 4.25E-16 
 
2.15E-133 0.000214 0 1.03E-184 1.54E-154 6.65E-153 2.41E-104 
RU486+NK 9.45E-19 2.02E-18 5.36E-105 7.10E-60 1.42E-131 
 
6.13E-15 1.455E-310 5.03E-68 1.65E-16 7.32E-159 9.45E-19 
ANAS 8.83E-05 0.1201 1 1 0.01414 4.05E-13 
 
4.25E-49 3.68E-36 5.50E-25 6.65E-43 8.83E-05 
DMSO 0 9.51E-204 0 0 0 0.00E+00 2.80E-47 
 
9.26E-148 4.88E-240 3.96E-159 0 
EP 4.40E-122 9.31E-82 3.62E-184 3.11E-144 6.77E-183 3.32E-66 2.43E-34 6.11E-146 
 
7.02E-24 1.13E-129 4.40E-122 
EPA 4.24E-57 9.02E-44 8.06E-143 3.95E-94 1.02E-152 1.09E-14 3.63E-23 3.22E-238 4.63E-22 
 
5.91E-139 4.24E-57 
EPR 2.70E-176 9.79E-150 9.33E-163 2.64E-154 4.39E-151 4.83E-157 4.39E-41 2.61E-157 7.48E-128 3.90E-137 
 
2.70E-176 
RU486 0 0.006508 1.34E-61 8.38E-28 3.65E-106 1.43E-20 1.34E-06 0 6.66E-124 6.42E-59 4.10E-178 
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5
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Table D13. The MFI values for MUC1 expression 
Treatment Overall (Cell) Cytoplasm Nucleus 
Media B 0.059778 0.05733 0.073299 
dDMSO 0.009678 0.009527 0.010388 
EP 0.00864 0.008629 0.008699 
ANAS 0.029673 0.028691 0.034401 
RU486 0.009015 0.009009 0.008684 
EPA 0.008613 0.008604 0.008716 
EPR 0.008635 0.008618 0.009032 
dDMSO+NK 0.008914347 0.00884887 0.009308086 
EP+NK 0.009468437 0.009339088 0.009856825 
ANAS+NK 0.009031498 0.00894496 0.009316275 
RU486+NK 0.008795786 0.008723785 0.009188384 
EPA+NK 0.009363321 0.009273702 0.009632213 
EPR+NK 0.009330416 0.009244919 0.00958858 
 
Table D14. The p-values for the normality tests performed on the MUC1data 
Treatment Category Shapiro-Wilk Jaque-Bera Chi2 
Anderson-
Darling 
dDMSO Overall 8.56E-08 0.00449 5.27E-07 3.31E-12 
 Cytoplasm 2.80E-08 0.005463 2.04E-06 6.80E-14 
 Nucleus 8.96E-10 4.67E-68 0.002599 5.91E-10 
EP Overall 1.22E-25 4.83E-84 2.42E-17 7.34E-64 
 Cytoplasm 7.65E-26 1.83E-86 6.03E-19 6.02E-65 
 Nucleus 6.80E-25 7.19E-247 3.95E-08 1.48E-43 
ANAS Overall 0.8121 0.8599 0.715 0.8928 
 Cytoplasm 0.9293 0.9007 0.27332 0.8771 
 Nucleus 0.7984 0.8442 0.11146 0.4778 
RU486 Overall 0.004514 0.1111 0.30411 0.09886 
 Cytoplasm 1.28E-07 3.15E-10 0.016106 6.16E-07 
 Nucleus 0.03354 0.05985 0.15825 0.06837 
EPA Overall <0.0001 <0.001 <0.001 <0.005 
 Cytoplasm 8.12E-32 4.39E-132 6.77E-174 7.17E-152 
 Nucleus <0.0001 <0.001 <0.001 <0.005 
EPR Overall 1.07E-33 1.78E-157 4.51E-163 6.84E-159 
 Cytoplasm 1.43E-33 9.78E-151 5.62E-154 1.28E-157 
 Nucleus 5.94E-34 2.60E-186 4.32E-189 1.73E-158 
dDMSO+NK Overall 2.28E-54 0 1.25E-215 1.29E-115 
 Cytoplasm 1.72E-54 0 1.59E-207 4.45E-114 
 Nucleus 2.42E-51 0 5.54E-172 4.61E-170 
EP+NK Overall 1.53E-35 0 5.25E-31 1.22E-95 
 Cytoplasm 2.54E-28 4.18E-81 1.74E-17 2.94E-67 
 Nucleus 6.44E-46 0 6.55E-81 4.94E-168 
ANAS+NK Overall 1.54E-28 3.88E-147 3.25E-15 7.73E-62 
 Cytoplasm 2.68E-22 5.54E-55 1.12E-08 7.60E-38 
 Nucleus <0.0001 <0.001 <0.001 <0.005 
RU486+NK Overall 3.14E-20 8.55E-34 5.70E-11 8.82E-30 
 Cytoplasm 1.68E-24 4.96E-58 1.76E-09 4.23E-52 
 Nucleus 3.69E-37 0 3.42E-52 1.05E-120 
EPA+NK Overall <0.0001 <0.001 <0.001 <0.005 
 Cytoplasm <0.0001 <0.001 <0.001 <0.005 
 Nucleus <0.0001 <0.001 <0.001 <0.005 
EPR+NK Overall 3.86E-29 2.63E-115 8.37E-14 3.66E-66 
 Cytoplasm 8.01E-31 2.99E-162 1.21E-16 1.21E-73 
 Nucleus 2.23E-36 0 2.78E-17 9.06E-87 
157 
 
 
 
 
Table D15. The p-values for the Mann Whitney pairwise tests performed on the hormone-therapy MUC1 data (p<0.001) (Bonferroni corrected \ uncorrected; 
Bonferroni corrected values used) 
 
 
ANAS DMSO EP EPA EPR RU486 
 
 
O N C O N C O N C O N C O N C O N C 
A
N
A
S
 
O 
 
7.22E-06 0.1335 4.28E-16 4.28E-16 4.28E-16 9.82E-21 1.00E-20 9.82E-21 3.31E-20 3.31E-20 3.31E-20 1.84E-20 1.90E-20 1.84E-20 1.32E-19 1.24E-19 1.32E-19 
N 0.003141 
 
1.87E-07 4.28E-16 4.28E-16 4.28E-16 9.82E-21 1.00E-20 9.82E-21 3.31E-20 3.31E-20 3.31E-20 1.84E-20 1.90E-20 1.84E-20 1.32E-19 1.24E-19 1.32E-19 
C 1 8.15E-05 
 
4.28E-16 4.28E-16 4.28E-16 9.82E-21 1.00E-20 9.82E-21 3.31E-20 3.31E-20 3.31E-20 1.84E-20 1.90E-20 1.84E-20 1.32E-19 1.24E-19 1.32E-19 
D
M
S
O
 O 1.86E-13 1.86E-13 1.86E-13  9.37E-07 0.03255 4.84E-45 3.67E-39 3.47E-46 1.50E-37 2.45E-35 7.61E-38 1.13E-34 2.39E-31 5.47E-36 0.002636 0.0006902 0.003529 
N 1.86E-13 1.86E-13 1.86E-13 0.0004074  6.10E-08 2.96E-53 7.11E-53 2.84E-53 2.43E-48 1.42E-47 1.52E-48 1.59E-47 4.79E-43 2.37E-48 2.05E-38 1.07E-34 8.76E-40 
C 1.86E-13 1.86E-13 1.86E-13 1 2.65E-05  3.30E-34 1.14E-25 1.23E-35 9.58E-34 4.50E-31 4.16E-34 5.16E-31 1.64E-28 4.20E-32 0.8087 0.417 0.9601 
E
P
 
O 4.27E-18 4.27E-18 4.27E-18 2.10E-42 1.29E-50 1.43E-31  2.21E-31 0.009524 5.40E-37 0.5208 1.86E-46 1.78E-48 4.32E-09 4.35E-56 1.09E-135 3.21E-129 6.26E-139 
N 4.36E-18 4.36E-18 4.36E-18 1.60E-36 3.09E-50 4.95E-23 9.61E-29  1.56E-41 2.02E-79 7.60E-30 9.34E-83 7.71E-71 7.91E-43 3.54E-76 1.12E-118 2.28E-109 1.39E-123 
C 4.27E-18 4.27E-18 4.27E-18 1.51E-43 1.24E-50 5.33E-33 1 6.81E-39  6.60E-25 0.008427 6.21E-34 3.88E-41 0.0002054 1.95E-49 2.57E-138 1.30E-132 6.55E-141 
E
P
A
 
O 1.44E-17 1.44E-17 1.44E-17 6.52E-35 1.06E-45 4.17E-31 2.35E-34 8.79E-77 2.87E-22  4.66E-52 0.001407 1.86E-13 5.78E-12 5.23E-21 1.89E-91 2.69E-92 7.03E-92 
N 1.44E-17 1.44E-17 1.44E-17 1.06E-32 6.16E-45 1.96E-28 1 3.31E-27 1 2.03E-49  2.25E-57 9.44E-46 8.82E-13 4.62E-50 1.30E-78 5.53E-82 5.13E-78 
C 1.44E-17 1.44E-17 1.44E-17 3.31E-35 6.59E-46 1.81E-31 8.09E-44 4.06E-80 2.70E-31 0.6122 9.80E-55  3.76E-08 9.56E-20 5.02E-15 2.99E-93 1.15E-93 1.46E-93 
E
P
R
 
O 7.99E-18 7.99E-18 7.99E-18 4.92E-32 6.92E-45 2.24E-28 7.74E-46 3.35E-68 1.69E-38 8.09E-11 4.11E-43 1.63E-05  5.80E-31 0.008481 4.36E-79 1.07E-81 3.14E-78 
N 8.26E-18 8.26E-18 8.26E-18 1.04E-28 2.08E-40 7.14E-26 1.88E-06 3.44E-40 0.08933 2.51E-09 3.84E-10 4.16E-17 2.52E-28  1.95E-39 1.10E-58 6.19E-63 2.58E-57 
C 7.99E-18 7.99E-18 7.99E-18 2.38E-33 1.03E-45 1.83E-29 1.89E-53 1.54E-73 8.47E-47 2.27E-18 2.01E-47 2.19E-12 1 8.50E-37  1.14E-85 1.12E-87 6.72E-85 
R
U
4
8
6
 O 5.75E-17 5.75E-17 5.75E-17 1 8.89E-36 1 4.76E-133 4.87E-116 1.12E-135 8.24E-89 5.67E-76 1.30E-90 1.90E-76 4.80E-56 4.97E-83  0.4374 0.5749 
N 5.38E-17 5.38E-17 5.38E-17 0.3003 4.63E-32 1 1.40E-126 9.92E-107 5.64E-130 1.17E-89 2.41E-79 5.02E-91 4.63E-79 2.69E-60 4.87E-85 1  0.232 
C 5.75E-17 5.75E-17 5.75E-17 1 3.81E-37 1 2.72E-136 6.03E-121 2.85E-138 3.06E-89 2.23E-75 6.37E-91 1.37E-75 1.12E-54 2.92E-82 1 1  
 
    1
5
6
 
   1
5
6
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Table D16. The p-values for the Mann Whitney pairwise tests performed on the combined hormone-therapy and immunotherapy MUC1 data (p<0.001) (Bonferroni 
corrected \ uncorrected; Bonferroni corrected values used) 
 
 
ANAS+NK DMSO+NK EP+NK EPA+NK EPR+NK RU486+NK 
 
 
O N C O N C O N C O N C O N C O N C 
A
N
A
S
+
N
K
 O 
 
1.45E-110 7.10E-19 6.73E-26 1.04E-166 3.30E-09 6.53E-226 0 5.55E-134 2.16E-57 1.44E-193 3.68E-25 6.00E-167 0 5.55E-97 2.56E-123 1.24E-17 4.84E-219 
N 6.32E-108 
 
1.63E-198 3.25E-06 1.23E-41 1.39E-17 7.25E-32 2.08E-181 0.0008114 0.0001454 3.77E-29 3.05E-21 2.12E-06 5.79E-95 0.01593 0 3.15E-24 0 
C 3.09E-16 7.08E-196 
 
9.25E-57 9.27E-222 3.92E-29 0 0 8.46E-222 1.67E-118 7.94E-282 3.35E-71 3.16E-271 0 1.20E-186 1.10E-56 1.08E-55 7.83E-132 
D
M
S
O
+
N
K
 
O 2.93E-23 0.001416 4.02E-54  1.05E-40 0.001371 5.51E-31 1.05E-118 1.82E-09 0.01198 3.90E-39 0.1395 3.09E-11 1.11E-66 0.02523 4.30E-127 0.002785 4.00E-183 
N 4.53E-164 5.33E-39 4.03E-219 4.57E-38  5.51E-56 5.96E-09 1.99E-14 5.42E-31 3.25E-43 0.001873 7.80E-69 3.99E-32 0.8213 1.62E-59 2.29E-287 9.06E-76 0 
C 1.44E-06 6.03E-15 1.71E-26 0.5962 2.40E-53  6.64E-49 1.35E-142 1.35E-21 1.25E-10 4.69E-60 0.008391 2.60E-24 1.42E-89 1.31E-09 9.76E-86 0.5056 6.84E-136 
E
P
+
N
K
 O 2.84E-223 3.15E-29 0 2.40E-28 2.59E-06 2.89E-46  2.33E-75 2.77E-16 5.36E-38 0.173 7.82E-74 3.26E-16 1.89E-18 2.11E-52 0 8.57E-85 0 
N 0 9.03E-179 0 4.58E-116 8.67E-12 5.85E-140 1.01E-72  1.32E-143 6.71E-163 2.42E-46 2.09E-221 5.91E-164 1.04E-27 5.63E-244 0 3.89E-232 0 
C 2.41E-131 0.353 3.68E-219 7.93E-07 2.36E-28 5.88E-19 1.21E-13 5.73E-141  5.59E-09 5.26E-18 2.30E-29 0.5267 5.69E-65 1.68E-10 0 1.28E-36 0 
E
P
A
+
N
K
 O 9.40E-55 0.06325 7.27E-116 1 1.41E-40 5.42E-08 2.33E-35 2.92E-160 2.43E-06  2.07E-40 2.57E-07 3.77E-13 8.51E-92 0.1622 4.39E-242 1.40E-09 0 
N 6.25E-191 1.64E-26 3.46E-279 1.70E-36 0.8148 2.04E-57 1 1.05E-43 2.29E-15 9.01E-38  1.16E-73 1.67E-15 1.37E-08 4.09E-43 0 6.68E-74 0 
C 1.60E-22 1.33E-18 1.46E-68 1 3.39E-66 1 3.40E-71 9.07E-219 1.00E-26 0.0001117 5.07E-71  4.52E-39 4.22E-144 3.44E-13 1.75E-187 0.1874 2.22E-283 
E
P
R
+
N
K
 O 2.61E-164 0.0009201 1.38E-268 1.35E-08 1.73E-29 1.13E-21 1.42E-13 2.57E-161 1 1.64E-10 7.24E-13 1.96E-36  9.52E-74 1.55E-15 0 3.03E-48 0 
N 0 2.52E-92 0 4.82E-64 1 6.17E-87 8.24E-16 4.53E-25 2.48E-62 3.70E-89 5.95E-06 1.83E-141 4.14E-71  3.42E-140 0 1.21E-156 0 
C 2.42E-94 1 5.21E-184 1 7.06E-57 5.69E-07 9.17E-50 2.45E-241 7.31E-08 1 1.78E-40 1.50E-10 6.74E-13 1.49E-137  0 1.33E-18 0 
R
U
4
8
6
+
N
K
 
O 1.11E-120 0 4.78E-54 1.87E-124 9.94E-285 4.24E-83 0 0 0 1.91E-239 0 7.61E-185 0 0 0  3.35E-161 6.61E-20 
N 5.40E-15 1.37E-21 4.68E-53 1 3.94E-73 1 3.73E-82 1.69E-229 5.59E-34 6.07E-07 2.91E-71 1 1.32E-45 5.28E-154 5.80E-16 1.46E-158  4.68E-238 
C 2.11E-216 0 3.41E-129 1.74E-180 0 2.98E-133 0 0 0 0 0 9.67E-281 0 0 0 2.88E-17 2.03E-235  
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Table D17. The p-values for the Mann Whitney pairwise tests performed on the hormone-therapy compared to combined hormone-therapy and immunotherapy 
MUC1 expression nucleus data (p<0.001) (Bonferroni corrected \ uncorrected; Bonferroni corrected values used) 
 
ANAS+NK DMSO+NK EP+NK EPA+NK EPR+NK RU486+NK ANAS DMSO EP EPA EPA RU486 
ANAS+NK 
 
1.23E-41 2.08E-181 3.77E-29 5.79E-95 3.15E-24 3.87E-21 6.00E-21 0 1.69E-207 1.78E-197 3.91E-21 
DMSO+NK 9.56E-40 
 
1.99E-14 0.001873 0.8213 9.06E-76 5.53E-21 7.73E-08 4.84E-269 5.64E-166 5.08E-168 9.30E-45 
EP+NK 1.62E-179 1.56E-12 
 
2.42E-46 1.04E-27 3.89E-232 3.92E-21 0.001022 0 9.37E-252 9.10E-267 3.50E-108 
EPA+NK 2.94E-27 0.1461 1.89E-44 
 
1.37E-08 6.68E-74 3.97E-21 2.76E-11 0 1.49E-216 2.31E-218 2.50E-38 
EPR+NK 4.51E-93 1 8.11E-26 1.07E-06 
 
1.21E-156 3.68E-21 2.40E-08 0 1.51E-245 8.15E-252 3.68E-81 
RU486+NK 2.46E-22 7.07E-74 3.03E-230 5.21E-72 9.46E-155 
 
4.94E-21 1.56E-27 5.92E-201 1.14E-136 2.61E-130 0.002622 
ANAS 3.02E-19 4.31E-19 3.06E-19 3.10E-19 2.87E-19 3.85E-19 
 
4.28E-16 1.00E-20 3.31E-20 1.90E-20 1.24E-19 
DMSO 4.68E-19 6.03E-06 0.07974 2.15E-09 1.87E-06 1.21E-25 3.34E-14 
 
7.11E-53 1.42E-47 4.79E-43 1.07E-34 
EP 0 3.78E-267 0 0 0 4.62E-199 7.81E-19 5.54E-51 
 
7.60E-30 7.91E-43 2.28E-109 
EPA 1.31E-205 4.40E-164 7.31E-250 1.16E-214 1.18E-243 8.86E-135 2.58E-18 1.11E-45 5.93E-28 
 
8.82E-13 5.53E-82 
EPR 1.39E-195 3.96E-166 7.10E-265 1.80E-216 6.36E-250 2.04E-128 1.48E-18 3.73E-41 6.17E-41 6.88E-11 
 
6.19E-63 
RU486 3.05E-19 7.26E-43 2.73E-106 1.95E-36 2.87E-79 0.2045 9.64E-18 8.31E-33 1.78E-107 4.31E-80 4.83E-61 
 
 
 
Table D18. The p-values for the Mann-Whitney pairwise comparison tests performed on the hormone-therapy compared to hormone-therapy and immunotherapy 
MUC1 expression cytoplasm data (p<0.001) (Bonferroni corrected \ uncorrected; Bonferroni corrected values used) 
 ANAS+NK DMSO+NK EP+NK EPA+NK EPR+NK RU486+NK ANAS DMSO EP EPA EPA RU486 
ANAS+NK 
 
3.92E-29 8.46E-222 3.35E-71 1.20E-186 7.83E-132 3.87E-21 2.75E-05 3.07E-199 2.38E-129 1.58E-141 2.84E-10 
DMSO+NK 3.06E-27 
 
1.35E-21 0.008391 1.31E-09 6.84E-136 5.53E-21 0.02136 3.16E-165 8.11E-117 2.54E-130 0.1348 
EP+NK 6.60E-220 1.05E-19 
 
2.30E-29 1.68E-10 0 3.92E-21 0.4851 0 3.97E-225 1.81E-255 3.02E-35 
EPA+NK 2.61E-69 0.6545 1.79E-27 
 
3.44E-13 2.22E-283 3.97E-21 0.3671 2.13E-314 1.35E-191 1.23E-212 0.001454 
EPR+NK 9.34E-185 1.02E-07 1.31E-08 2.68E-11 
 
0 3.68E-21 0.8778 0 2.34E-221 2.80E-249 8.86E-29 
RU486+NK 6.11E-130 5.34E-134 0 1.73E-281 0 
 
4.94E-21 6.82E-20 1.06E-17 8.75E-31 4.07E-41 1.88E-87 
ANAS 3.02E-19 4.31E-19 3.06E-19 3.10E-19 2.87E-19 3.85E-19 
 
4.28E-16 9.82E-21 3.31E-20 1.84E-20 1.32E-19 
DMSO 0.002146 1 1 1 1 5.32E-18 3.34E-14 
 
1.23E-35 4.16E-34 4.20E-32 0.9601 
EP 2.40E-197 2.46E-163 0 1.662E-312 0 8.28E-16 7.66E-19 9.57E-34 
 
6.21E-34 1.95E-49 6.55E-141 
EPA 1.86E-127 6.33E-115 3.09E-223 1.06E-189 1.83E-219 6.83E-29 2.58E-18 3.25E-32 4.84E-32 
 
5.02E-15 1.46E-93 
EPA 1.23E-139 1.98E-128 1.41E-253 9.58E-211 2.18E-247 3.17E-39 1.43E-18 3.28E-30 1.52E-47 3.92E-13 
 
6.72E-85 
RU486 2.22E-08 1 2.35E-33 0.1134 6.91E-27 1.46E-85 1.03E-17 1 5.11E-139 1.14E-91 5.24E-83 
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Table D19. Spearman’s correlation values (>0.8 = very strong correlation) 
 
 >0.8 Strong correlation 
 
Treatment 
PR and MUC1 ERα and MUC1 
Cell Nuclei Cytoplasm Cell Nuclei Cytoplasm 
Media B 0.26358 0.26534 0.24547 0.80345 0.74945 0.81993 
dDMSO 0.65613 0.63834 0.63794 0.045766 -0.32812 0.31761 
EP 0.62598 0.73607 0.54462 0.72285 0.64565 0.71779 
ANAS 0.82469 0.68988 0.83849 -0.11666 -0.09598 0.08725 
RU486 0.90168 0.87731 0.91569 0.85537 0.91687 0.79828 
EPA 0.77809 0.56283 0.79516 0.52863 0.50962 0.52706 
EPR 0.25918 0.86674 -0.2603 -0.16552 -0.23797 -0.10123 
dDMSO+NK 0.739 0.62803 0.7504 0.7994 0.82531 0.78399 
EP+NK 0.87304 0.93143 0.81242 0.90408 0.92779 0.88392 
ANAS+NK 0.69715 0.8247 0.64088 0.91365 0.89503 0.91762 
RU486+NK 0.9144 0.97233 0.91122 0.91836 0.90047 0.93153 
EPA+NK 0.83769 0.85363 0.84121 0.83239 0.81633 0.82742 
EPR+NK 0.78676 0.86093 0.77719 0.93116 0.93997 0.92311 
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Table D20. The Ki67
+
 values 
 
Treatment % Ki67
+ 
Media B 4.3 
dDMSO 2.0 
EP 3.0 
ANAS 4.3 
RU486 2.5 
EPA 2.6 
EPR 5.0 
ANAS+NK 0.9 
RU486+NK 2.1 
EPA+NK 2.0 
EPR+NK 3.7 
 
 
Table D21. The p-values for the normality tests performed on the Ki67 data (p<0.05)  
 
Treatment Shapiro-Wilk Jaque-Bera Anderson-Darling 
dDMSO 0.656 0.8405 0.5033 
EP 0.9178 0.9041 0.698 
ANAS 0.31 0.786 0.285 
RU486 0.6704 0.8086 0.5588 
EPA 0.5329 0.7781 0.4295 
EPR 0.7682 0.821 0.6545 
dDMSO+NK 0.04432 0.6455 0.04629 
EP+NK 0.4919 0.7872 0.3322 
ANAS+NK 0.3624 0.6488 0.3462 
RU486+NK 0.8232 0.8355 0.784 
EPA+NK 0.1057 0.6242 0.1165 
EPR+NK 0.1243 0.6166 0.08019 
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Table D22. The values for the Tukey’s pairwise tests performed on the Ki67 data (significance set at p<0.05) (Q \ p-value) 
 
EPA EPR EP ANAS RU486 DMSO Media B EPA+NK EPR+NK EP+NK ANAS+NK RU486+NK 
EPA 
 
1 1 1 1 0.9894 1 0.9903 1 0.9296 0.5439 0.9935 
EPR 0.6138 
 
0.9999 1 1 0.9001 1 0.9048 1 0.7208 0.2759 0.9235 
EP 0.5088 1.123 
 
1 1 0.9996 0.9996 0.9996 1 0.9903 0.7798 0.9998 
ANAS 0.4019 1.016 0.1069 
 
1 0.9991 0.9998 0.9992 1 0.984 0.7343 0.9996 
RU486 0.3713 0.2425 0.8801 0.7732 
 
0.9519 1 0.9547 1 0.8209 0.3718 0.9657 
DMSO 1.815 2.429 1.306 1.413 2.186 
 
0.8465 1 0.9296 1 0.9985 1 
Media B 0.7898 0.176 1.299 1.192 0.4185 2.605 
 
0.8526 1 0.6387 0.2171 0.8773 
EPA+NK 1.797 2.411 1.288 1.395 2.169 0.1788 2.587 
 
0.9333 1 0.9983 1 
EPR+NK 0.4905 0.1234 0.9993 0.8924 0.1192 2.306 0.2993 2.288 
 
0.7741 0.3226 0.9479 
EP+NK 2.305 2.919 1.797 1.904 2.677 0.4903 3.095 0.5081 2.796 
 
1 1 
ANAS+NK 3.291 3.905 2.782 2.889 3.662 1.476 4.081 1.493 3.781 0.9853 
 
0.9973 
RU486+NK 1.72 2.333 1.211 1.318 2.091 0.09567 2.509 0.07779 2.21 0.5859 1.571 
 
 
   1
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Table D23. The mean percentage values for each quadrant (Q1: Annexin
+
 PI
-
 , Q2: Annexin
+
 PI
+
, Q3: 
Annexin
-
 PI
+
, Q4: Annexin
-
 PI
-
)
 
in all treatment groups 
Treatment Q1 Q2 Q3 Q4 
Media B 4.31 15.57 8.25 71.87 
dDMSO 12.45 14.70 8.27 64.63 
CPT 2.66 11.69 3.87 81.77 
EP 5.70 11.83 8.21 74.27 
ANAS 4.84 11.52 5.02 78.60 
RU486 3.00 11.75 9.78 75.43 
EPA 8.73 13.23 5.33 72.73 
EPR 2.16 9.55 8.27 80.00 
Media B+NK 4.28 26.00 6.82 62.93 
dDMSO+NK 3.98 10.20 12.55 73.27 
EP+NK 5.80 7.93 3.94 82.30 
ANAS+NK 4.69 9.05 6.60 79.67 
RU486+NK 2.87 10.07 9.07 78.00 
EPA+NK 4.34 7.57 4.82 83.30 
EPR+NK 2.12 10.29 6.79 80.80 
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Table D24. The p-values for the normality tests performed on the quadrant data (Q1: Annexin
+
 PI
-
 , Q2: 
Annexin
+
 PI
+
, Q3: Annexin
-
 PI
+
, Q4: Annexin
-
 PI
-
) (p<0.05) 
Treatment Quadrant Shapiro-Wilk Jaque-Bera 
dDMSO Q1 0.502 0.8165 
 Q2 0.7941 0.8579 
 Q3 0.002779 0.7667 
 Q4 0.1975 0.7757 
EP Q1 0.4082 0.8018 
 Q2 0.9525 0.8682 
 Q3 0.1438 0.7716 
 Q4 0.03773 0.7671 
ANAS Q1 0.4108 0.8022 
 Q2 0.7127 0.8484 
 Q3 0.6458 0.839 
 Q4 0.6536 0.8402 
RU486 Q1 0.4514 0.8085 
 Q2 0.6962 0.8462 
 Q3 0.1882 0.7749 
 Q4 0.3493 0.7933 
EPA Q1 0.2788 0.7842 
 Q2 0.2273 0.7785 
 Q3 0.3244 0.7899 
 Q4 0.8114 0.8596 
EPR Q1 0.9286 0.8675 
 Q2 0.1701 0.7734 
 Q3 0.1716 0.7736 
 Q4 0.7875 0.8572 
dDMSO+NK Q1 0.2136 0.7772 
 Q2 0.6801 0.844 
 Q3 0.8701 0.8644 
 Q4 0.1239 0.7703 
EP+NK Q1 0.376 0.797 
 Q2 0.5426 0.823 
 Q3 0.6084 0.8334 
 Q4 0.154 0.7722 
ANAS+NK Q1 0.9531 0.8682 
 Q2 0.1465 0.7717 
 Q3 0.8802 0.865 
 Q4 0.9277 0.8674 
RU486+NK Q1 0.9082 0.8666 
 Q2 0.1321 0.7708 
 Q3 0.5788 0.8288 
 Q4 0.8632 0.8639 
EPA+NK Q1 0.6079 0.8333 
 Q2 0.3399 0.792 
 Q3 0.4913 0.8148 
 Q4 0.3517 0.7936 
EPR+NK Q1 0.3725 0.7965 
 Q2 0.3518 0.7936 
 Q3 0.251 0.781 
 Q4 0.9186 0.867 
 
  
165 
 
 
Table D25. The p-values for the Kruskal Wallis tests performed on the Q1 data (Annexin
+
 PI
-
 ) (p<0.05) 
 EPA EPR EP ANAS RU486 DMSO PRF CPT EPA+NK EPR+NK EP+NK ANAS+NK RU486+NK 
EPA              
EPR              
EP 0.8273 0.04953            
ANAS 0.8273             
RU486  0.2752            
DMSO 0.5127 0.04953 0.1266 0.04953 0.04953         
PRF 0.8273 0.1266 0.2752 0.8273 0.2752 0.04953        
CPT      0.04953 0.2752       
EPA+NK 0.5127     0.1266 0.8273       
EPR+NK  0.8273    0.04953 0.2752       
EP+NK   0.8273   0.1266 0.8273       
ANAS+NK    0.8273  0.04953 0.8273  0.8273     
RU486+NK     0.8273 0.04953 0.2752   0.5127    
 
 
Table D26. The p-values for the Kruskal Wallis tests performed on the Q2 data (Annexin
+
 PI
+
) (p<0.05) 
 EPA EPR EP ANAS RU486 DMSO PRF CPT EPA+NK EPR+NK EP+NK ANAS+NK RU486+NK 
EPA              
EPR              
EP 0.8273 0.5127            
ANAS 0.8273             
RU486  0.5127            
DMSO 0.5127 0.1266 0.5127 0.5127 0.5127         
PRF 0.5127 0.04953 0.2752 0.1266 0.2612 0.8273        
CPT      0.5127 0.5127       
EPA+NK 0.1266     0.04953 0.04953       
EPR+NK  0.5127    0.5127 0.2752       
EP+NK   0.2752   0.1266 0.04953       
ANAS+NK    0.5127  0.1266 0.04953  0.2752     
RU486+NK     0.5127 0.2752 0.04953   0.5127    
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Table D27. The p-values for the Kruskal Wallis tests performed on the Q3 (Annexin
-
 PI
+
) data (p<0.05) 
 EPA EPR EP ANAS RU486 DMSO PRF CPT EPA+NK EPR+NK EP+NK ANAS+NK RU486+NK 
EPA              
EPR              
EP 0.1266 0.8273            
ANAS 0.8273             
RU486  0.8273            
DMSO 0.8273 0.5127 0.5127 0.8273 0.8273         
PRF 0.2752 0.5127 0.8273 0.2752 0.5127 0.5127        
CPT      0.8273 0.04953       
EPA+NK 0.8273     1 0.04953       
EPR+NK  0.5127    0.5127 0.2752       
EP+NK   0.1266   0.8273 0.04953       
ANAS+NK    0.5127  0.8273 0.5127  0.5127     
RU486+NK     0.8273 1 0.8273   0.8273    
 
 
Table D28. The p-values for the Kruskal Wallis tests performed on the Q4 (Annexin
-
 PI
-
) data (p<0.05) 
 EPA EPR EP ANAS RU486 DMSO PRF CPT EPA+NK EPR+NK EP+NK ANAS+NK RU486+NK 
EPA              
EPR              
EP 0.8273 0.2752            
ANAS 0.5127             
RU486  0.2752            
DMSO 0.2752 0.04953 0.2752 0.04953 0.04953         
PRF 0.8273 0.1266 0.5127 0.2752 0.2752 0.1266        
CPT      0.2752 0.5127       
EPA+NK 0.1266     0.04953 0.04953       
EPR+NK  0.8273    0.04953 0.2752       
EP+NK   0.2752   0.04953 0.2752       
ANAS+NK    0.8273  0.04953 0.1266  0.5127     
RU486+NK     0.5127 0.04953 0.2752   0.5127    
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Table D29. The p-values for the Kruskal Wallis tests performed on the total apoptosis (Q1+Q2) data (Q1: Annexin
+
 PI
-
 , Q2: Annexin
+
 PI
+
) (p<0.05) 
 EPA EPR EP ANAS RU486 DMSO PRF CPT EPA+NK EPR+NK EP+NK ANAS+NK RU486+NK 
EPA              
EPR              
EP 0.5172 0.2752            
ANAS 0.2752             
RU486  0.2752            
DMSO 0.5127 0.04953 0.04953 0.04953 0.04953         
PRF 0.8273 0.04953 0.8273 0.5127 0.2752 0.04953        
CPT      0.1266 0.5127       
EPA+NK 0.1266     0.04953 0.1266       
EPR+NK  0.5127    0.04953 0.1266       
EP+NK   0.3758   0.04953 0.2752       
ANAS+NK    0.5127  0.04953 0.04953  0.5127     
RU486+NK     0.5127 0.04953 0.04953   0.8273    
 
 
 
   1
6
7
 
 
